Page last updated: 2024-12-04

cantharidin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cantharidin: A toxic compound, isolated from the Spanish fly or blistering beetle (Lytta (Cantharis) vesicatoria) and other insects. It is a potent and specific inhibitor of protein phosphatases 1 (PP1) and 2A (PP2A). This compound can produce severe skin inflammation, and is extremely toxic if ingested orally. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cantharidin : A monoterpenoid with an epoxy-bridged cyclic dicarboxylic anhydride structure secreted by many species of blister beetle, and most notably by the Spanish fly, Lytta vesicatoria. Natural toxin inhibitor of protein phosphatases 1 and 2A. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5944
CHEMBL ID48449
CHEBI ID64213
SCHEMBL ID152262
MeSH IDM0003285
PubMed CID2545
CHEMBL ID8066
CHEBI ID93862
SCHEMBL ID1805181
MeSH IDM0003285

Synonyms (177)

Synonym
NCI60_005413
NCIMECH_000301
(1r,2s,3r,6s)-1,2-dimethyl-3,6-epoxycyclohexane-1,2-dicarboxylic anhydride
7-oxabicyclo(2.2.1)heptane-2,3-dicarboxylic anhydride, 2,3-dimethyl-
kantharidin [german]
1,2-dimethyl-3,6-epoxyperhydrophthalic anhydride
epa pesticide chemical code 013101
2,3-dimethyl-7-oxabicyclo(2.2.1)heptane-2,3-dicarboxylic anhydride
hexahydro-3aalpha,7aalpha-dimethyl-4beta,7beta-epoxyisobenzofuran-1,3-dione
caswell no. 157
ai3-04021
hsdb 2181
4,7-epoxyisobenzofuran-1,3-dione, hexahydro-3a,7a-dimethyl-, (3a-alpha,4-beta,7-beta,7a-alpha)
ccris 635
einecs 200-263-3
brn 0085302
exo-1,2-cis-dimethyl-3,6-epoxyhexahydrophthalic anhydride
exo-1,6-epoxyhexahydrophthalic anhydride
wln: t c555 a ao dvovtj c1 g1
cantharides camphor
nsc-61805
hexahydro-3a,7-epoxyisobenzofuran-1,3-dione
1,6-epoxyperhydrophthalic anhydride
7-oxabicyclo[2.2.1]heptane-2, 2,3-dimethyl-
cantharidine
4,3-dione, hexahydro-3a,7a-dimethyl-, (3a.alpha.,4.beta.,7.beta.,7a.alpha.)-
2,3-dicarboxylic anhydride
4,3-dione, hexahydro-3a,7a-dimethyl-
cas-56-25-7
NCGC00016247-01
56-25-7
kantaridin
NSC61805 ,
cantharidin
cantharone
4,7-epoxyisobenzofuran-1,3-dione, hexahydro-3a,7a-dimethyl-, (3ar,4s,7r,7as)-rel-
BPBIO1_000738
PRESTWICK3_000885
AB00513946
BSPBIO_000670
NCGC00025212-02
cid_6708701
(1s,2r,6s,7r)-2,6-dimethyl-4,10-dioxa-tricyclo[5.2.1.0*2,6*]decane-3,5-dione
(1r,2s,6r,7s)-2,6-dimethyl-4,10-dioxa-tricyclo[5.2.1.0*2,6*]decane-3,5-dione
(1s,3s,4r,7r)-2,6-dimethyl-4,10-dioxa-tricyclo[5.2.1.0-2,6]decane-3,5-dione
(1r,7s)-2,6-dimethyl-4,10-dioxa-tricyclo[5.2.1.0*2,6*]decane-3,5-dione
bdbm50090505
CHEMBL48449 ,
cantaridina
chebi:64213 ,
cantharidinum
(3ar,4s,7r,7as)-3a,7a-dimethylhexahydro-4,7-epoxy-2-benzofuran-1,3-dione
NCGC00025212-04
NCGC00025212-03
NCGC00025212-05
HMS2097B12
5-19-05-00051 (beilstein handbook reference)
unii-igl471wq8p
cantharidin [usan]
who 11470
igl471wq8p ,
kantharidin
CCG-36082
CCG-35382
AKOS015895930
3a,7a-dimethylhexahydro-4,7-epoxyisobenzofuran-1,3-dione
7a-dimethylhexahydro-3a,4,7-epoxyisobenzofuran
BRD-K80684056-001-01-0
cantharidine [hsdb]
cantharidin [mi]
cantharidin [iarc]
cantharidin [inn]
cantharidin [who-dd]
cantharidinum [hpus]
(1r,5s,6r,9s)-rel-1,5-dimethyl-3,10-dioxatricyclo[3.2.1.01,5]decane-2,4-dione
hexahydro-3a.alpha.,7a.alpha.-dimethyl-4.beta.,7.beta.-epoxyisobenzofuran-1,3-dione
cantharidin [mart.]
cantharidin [vandf]
SCHEMBL152262
CS-4979
HY-N0209
(3a?,4?,7?,7a?)-hexahydro-3a,7a-dimethyl-4,7-epoxyisobenzofuran-1,3-dione
mfcd00134968
SR-01000597585-1
sr-01000597585
AC-7967
DB12328
Q410884
cantharidin:4,7-epoxyisobenzofuran-1,3-dione,hexahydro-3a,7a- dimethyl-, (3a,4,7,7a)-,
(3ar,4s,7r,7as)-3a,7a-dimethylhexahydro-4,7-epoxyisobenzofuran-1,3-dione
HMS3676J13
AS-18735
BCP09819
HMS3412J13
NCGC00025212-31
AMY33451
D11745
cantharidin (usan)
4,7-epoxyisobenzofuran-1,3-dione, hexahydro-3a,7a-dimethyl-,(3ar,4s,7r,7as)-rel-
hexahydro-3a,7a-dimethyl-4,7-epoxyisobenzo-furan-1,3-dione
(1s,2r,6s,7r)-2,6-dimethyl-4,10-dioxatricyclo[5.2.1.02,6]decane-3,5-dione
EN300-24727854
(1r,2s,6r,7s)-2,6-dimethyl-4,10-dioxatricyclo[5.2.1.0,2,6]decane-3,5-dione
LS-13796
HMS3268C21
BRD-A43076080-001-03-3
80558-50-5
nsc190421
nsc-190421
4,7-epoxyisobenzofuran-1,3-dione, hexahydro-3a,7a-dimethyl-, (3a.alpha.,4.beta.,7.beta.,7a.alpha.)-
EU-0100248
nsc 61805
4,7-epoxyisobenzofuran-1,3-dione, hexahydro-3a,7a-dimethyl-, (3aalpha,4beta,7beta,7aalpha)-
4,7-epoxyisobenzofuran-1,3-dione, hexahydro-3a,7a-dimethyl-
BIO1_000380
BIO1_001358
BIO2_000266
BIO1_000869
BIO2_000746
BSPBIO_001546
LOPAC0_000248
NCGC00093710-04
NCGC00093710-02
hexahydro-3a,7a-dimethyl-4,7-epoxyisobenzofuran-1,3-dione
KBIO2_002834
KBIOGR_000266
KBIO3_000531
KBIOSS_000266
KBIO3_000532
KBIO2_000266
KBIO2_005402
IDI1_034016
NCGC00093710-01
NCGC00093710-03
NCGC00093710-05
NCGC00015266-03
C 7632
HMS1989N08
NCGC00015266-08
CHEMBL8066
BMK1-G12
HMS1791N08
HMS1361N08
HMS3260B18
can [alkaloid]
CCG-204343
4,7-epoxyisobenzofuran-1,3-dione, hexahydro-3a,7a-dimethyl-, (3aalpha,4alpha,7alpha,7aalpha)
nsc 190421
NCGC00015266-05
NCGC00015266-10
NCGC00015266-07
NCGC00015266-06
NCGC00015266-09
NCGC00015266-04
LP00248
PR-105
2,6-dimethyl-4,10-dioxatricyclo-[5.2.1.02,6]decane-3,5-dione
NCGC00260933-01
tox21_500248
SCHEMBL1805181
AKOS024282737
7-oxabicyclo[2.2.1]heptane-2,3-dicarboxylic anhydride, 2,3-dimethyl-
HMS3402N08
SR-01000075779-1
sr-01000075779
CHEBI:93862
SR-01000075779-6
SR-01000075779-7
SR-01000075779-8
2,3-dimethyl-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxylic acid anhydride
lsm-4433
Q27165615
DTXSID10858998
10385-74-7
SDCCGSBI-0050236.P002
2,6-dimethyl-4,10-dioxatricyclo[5.2.1.02,6]decane-3,5-dione
cantharidin; dimethyl-3,6-epoxyperhydrophthalic anhydride; (1r,2s,3r,6s)-1,2-dimethyl-3,6-epoxycyclohexane-1,2-dicarboxylic anhydride

Research Excerpts

Toxicity

The results contribute to the data supporting cantharidin as a safe and effective treatment of molluscum contagiosum. However, clinical application of canthAridin is relatively restricted due to its potential toxic effects, especially hepatotoxicity.

ExcerptReferenceRelevance
" The findings of damaged mitochondria in the cantharidin treated Hep 3B cells in this study suggest that cantharidin can induce acute and lethal toxic effects on Hep 3B cells by inhibiting the mitochondria energy system."( Cytotoxic effects of cantharidin on the growth of normal and carcinoma cells.
Hsieh, KJ; Wang, CC; Wu, CH; Yang, LL; Yen, KY, 2000
)
0.31
" Although previous experimental studies have demonstrated that histone deacetylase (HDAC) inhibitors are therapeutically active, known HDAC inhibitors have considerable adverse effects clinically."( Cytoprotective effect of novel histone deacetylase inhibitors against polyglutamine toxicity.
Asai, H; Fujikake, N; Furiya, Y; Hirano, M; Kariya, S; Nagai, Y; Nagaoka, Y; Toda, T; Ueno, S; Uesato, S, 2006
)
0.33
" The toxic effects of mylabris on bladder are attributed to its active principle: cantharidin."( Cantharidin-induced cytotoxicity and cyclooxygenase 2 expression in human bladder carcinoma cell line.
Huan, SK; Lee, HH; Liu, DZ; Wang, CC; Wu, CC, 2006
)
0.33
"A remarkable control of the potency of cantharimide is described based on the electronic properties of functional group and it exhibits a relatively less toxic effect to the non-malignant hematological disorder bone marrow cells."( Synthesis and structure evaluation of a novel cantharimide and its cytotoxicity on SK-Hep-1 hepatoma cells.
Chan, AS; Chen, J; Cheng, GY; Chui, CH; Kok, SH; Lai, PB; Lam, WS; Lau, FY; Leung, TW; Tang, JC; Wong, RS; Yu, MW, 2007
)
0.34
" A total of 54 were available for follow-up by telephone interview regarding adverse effects, parental satisfaction, and overall clearance of the infection."( Parental satisfaction, efficacy, and adverse events in 54 patients treated with cantharidin for molluscum contagiosum infection.
Cathcart, S; Coloe, J; Morrell, DS, 2009
)
0.35
" Overall, 46% of patients experienced adverse events, including pain, pruritus, secondary infection, brisk immune response, and temporary hypopigmentation and 9% experienced an adverse event that they classified as severe."( Parental satisfaction, efficacy, and adverse events in 54 patients treated with cantharidin for molluscum contagiosum infection.
Cathcart, S; Coloe, J; Morrell, DS, 2009
)
0.35
"The results contribute to the data supporting cantharidin as a safe and effective treatment of molluscum contagiosum."( Parental satisfaction, efficacy, and adverse events in 54 patients treated with cantharidin for molluscum contagiosum infection.
Cathcart, S; Coloe, J; Morrell, DS, 2009
)
0.35
" Information related to treatment with cantharidin and adverse effects was abstracted from medical records."( Safety of cantharidin: a retrospective review of cantharidin treatment in 405 children with molluscum contagiosum.
Cathcart, S; Morrell, DS; Moye, VA,
)
0.13
" Adverse effects on the gastrointestinal tract also were lower than in controls (p<0."( Safety of Brucea javanica and cantharidin combined with chemotherapy for treatment of NSCLC patients.
Huang, XE; Ji, ZQ; Liu, J; Tang, JH; Wang, L; Wu, XY, 2014
)
0.4
" Concurrently, the growth curve of photosynthetic bacteria was used to determine the inoculation amount of the photosynthetic bacteria and the safe concentration of cantharis."( Cantharis by photosynthetic bacteria biotransformation: Reduced toxicity and improved antitumor efficacy.
Yu, M; Zhao, Y, 2016
)
0.43
" Information related to treatment with CPS and adverse effects was abstracted from medical records."( Safety and effectiveness of cantharidin-podophylotoxin-salicylic acid in the treatment of recalcitrant plantar warts.
Álvarez Castro, C; Becerro de Bengoa Vallejo, R; García Sánchez, MM; López López, D; Losa Iglesias, ME; Romero Morales, C; Vilar Fernández, JM, 2016
)
0.43
" In conclusion, the results of this study revealed the toxicity of cantharidin against house flies and the adverse effects of sublethal concentrations on biological parameters which may have positive implications for effective management of house flies."( Toxicity and Sublethal Effects of Cantharidin on Musca domestica (Diptera: Muscidae).
Ali Khan, HA; Yasoob, H; Zhang, Y, 2017
)
0.46
" Secondary outcomes included post-treatment lesion count, adverse events, and side effects."( Safety and efficacy of topical cantharidin for the treatment of pediatric molluscum contagiosum: a prospective, randomized, double-blind, placebo-controlled pilot trial.
Cohen, SR; Garelik, JL; Guzman, AK; Schairer, DO, 2018
)
0.48
"3%) were the most commonly occurring adverse effects with cantharidin treatment."( Efficacy and Safety of Topical Cantharidin Treatment for Molluscum Contagiosum and Warts: A Systematic Review.
Chopra, R; Silverberg, JI; Silverberg, NB; Vakharia, PP, 2018
)
0.48
" However, clinical application of cantharidin is relatively restricted due to its potential toxic effects, especially hepatotoxicity."( UPLC-Q-TOF/MS Based Metabolomics Approach to Study the Hepatotoxicity of Cantharidin on Mice.
Dai, YL; Liu, SW; Long, R; Song, T; Zhang, L; Zhang, P; Zhu, SS, 2019
)
0.51
" Safety outcomes included assessment of adverse events, including expected local skin reactions."( Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials.
Brabec, B; Burnett, P; Davidson, M; Eichenfield, LF; Kwong, P; McBride, M; McFalda, W; Rieger, J; Siegfried, E; Willson, C, 2020
)
0.56
" Adverse events were observed in 99% (CAMP-1) and 95% (CAMP-2) of VP-102-treated participants and 73% (CAMP-1) and 66% (CAMP-2) of vehicle-treated participants."( Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials.
Brabec, B; Burnett, P; Davidson, M; Eichenfield, LF; Kwong, P; McBride, M; McFalda, W; Rieger, J; Siegfried, E; Willson, C, 2020
)
0.56
"In the 2 phase 3 trials reported herein, VP-102 was statistically significantly superior to vehicle in achieving complete clearance of MC lesions at the end of the study visit in both trials, with adverse events that were generally mild to moderate and confined to application sites."( Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials.
Brabec, B; Burnett, P; Davidson, M; Eichenfield, LF; Kwong, P; McBride, M; McFalda, W; Rieger, J; Siegfried, E; Willson, C, 2020
)
0.56
" However, its clinical application is relatively limited due to its potential toxic effects, especially nephrotoxicity."( Analysis of cantharidin-induced nephrotoxicity in HK-2 cells using untargeted metabolomics and an integrative network pharmacology analysis.
Duan, C; He, T; Li, X; Liu, J; Wang, X; Zhang, J, 2020
)
0.56
" Adverse events experienced by the VP-102-treated participants were consistent with the pharmacodynamic action of cantharidin as a vesicant and were primarily mild to moderate in severity."( Phase II, Double-Blind, Vehicle-Controlled Study to Determine the Cantharidin Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts.
Andres, J; Eads, K; Glover, DK; Guenthner, S; McFalda, W; Olivadoti, M; Rieger, J; Rosen, T; Rumney, P; Tate, M; Willson, C, 2021
)
0.62
"The adverse event profile and efficacy of VP-102 under occlusion demonstrated in this study support the conclusion that a 6-h or up to 24-h exposure regimen represents an acceptable risk:benefit profile and justifies the conduct of a larger vehicle-controlled phase III study in external genital warts."( Phase II, Double-Blind, Vehicle-Controlled Study to Determine the Cantharidin Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts.
Andres, J; Eads, K; Glover, DK; Guenthner, S; McFalda, W; Olivadoti, M; Rieger, J; Rosen, T; Rumney, P; Tate, M; Willson, C, 2021
)
0.62
" In this study, we proved that activation of the endoplasmic reticulum (ER) stress-dependent PERK/CHOP pathway exerts a toxic role in rats and HK-2 cells through inducing autophagy and apoptosis."( Endoplasmic reticulum stress contributes to autophagy and apoptosis in cantharidin-induced nephrotoxicity.
Ao, J; Chen, K; Duan, C; He, T; Li, X; Wang, Q; Zhang, J, 2022
)
0.72
" However, the clinical use of NCTD is limited due to its poor solubility, low bioavailability, and toxic effects on normal cells."( Strategies for Solubility and Bioavailability Enhancement and Toxicity Reduction of Norcantharidin.
Li, X; Liu, Q; Sheng, H; Sun, H; Zhu, L, 2022
)
0.72
" In this study, we investigated the toxic effects in mouse kidneys following CTD treatment by pathological and ultrastructure observations, biochemical index detection, and transcriptomics, and explored the underlying molecular mechanisms by RNA sequencing (RNA-seq)."( Transcriptomic profiling and differential analysis reveal the renal toxicity mechanisms of mice under cantharidin exposure.
Liu, X; Shen, Q; Tang, W; Xiang, P; Xiao, Y; Ye, T; Zhang, L; Zhang, T, 2023
)
0.91

Pharmacokinetics

The main pharmacokinetic parameters of cantharidin by iv in dogs (34 mL x h(-1) x kg(-1)) were AUC (203.5 mg/h) and CUC (204.4 mg/H) We present a simple, sensitive, and reliable gas chromatography-mass spectrometry (GC-MS) method to monitor the plasma canthAridin.

ExcerptReferenceRelevance
" The mean peak concentration in plasma of 10."( Single-dose pharmacokinetics and penetration of BMS 284756 into an inflammatory exudate.
Andrews, JM; Gee, T; Marshall, G; Wise, R, 2002
)
0.31
"The pharmacokinetic disposition of meropenem, administered at 500 mg every 8 h, in plasma and cantharidin-induced blister fluid is described."( Pharmacokinetic profile of meropenem, administered at 500 milligrams every 8 hours, in plasma and cantharidin-induced skin blister fluid.
Maglio, D; Nicolau, DP; Nightingale, CH; Teng, R; Thyrum, PT, 2003
)
0.32
"The mean (SD) peak concentration of dalbavancin in plasma and blister fluid was 285 (31."( Pharmacokinetics of dalbavancin in plasma and skin blister fluid.
Buckwalter, M; Dowell, JA; Nicolau, DP; Seltzer, E; Sun, HK, 2007
)
0.34
" These pharmacokinetic data support the use of dalbavancin in the treatment of cSSSIs caused by susceptible Gram-positive pathogens."( Pharmacokinetics of dalbavancin in plasma and skin blister fluid.
Buckwalter, M; Dowell, JA; Nicolau, DP; Seltzer, E; Sun, HK, 2007
)
0.34
" Here, we present a simple, sensitive, and reliable gas chromatography-mass spectrometry (GC-MS) method to monitor the plasma cantharidin and perform the pharmacokinetic study of cantharidin in beagle dogs."( Determination of trace cantharidin in plasma and pharmacokinetic study in beagle dogs using gas chromatography-mass spectrometry.
Dang, YJ; Zhu, CY, 2009
)
0.35
"To study the pharmacokinetics and bioavailability of cantharidin in beagle dogs to evaluate the pharmacokinetic parameters and bioavailability of cantharidin in beagle dogs by determining dose-time curve and by comparing with the pharmacokinetics of cantharidin injection."( [Pharmacokinetics and bioavailability of cantharidin in beagle dogs].
Dang, Y; Zhu, C, 2009
)
0.35
" The WinNonLin program was used to calculate the pharmacokinetic parameters and bioavailability."( [Pharmacokinetics and bioavailability of cantharidin in beagle dogs].
Dang, Y; Zhu, C, 2009
)
0.35
"The main pharmacokinetic parameters of cantharidin by iv in dogs (34 mL x h(-1) x kg(-1)) were AUC (203."( [Pharmacokinetics and bioavailability of cantharidin in beagle dogs].
Dang, Y; Zhu, C, 2009
)
0.35
" It can be used for determination of N-methylcantharidimide in dogs' plasma and pharmacokinetic studies."( [Determination of plasma concentration of N-methylcantharidimide by HPLC and its pharmacokinetics after intravenous administration in dogs].
Luo, X; Wu, X, 2010
)
0.36

Compound-Compound Interactions

Cartharidin sodium and Shenmai injection combined with chemotherapy in treating patients with breast cancer postoperatively. To study the synergistic effect on hepatoma cell.

ExcerptReferenceRelevance
"Transcatheter arterial embolization (TAE) using hydroxycamptothecin, cantharidin and cisplatin which were mixed thoroughly with lipiodol, combined with large doses interferon and interleukin-2 as adoptive immunotherapy were carried out in the treatment of 48 patients with unresectable advanced stage primary hepatoma, evaluation of therapeutic effect showed that partial remission rate was 54."( [Chinese material medica combined with cisplatin and lipiodol through transcatheter arterial embolization in the treatment of primary hepatoma].
Yu, ZJ, 1993
)
0.29
"To assess the efficacy, side effects, and the impact on quality of life with Qinin® (Cantharidin sodium) injection combined with chemotherapy for gastric cancer patients."( Clinical study on safety and efficacy of Qinin® (cantharidin sodium) injection combined with chemotherapy in treating patients with gastric cancer.
Cao, J; Huang, XE; Liu, J; Lu, YY; Wu, XY; Xiang, J; Xu, L; Xu, X; Ye, LH; Zhan, YP, 2012
)
0.38
"A consecutive cohort of 70 patients were divided into two groups: experimental group with cantharidin sodium injection combined with chemotherapy, while the control group received chemotherapy alone."( Clinical study on safety and efficacy of Qinin® (cantharidin sodium) injection combined with chemotherapy in treating patients with gastric cancer.
Cao, J; Huang, XE; Liu, J; Lu, YY; Wu, XY; Xiang, J; Xu, L; Xu, X; Ye, LH; Zhan, YP, 2012
)
0.38
"Qinin® (Cantharidin sodium) injection combined with chemotherapy enhances clinical benefit response, improving quality of life of gastric cancer patients and reducing side effects of chemotherapy."( Clinical study on safety and efficacy of Qinin® (cantharidin sodium) injection combined with chemotherapy in treating patients with gastric cancer.
Cao, J; Huang, XE; Liu, J; Lu, YY; Wu, XY; Xiang, J; Xu, L; Xu, X; Ye, LH; Zhan, YP, 2012
)
0.38
"To assess side effects on Cantharidin sodium and Shenmai injection combined with chemotherapy in treating patients with breast cancer postoperatively."( Clinical study on safety of cantharidin sodium and shenmai injection combined with chemotherapy in treating patients with breast cancer postoperatively.
Cao, J; Huang, XE; Wang, L, 2014
)
0.4
"Patients with breast cancer receiving postoperative chemotherapy were retrospectively collected, and divided into four groups: group A with cantharidin sodium injection combined with chemotherapy; group B with Shenmai injection combined with chemotherapy; group C with both cantharidin sodium and Shenmai injection combined with chemotherapy; while group D (control group) received chemotherapy alone."( Clinical study on safety of cantharidin sodium and shenmai injection combined with chemotherapy in treating patients with breast cancer postoperatively.
Cao, J; Huang, XE; Wang, L, 2014
)
0.4
"Thus cantharidin sodium and Shenmai injection combined with chemotherapy reduce side effects and deserve to be further investigated in randomized clinical control trials."( Clinical study on safety of cantharidin sodium and shenmai injection combined with chemotherapy in treating patients with breast cancer postoperatively.
Cao, J; Huang, XE; Wang, L, 2014
)
0.4
"To assess the safety of Brucea javanica and Cantharidin combined with chemotherapy in treating patients with non-small-cell lung carcinoma."( Safety of Brucea javanica and cantharidin combined with chemotherapy for treatment of NSCLC patients.
Huang, XE; Ji, ZQ; Liu, J; Tang, JH; Wang, L; Wu, XY, 2014
)
0.4
"A consecutive cohort of patients with NSCLC were divided into four groups: experimental group A treated with Brucea javanica injection combined with chemotherapy; experimental group B with Cantharidin injection combined with chemotherapy; experimental group C treated with Brucea javanica and Cantharidin injection combined with chemotherapy; and the control group receiving only chemotherapy."( Safety of Brucea javanica and cantharidin combined with chemotherapy for treatment of NSCLC patients.
Huang, XE; Ji, ZQ; Liu, J; Tang, JH; Wang, L; Wu, XY, 2014
)
0.4
"Brucea javanica or Cantharidin combined with chemotherapy could in both cases improve quality of life in our cohort of NSCLC patients without any increase in toxicity."( Safety of Brucea javanica and cantharidin combined with chemotherapy for treatment of NSCLC patients.
Huang, XE; Ji, ZQ; Liu, J; Tang, JH; Wang, L; Wu, XY, 2014
)
0.4
"This systematic analysis was conducted to evaluate the efficacy and safety of cantharidin combined with chemotherapy in treating Chinese patients with metastatic colorectal cancer."( Cantharidin combined with chemotherapy for Chinese patients with metastatic colorectal cancer.
Chen, X; Ding, H; Han, L; Pan, YF; Sun, YJ; Zhang, X, 2014
)
0.4
"Clinical studies evaluating the efficacy and safety of cantharidin combined with chemotherapy on response and safety for Chinese patients with colorectal cancer were identified using a predefined search strategy."( Cantharidin combined with chemotherapy for Chinese patients with metastatic colorectal cancer.
Chen, X; Ding, H; Han, L; Pan, YF; Sun, YJ; Zhang, X, 2014
)
0.4
"When cantharidin combined with chemotherapy, 4 clinical studies which included 155 patients with advanced colorectal cancer were considered eligible for inclusion."( Cantharidin combined with chemotherapy for Chinese patients with metastatic colorectal cancer.
Chen, X; Ding, H; Han, L; Pan, YF; Sun, YJ; Zhang, X, 2014
)
0.4
"To evaluate the efficacy of mannatide combined with sodium cantharidate vitamin B6 in the treatment of malignant pleural effusions."( Efficacy of mannatide combined with sodium cantharidate vitamin B6 in the treatment of malignant pleural effusions.
Song, J; Wang, LZ; Zhang, HJ, 2015
)
0.42
" Injection into the thorax using mannatide combined with sodium cantharidate vitamin B6 was performed for 37 patients in the experimental group and mannatide combined with cisplatin for 32 patients in the control group."( Efficacy of mannatide combined with sodium cantharidate vitamin B6 in the treatment of malignant pleural effusions.
Song, J; Wang, LZ; Zhang, HJ, 2015
)
0.42
"Regimen of mannatide combined with sodium cantharidate vitamin B6 had better improvement in quality-of-life and symptom relief, with a lower side-effect incidence in treatment of malignant pleural effusions."( Efficacy of mannatide combined with sodium cantharidate vitamin B6 in the treatment of malignant pleural effusions.
Song, J; Wang, LZ; Zhang, HJ, 2015
)
0.42
"To study the synergistic effect on hepatoma cell(SMMC-7721) and the reduction killing effect on normal liver cells(LO-2) treated with sodium cantharidinate (SCA) in combination with fluorouracil(5-FU) or cisplatin(DDP) as well as the related mechanism."( [Study on synergistic effect of sodium cantharidinate combined with chemotherapeutic drugs on hepatic carcinoma and its effective mechanism].
Chen, MJ; Xu, DQ; Zhang, X; Zhao, FM; Zhao, RL; Zhou, KF, 2014
)
0.4
" In the present study, the hepatotoxicity of CTD in the rat was investigated using a metabolomic approach combined with conventional pathology methods."( Study on the mechanism of cantharidin-induced hepatotoxicity in rat using serum and liver metabolomics combined with conventional pathology methods.
Chen, K; Chen, Q; Duan, C; Li, X; Mu, W; Wang, L; Zhang, J, 2020
)
0.56

Bioavailability

To study the pharmacokinetic parameters and bioavailability of cantharidin in beagle dogs. To evaluate the dose-time curve and by comparing with the  pharmacokinetics of canthAridin injection.

ExcerptReferenceRelevance
"To study the pharmacokinetics and bioavailability of cantharidin in beagle dogs to evaluate the pharmacokinetic parameters and bioavailability of cantharidin in beagle dogs by determining dose-time curve and by comparing with the pharmacokinetics of cantharidin injection."( [Pharmacokinetics and bioavailability of cantharidin in beagle dogs].
Dang, Y; Zhu, C, 2009
)
0.35
"As compared with cantharidin injection, the absorption of catharidin by op is poor and the bioavailability is also low, indicating that enhancement of the bioavailability will be beneficial to the clinical application."( [Pharmacokinetics and bioavailability of cantharidin in beagle dogs].
Dang, Y; Zhu, C, 2009
)
0.35
" The physicochemical properties of this solid dispersion (SD) were evaluated immediately after preparation by differential scanning calorimetry (DSC), powder X-ray diffraction (PXRD) and scanning electron microscopy (SEM), and the oral in vivo bioavailability was studied."( Study of the physicochemical properties and oral bioavailability of the solid dispersion of cantharidin with polyethylene glycol 4000.
An, LN; Dang, YJ; Hu, CH; Zhu, CY, 2010
)
0.36
" Water solubility and bioavailability could be improved by opening the five fivemembered anhydride ring to form carboxylic acid, salt, amide, and ester derivatives."( Exploring Cantharidin and its Analogues as Anticancer Agents: A Review.
Deng, L; Du, K; Fan, G; Li, S; Wu, X, 2023
)
0.91
" This review summarizes the structure-activity relationship of NCTD and novel strategies to improve the solubility and bioavailability of NCTD as well as reduce the toxicity."( Strategies for Solubility and Bioavailability Enhancement and Toxicity Reduction of Norcantharidin.
Li, X; Liu, Q; Sheng, H; Sun, H; Zhu, L, 2022
)
0.72

Dosage Studied

Cantharidin (CTD) is a promising anticancer drug. Its dosage is limited by hepatotoxicity.

ExcerptRelevanceReference
" Thus, the chosen dosage regimens considered apt for gonorrhea led to high initial as well as long-standing drug levels."( Plasma and skin blister fluid levels of cefotiam and cefmenoxime after single intramuscular application of 1 g in gonorrhea.
Korting, HC, 1984
)
0.27
"Crystalline cantharidin in an alfalfa cake or in aqueous suspension was given to 8 horses at a dosage level of 450 to 489 micrograms/kg of body weight (group 1) and 2 horses at a dosage level of 720 micrograms/kg (group 2) via nasogastric tube."( Experimental cantharidiasis in the horse.
Rolf, LL; Shawley, RV, 1984
)
0.27
" The dose-response relationship was determined, and the validity of the tetrazolium test was confirmed."( Dose response in the tetrazolium test for skin carcinogenicity.
Iversen, OH, 1980
)
0.26
" The dose-response and temporal analysis of CGRP effect show that the maximal activity is present at the dose of 30 pmol/ear and when administered 30 min after the irritating agent."( Effects of CGRP in different models of mouse ear inflammation.
Amico-Roxas, M; Caruso, A; Catena Cutuli, VM; Clementi, G; de Bernardis, E; Maugeri, S; Prato, A; Scapagnini, U, 1994
)
0.29
" Our data suggest that gatifloxacin dosed at 400 mg od should be adequate to treat systemic infections caused by most bacterial species."( A study to determine the pharmacokinetics and inflammatory fluid penetration of gatifloxacin following a single oral dose.
Andrews, JM; Ashby, JP; Marshall, J; Wise, R, 1999
)
0.3
" Here, dose-response studies confirm a strong correlation between the suppression of phosphatase activity and cell death."( Cantharidin-induced mitotic arrest is associated with the formation of aberrant mitotic spindles and lagging chromosomes resulting, in part, from the suppression of PP2Aalpha.
Aragon, IV; Bonness, K; Dean, NM; Honkanen, RE; Ofori-Acquah, S; Rutland, B, 2006
)
0.33
" Another two methods were also used to reduce the dosage of cantharidin, including labeling liposomal cantharidin with octreotide and exposing cells to hyperbaric oxygen."( Liposome encapsulation reduces cantharidin toxicity.
Chang, CC; Chang, CH; Ho, FM; Hou, WC; Huang, WJ; Liang, HJ; Liang, YC; Lin, SY; Liu, DZ, 2008
)
0.35
" Thus, we hypothesized that Mad2 overexpression could specifically make cancer cells susceptible to death by inducing a synthetic dosage lethality defect."( Synthetic genetic array screen identifies PP2A as a therapeutic target in Mad2-overexpressing tumors.
Bansal, PK; Bian, Y; Fujii, Y; Kitagawa, K; Kitagawa, R; Stepanov, A, 2014
)
0.4
" Here we use synthetic dosage lethality (SDL), where the overexpression of PLK1 is lethal only when another, normally non-lethal, mutation or deletion is present."( Therapeutic relevance of the protein phosphatase 2A in cancer.
Abuhussein, O; Alli, N; Anderson, DH; Bhanumathy, KK; Bonham, K; Boyd, F; Cunningham, CE; El Zawily, AM; Freywald, A; Furber, L; Geyer, R; Lee, JS; Li, S; McDonald, M; Mousseau, DD; Parameswaran, S; Paul, JM; Ruppin, E; Sablina, A; Shukla, H; Templeton, SD; Uppalapati, M; Vizeacoumar, FJ; Vizeacoumar, FS; Weaver, BA; Yan, J; Yu-Lee, LY, 2016
)
0.43
"Cantharidin (CTD) is a promising anticancer drug; however, its dosage is limited by hepatotoxicity."( Protective mechanism of Astragalus Polysaccharides against Cantharidin-induced liver injury determined in vivo by liquid chromatography/mass spectrometry metabolomics.
Chen, Y; Huang, X; Li, W; Lin, C; Liu, J; Sa, Z; Tang, W; Wang, L; Xu, M; Yang, C, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitorAny EC 3.1.3.* (phosphoric monoester hydrolase) inhibitor that interferes with the action of phosphoprotein phosphatase (EC 3.1.3.16).
herbicideA substance used to destroy plant pests.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
monoterpenoidAny terpenoid derived from a monoterpene. The term includes compounds in which the C10 skeleton of the parent monoterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
cyclic dicarboxylic anhydrideAn acid anhydride derived by loss of water between two carboxylic groups in the same molecule so as to close a ring.
furofuranOrganic heterobicyclic compounds containing a two furan rings ortho-fused to each other.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (40)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PPM1D proteinHomo sapiens (human)Potency5.86820.00529.466132.9993AID1347411
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency2.51190.00137.762544.6684AID914; AID915
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency10.00000.316212.443531.6228AID924
mitogen-activated protein kinase 1Homo sapiens (human)Potency10.43040.039816.784239.8107AID1454; AID995
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency5.01190.00798.23321,122.0200AID2546
gemininHomo sapiens (human)Potency0.90350.004611.374133.4983AID624296
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency1.99530.005612.367736.1254AID624032; AID624044
survival motor neuron protein isoform dHomo sapiens (human)Potency10.00000.125912.234435.4813AID1458
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency15.84890.251215.843239.8107AID504327
lamin isoform A-delta10Homo sapiens (human)Potency1.12200.891312.067628.1838AID1487
Interferon betaHomo sapiens (human)Potency5.86820.00339.158239.8107AID1347411
Integrin beta-3Homo sapiens (human)Potency10.00000.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency10.00000.316211.415731.6228AID924
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.05010.003245.467312,589.2998AID2517
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency39.81070.177814.390939.8107AID2147
ATAD5 protein, partialHomo sapiens (human)Potency8.74150.004110.890331.5287AID493106; AID493107
Fumarate hydrataseHomo sapiens (human)Potency3.98110.00308.794948.0869AID1347053
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency5.62340.28189.721235.4813AID2326
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency12.70290.001530.607315,848.9004AID1224819; AID1224820; AID1224821; AID1224823
polyproteinZika virusPotency3.98110.00308.794948.0869AID1347053
ParkinHomo sapiens (human)Potency7.30780.819914.830644.6684AID720573
arylsulfatase AHomo sapiens (human)Potency0.84921.069113.955137.9330AID720538
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.04470.540617.639296.1227AID2364; AID2528
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency36.62570.01262.451825.0177AID485313
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency21.331323.934123.934123.9341AID1967
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency19.78310.316212.443531.6228AID902; AID924
atrial natriuretic peptide receptor 1 precursorHomo sapiens (human)Potency26.85450.134610.395030.1313AID1347049
mitogen-activated protein kinase 1Homo sapiens (human)Potency35.71680.039816.784239.8107AID1454; AID995
atrial natriuretic peptide receptor 2 precursorHomo sapiens (human)Potency14.68920.00669.809418.4927AID1347050
flap endonuclease 1Homo sapiens (human)Potency37.68580.133725.412989.1251AID588795
ras-related protein Rab-9AHomo sapiens (human)Potency19.95260.00022.621531.4954AID485297
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency13.68100.00378.618923.2809AID2660; AID2666; AID2667; AID2668
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency11.22020.00798.23321,122.0200AID2551
gemininHomo sapiens (human)Potency1.99530.004611.374133.4983AID463097
survival motor neuron protein isoform dHomo sapiens (human)Potency7.41660.125912.234435.4813AID1458
lamin isoform A-delta10Homo sapiens (human)Potency3.35280.891312.067628.1838AID1459; AID1487
Integrin beta-3Homo sapiens (human)Potency7.94330.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency7.94330.316211.415731.6228AID924
Alpha-synucleinHomo sapiens (human)Potency4.61090.56239.398525.1189AID652106
D(1A) dopamine receptorSus scrofa (pig)Potency4.64510.00378.108123.2809AID2667
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency10.00001.000010.475628.1838AID1457
Ataxin-2Homo sapiens (human)Potency7.07950.011912.222168.7989AID588378
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.75690.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Protein phosphatase 1BHomo sapiens (human)IC50 (µMol)1.78000.00031.51235.3100AID164498
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)IC50 (µMol)3.60000.00053.49849.7600AID164503
Serine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)IC50 (µMol)1.78000.00000.15921.7800AID200722
Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B Gallus gallus (chicken)IC50 (µMol)0.63000.00010.41982.9000AID164510; AID200731; AID200735; AID200737
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (290)

Processvia Protein(s)Taxonomy
protein dephosphorylationProtein phosphatase 1BHomo sapiens (human)
N-terminal protein myristoylationProtein phosphatase 1BHomo sapiens (human)
negative regulation of interferon-beta productionProtein phosphatase 1BHomo sapiens (human)
peptidyl-threonine dephosphorylationProtein phosphatase 1BHomo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionProtein phosphatase 1BHomo sapiens (human)
negative regulation of defense response to virusProtein phosphatase 1BHomo sapiens (human)
negative regulation of non-canonical NF-kappaB signal transductionProtein phosphatase 1BHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayProtein phosphatase 1BHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
positive regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of endocytosisTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulum unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of intracellular protein transportTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cellular response to unfolded proteinTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of protein tyrosine kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of receptor catabolic processTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
MAPK cascadeSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
blastocyst developmentSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
glycogen metabolic processSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
protein dephosphorylationSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
spermatogenesisSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
neuron differentiationSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
circadian regulation of gene expressionSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
regulation of circadian rhythmSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
entrainment of circadian clock by photoperiodSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
regulation of nucleocytoplasmic transportSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
cell divisionSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
positive regulation of glial cell proliferationSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
mitotic sister chromatid segregationSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
cognitionAmyloid-beta precursor proteinHomo sapiens (human)
G2/M transition of mitotic cell cycleAmyloid-beta precursor proteinHomo sapiens (human)
microglial cell activationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of protein phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
suckling behaviorAmyloid-beta precursor proteinHomo sapiens (human)
astrocyte activation involved in immune responseAmyloid-beta precursor proteinHomo sapiens (human)
regulation of translationAmyloid-beta precursor proteinHomo sapiens (human)
protein phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
intracellular copper ion homeostasisAmyloid-beta precursor proteinHomo sapiens (human)
endocytosisAmyloid-beta precursor proteinHomo sapiens (human)
response to oxidative stressAmyloid-beta precursor proteinHomo sapiens (human)
cell adhesionAmyloid-beta precursor proteinHomo sapiens (human)
regulation of epidermal growth factor-activated receptor activityAmyloid-beta precursor proteinHomo sapiens (human)
Notch signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
axonogenesisAmyloid-beta precursor proteinHomo sapiens (human)
learning or memoryAmyloid-beta precursor proteinHomo sapiens (human)
learningAmyloid-beta precursor proteinHomo sapiens (human)
mating behaviorAmyloid-beta precursor proteinHomo sapiens (human)
locomotory behaviorAmyloid-beta precursor proteinHomo sapiens (human)
axo-dendritic transportAmyloid-beta precursor proteinHomo sapiens (human)
cholesterol metabolic processAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of cell population proliferationAmyloid-beta precursor proteinHomo sapiens (human)
adult locomotory behaviorAmyloid-beta precursor proteinHomo sapiens (human)
visual learningAmyloid-beta precursor proteinHomo sapiens (human)
regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of peptidyl-threonine phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleAmyloid-beta precursor proteinHomo sapiens (human)
microglia developmentAmyloid-beta precursor proteinHomo sapiens (human)
axon midline choice point recognitionAmyloid-beta precursor proteinHomo sapiens (human)
neuron remodelingAmyloid-beta precursor proteinHomo sapiens (human)
dendrite developmentAmyloid-beta precursor proteinHomo sapiens (human)
regulation of Wnt signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
extracellular matrix organizationAmyloid-beta precursor proteinHomo sapiens (human)
forebrain developmentAmyloid-beta precursor proteinHomo sapiens (human)
neuron projection developmentAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of chemokine productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of interleukin-1 beta productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of interleukin-6 productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of tumor necrosis factor productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
regulation of multicellular organism growthAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of neuron differentiationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of glycolytic processAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of mitotic cell cycleAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of JNK cascadeAmyloid-beta precursor proteinHomo sapiens (human)
astrocyte activationAmyloid-beta precursor proteinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAmyloid-beta precursor proteinHomo sapiens (human)
collateral sprouting in absence of injuryAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of inflammatory responseAmyloid-beta precursor proteinHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
regulation of synapse structure or activityAmyloid-beta precursor proteinHomo sapiens (human)
synapse organizationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of calcium-mediated signalingAmyloid-beta precursor proteinHomo sapiens (human)
neuromuscular process controlling balanceAmyloid-beta precursor proteinHomo sapiens (human)
synaptic assembly at neuromuscular junctionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of protein metabolic processAmyloid-beta precursor proteinHomo sapiens (human)
neuron apoptotic processAmyloid-beta precursor proteinHomo sapiens (human)
smooth endoplasmic reticulum calcium ion homeostasisAmyloid-beta precursor proteinHomo sapiens (human)
neuron cellular homeostasisAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeAmyloid-beta precursor proteinHomo sapiens (human)
response to interleukin-1Amyloid-beta precursor proteinHomo sapiens (human)
modulation of excitatory postsynaptic potentialAmyloid-beta precursor proteinHomo sapiens (human)
NMDA selective glutamate receptor signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
regulation of spontaneous synaptic transmissionAmyloid-beta precursor proteinHomo sapiens (human)
cytosolic mRNA polyadenylationAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of long-term synaptic potentiationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of long-term synaptic potentiationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionAmyloid-beta precursor proteinHomo sapiens (human)
cellular response to amyloid-betaAmyloid-beta precursor proteinHomo sapiens (human)
regulation of presynapse assemblyAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of amyloid fibril formationAmyloid-beta precursor proteinHomo sapiens (human)
amyloid fibril formationAmyloid-beta precursor proteinHomo sapiens (human)
neuron projection maintenanceAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of T cell migrationAmyloid-beta precursor proteinHomo sapiens (human)
central nervous system developmentAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (78)

Processvia Protein(s)Taxonomy
magnesium ion bindingProtein phosphatase 1BHomo sapiens (human)
protein serine/threonine phosphatase activityProtein phosphatase 1BHomo sapiens (human)
protein bindingProtein phosphatase 1BHomo sapiens (human)
myosin phosphatase activityProtein phosphatase 1BHomo sapiens (human)
manganese ion bindingProtein phosphatase 1BHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
RNA bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
zinc ion bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
enzyme bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein phosphatase 2A bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
RNA bindingSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
phosphoprotein phosphatase activitySerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
protein serine/threonine phosphatase activitySerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
protein bindingSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
lamin bindingSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
protein phosphatase 1 bindingSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
phosphatase activitySerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
myosin phosphatase activitySerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
protein kinase bindingSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
protein domain specific bindingSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
protein-containing complex bindingSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
metal ion bindingSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingAmyloid-beta precursor proteinHomo sapiens (human)
DNA bindingAmyloid-beta precursor proteinHomo sapiens (human)
serine-type endopeptidase inhibitor activityAmyloid-beta precursor proteinHomo sapiens (human)
signaling receptor bindingAmyloid-beta precursor proteinHomo sapiens (human)
protein bindingAmyloid-beta precursor proteinHomo sapiens (human)
heparin bindingAmyloid-beta precursor proteinHomo sapiens (human)
enzyme bindingAmyloid-beta precursor proteinHomo sapiens (human)
identical protein bindingAmyloid-beta precursor proteinHomo sapiens (human)
transition metal ion bindingAmyloid-beta precursor proteinHomo sapiens (human)
receptor ligand activityAmyloid-beta precursor proteinHomo sapiens (human)
PTB domain bindingAmyloid-beta precursor proteinHomo sapiens (human)
protein serine/threonine kinase bindingAmyloid-beta precursor proteinHomo sapiens (human)
signaling receptor activator activityAmyloid-beta precursor proteinHomo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (92)

Processvia Protein(s)Taxonomy
nucleolusProtein phosphatase 1BHomo sapiens (human)
cytosolProtein phosphatase 1BHomo sapiens (human)
membraneProtein phosphatase 1BHomo sapiens (human)
nucleusProtein phosphatase 1BHomo sapiens (human)
cytosolProtein phosphatase 1BHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
plasma membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial matrixTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial cristaTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
sorting endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
chromosome, telomeric regionSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
kinetochoreSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
nucleusSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
nucleolusSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
cytoplasmSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
mitochondrionSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
mitochondrial outer membraneSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
microtubule organizing centerSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
cytosolSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
focal adhesionSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
nuclear speckSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
midbodySerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
cleavage furrowSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
dendritic spineSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
presynapseSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
glutamatergic synapseSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
protein-containing complexSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
PTW/PP1 phosphatase complexSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
nucleusSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
cytoplasmSerine/threonine-protein phosphatase PP1-gamma catalytic subunitHomo sapiens (human)
extracellular spaceAmyloid-beta precursor proteinHomo sapiens (human)
dendriteAmyloid-beta precursor proteinHomo sapiens (human)
extracellular regionAmyloid-beta precursor proteinHomo sapiens (human)
extracellular spaceAmyloid-beta precursor proteinHomo sapiens (human)
nuclear envelope lumenAmyloid-beta precursor proteinHomo sapiens (human)
cytoplasmAmyloid-beta precursor proteinHomo sapiens (human)
mitochondrial inner membraneAmyloid-beta precursor proteinHomo sapiens (human)
endosomeAmyloid-beta precursor proteinHomo sapiens (human)
early endosomeAmyloid-beta precursor proteinHomo sapiens (human)
endoplasmic reticulumAmyloid-beta precursor proteinHomo sapiens (human)
endoplasmic reticulum lumenAmyloid-beta precursor proteinHomo sapiens (human)
smooth endoplasmic reticulumAmyloid-beta precursor proteinHomo sapiens (human)
Golgi apparatusAmyloid-beta precursor proteinHomo sapiens (human)
Golgi lumenAmyloid-beta precursor proteinHomo sapiens (human)
Golgi-associated vesicleAmyloid-beta precursor proteinHomo sapiens (human)
cytosolAmyloid-beta precursor proteinHomo sapiens (human)
plasma membraneAmyloid-beta precursor proteinHomo sapiens (human)
clathrin-coated pitAmyloid-beta precursor proteinHomo sapiens (human)
cell-cell junctionAmyloid-beta precursor proteinHomo sapiens (human)
synaptic vesicleAmyloid-beta precursor proteinHomo sapiens (human)
cell surfaceAmyloid-beta precursor proteinHomo sapiens (human)
membraneAmyloid-beta precursor proteinHomo sapiens (human)
COPII-coated ER to Golgi transport vesicleAmyloid-beta precursor proteinHomo sapiens (human)
axonAmyloid-beta precursor proteinHomo sapiens (human)
growth coneAmyloid-beta precursor proteinHomo sapiens (human)
platelet alpha granule lumenAmyloid-beta precursor proteinHomo sapiens (human)
neuromuscular junctionAmyloid-beta precursor proteinHomo sapiens (human)
endosome lumenAmyloid-beta precursor proteinHomo sapiens (human)
trans-Golgi network membraneAmyloid-beta precursor proteinHomo sapiens (human)
ciliary rootletAmyloid-beta precursor proteinHomo sapiens (human)
dendritic spineAmyloid-beta precursor proteinHomo sapiens (human)
dendritic shaftAmyloid-beta precursor proteinHomo sapiens (human)
perikaryonAmyloid-beta precursor proteinHomo sapiens (human)
membrane raftAmyloid-beta precursor proteinHomo sapiens (human)
apical part of cellAmyloid-beta precursor proteinHomo sapiens (human)
synapseAmyloid-beta precursor proteinHomo sapiens (human)
perinuclear region of cytoplasmAmyloid-beta precursor proteinHomo sapiens (human)
presynaptic active zoneAmyloid-beta precursor proteinHomo sapiens (human)
spindle midzoneAmyloid-beta precursor proteinHomo sapiens (human)
recycling endosomeAmyloid-beta precursor proteinHomo sapiens (human)
extracellular exosomeAmyloid-beta precursor proteinHomo sapiens (human)
receptor complexAmyloid-beta precursor proteinHomo sapiens (human)
early endosomeAmyloid-beta precursor proteinHomo sapiens (human)
membrane raftAmyloid-beta precursor proteinHomo sapiens (human)
cell surfaceAmyloid-beta precursor proteinHomo sapiens (human)
Golgi apparatusAmyloid-beta precursor proteinHomo sapiens (human)
plasma membraneAmyloid-beta precursor proteinHomo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (140)

Assay IDTitleYearJournalArticle
AID8430050% growth inhibition of HT-29 (human colorectal carcinoma) cell line compared with untreated control cells2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Modified norcantharidins; synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity.
AID1915848Inhibition of rabbit liver PP2C assessed as dephosphorylation of substrate using P32 labelled peptide as substrate by radiometric analysis2021Bioorganic & medicinal chemistry, 02-15, Volume: 32Antitumor potential of the protein phosphatase inhibitor, cantharidin, and selected derivatives.
AID164508Inhibitory activity against partially purified (chicken skeletal muscle) Protein phosphatase 2A2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Anhydride modified cantharidin analogues: synthesis, inhibition of protein phosphatases 1 and 2A and anticancer activity.
AID84450Inhibitory activity against colon tumor cell line HT-29 after 72 hr continuous exposure to compound2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Anhydride modified cantharidin analogues: synthesis, inhibition of protein phosphatases 1 and 2A and anticancer activity.
AID526435Inhibition of human PP2A expressed in Escherichia coli BL212010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
The antiplasmodial activity of norcantharidin analogs.
AID478767Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and biological activity of Delta-5,6-norcantharimides: importance of the 5,6-bridge.
AID1915857Anticancer activity against human Lung cancer cell line assessed as cell growth inhibition2021Bioorganic & medicinal chemistry, 02-15, Volume: 32Antitumor potential of the protein phosphatase inhibitor, cantharidin, and selected derivatives.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID200558Inhibitory concentration against PP1 was determined2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
The first two cantharidin analogues displaying PP1 selectivity.
AID478769Cytotoxicity against human H460 cells after 72 hrs by MTT assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and biological activity of Delta-5,6-norcantharimides: importance of the 5,6-bridge.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID219868Inhibition of growth after 72 hr continuous exposure to test compounds in Colon HCT 116 tumor cell lines2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID7840150% growth inhibition of H460 (human lung carcinoma) cell line compared with untreated control cells2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Modified norcantharidins; synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity.
AID81703Inhibitory activity against colon tumor cell line HCT116 after 72 hr continuous exposure to compound2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Anhydride modified cantharidin analogues: synthesis, inhibition of protein phosphatases 1 and 2A and anticancer activity.
AID301931Inhibition of PP2A in human red blood cells2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Synthesis and biological evaluation of norcantharidin analogues: towards PP1 selectivity.
AID1915850Anticancer activity against human HT-29 cells assessed as cell growth inhibition by MTT assay2021Bioorganic & medicinal chemistry, 02-15, Volume: 32Antitumor potential of the protein phosphatase inhibitor, cantharidin, and selected derivatives.
AID514324Antimicrobial activity against glc7-127 allele containing Saccharomyces cerevisiae harboring cdc28-as transfected with 2 uM expression vector TEplac195 at 2.5 nM using deletion pool construction2008Nature chemical biology, Aug, Volume: 4, Issue:8
An integrated platform of genomic assays reveals small-molecule bioactivities.
AID296224Cytotoxicity against human MCF7 cells2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Heterocyclic substituted cantharidin and norcantharidin analogues--synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity.
AID300556Cytotoxicity against human SJG2 cells after 72 hrs by MTT assay2007Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18
Norcantharimides, synthesis and anticancer activity: Synthesis of new norcantharidin analogues and their anticancer evaluation.
AID1915855Anticancer activity against human Colon carcinoma cell assessed as cell growth inhibition2021Bioorganic & medicinal chemistry, 02-15, Volume: 32Antitumor potential of the protein phosphatase inhibitor, cantharidin, and selected derivatives.
AID478770Cytotoxicity against human A431 cells after 72 hrs by MTT assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and biological activity of Delta-5,6-norcantharimides: importance of the 5,6-bridge.
AID514323Antimicrobial activity against glc7-129 allele containing Saccharomyces cerevisiae harboring cdc28-as transfected with 2 uM expression vector TEplac195 at 2.5 nM using deletion pool construction2008Nature chemical biology, Aug, Volume: 4, Issue:8
An integrated platform of genomic assays reveals small-molecule bioactivities.
AID1915858Anticancer activity against human oral cancer cell assessed as cell growth inhibition2021Bioorganic & medicinal chemistry, 02-15, Volume: 32Antitumor potential of the protein phosphatase inhibitor, cantharidin, and selected derivatives.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID296222Cytotoxicity against human HT29 cells2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Heterocyclic substituted cantharidin and norcantharidin analogues--synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity.
AID478766Cytotoxicity against human SW480 cells after 72 hrs by MTT assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and biological activity of Delta-5,6-norcantharimides: importance of the 5,6-bridge.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID7243450% growth inhibition of G401 (human kidney carcinoma) cell line compared with untreated control cells2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Modified norcantharidins; synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity.
AID164513Inhibitory activity against protein phosphatase 2A from human red blood cells2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Modified norcantharidins; synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity.
AID164511Selectivity expressed as the ratio of Protein phosphatase 2A/Protein phosphatase 1 was determined2001Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22
Cantharimides: a new class of modified cantharidin analogues inhibiting protein phosphatases 1 and 2A.
AID478768Cytotoxicity against human A2780 cells after 72 hrs by MTT assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and biological activity of Delta-5,6-norcantharimides: importance of the 5,6-bridge.
AID200731Concentration required to inhibit the action of protein phosphatase 2A2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
The first two cantharidin analogues displaying PP1 selectivity.
AID151161Inhibition of growth after 72 hr continuous exposure to test compounds in Osteosarcoma 143B tumor cell lines2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID526427Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 assessed as inhibition of parasite LDH activity at 100 uM after 72 hrs by malstat reagent method2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
The antiplasmodial activity of norcantharidin analogs.
AID524793Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID324411Induction of light chain 3-GFP level in human H4 cells at 12.7 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID151322Inhibition of growth after 72 hr continuous exposure to test compounds in Ovarian ADDP tumor cell lines2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID512130Cytotoxicity against human SKHEP1 cells after 48 hrs by MTT assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Therapeutic effects of cantharidin analogues without bridging ether oxygen on human hepatocellular carcinoma cells.
AID324515Increase in light chain 3-GFP+ autophagosome vesicle area per cell in human H4 cells at 12.7 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID301932Inhibition of bovine brain PP2B2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Synthesis and biological evaluation of norcantharidin analogues: towards PP1 selectivity.
AID226624Selectivity was evaluated against Protein phosphatase 2A2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
The first two cantharidin analogues displaying PP1 selectivity.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID296226Cytotoxicity against human H460 cells2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Heterocyclic substituted cantharidin and norcantharidin analogues--synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity.
AID1915851Anticancer activity against human HCT-116 cells assessed as cell growth inhibition by MTT assay2021Bioorganic & medicinal chemistry, 02-15, Volume: 32Antitumor potential of the protein phosphatase inhibitor, cantharidin, and selected derivatives.
AID10182Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Anhydride modified cantharidin analogues: synthesis, inhibition of protein phosphatases 1 and 2A and anticancer activity.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID200735Exogenous inhibition concentration of Serine/threonine protein phosphatase 2A (PP2A)2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID1915849Toxicity in mouse assessed as lethal dose administered intraperitoneally2021Bioorganic & medicinal chemistry, 02-15, Volume: 32Antitumor potential of the protein phosphatase inhibitor, cantharidin, and selected derivatives.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID324463Increase in light chain 3-GFP+ autophagosome vesicle number per cell in human H4 cells at 12.7 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1915853Anticancer activity against human HL-60 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay2021Bioorganic & medicinal chemistry, 02-15, Volume: 32Antitumor potential of the protein phosphatase inhibitor, cantharidin, and selected derivatives.
AID478772Cytotoxicity against human BE(2)-C cells after 72 hrs by MTT assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and biological activity of Delta-5,6-norcantharimides: importance of the 5,6-bridge.
AID151320Inhibition of growth after 72 hr continuous exposure to test compounds in Ovarian A2780 tumor cell lines2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID200737Inhibition of Serine/threonine protein phosphatase 2A by anhydride modified Cantharidin analogues2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID10058Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Anhydride modified cantharidin analogues: synthesis, inhibition of protein phosphatases 1 and 2A and anticancer activity.
AID164510Inhibitory concentration against protein phosphatase 2A was determined2001Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22
Cantharimides: a new class of modified cantharidin analogues inhibiting protein phosphatases 1 and 2A.
AID296228Cytotoxicity against human DU145 cells2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Heterocyclic substituted cantharidin and norcantharidin analogues--synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity.
AID296220Inhibition of Protein phosphatase 12007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Heterocyclic substituted cantharidin and norcantharidin analogues--synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity.
AID512129Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Therapeutic effects of cantharidin analogues without bridging ether oxygen on human hepatocellular carcinoma cells.
AID9818850% growth inhibition of L1210 (murine leukemia) cell line compared with untreated control cells2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Modified norcantharidins; synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity.
AID300550Cytotoxicity against human A431 cells after 72 hrs by MTT assay2007Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18
Norcantharimides, synthesis and anticancer activity: Synthesis of new norcantharidin analogues and their anticancer evaluation.
AID324567Increase in light chain 3-GFP+ autophagosome vesicle intensity per cell in human H4 cells at 12.7 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID296227Cytotoxicity against human A431 cells2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Heterocyclic substituted cantharidin and norcantharidin analogues--synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity.
AID296230Cytotoxicity against human SJ-G2 cells2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Heterocyclic substituted cantharidin and norcantharidin analogues--synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity.
AID200742Exogenous inhibition concentration of Serine/threonine protein phosphatase 2B (PP2B)2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID478765Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and biological activity of Delta-5,6-norcantharimides: importance of the 5,6-bridge.
AID164498Inhibitory activity against recombinant Protein phosphatase 12000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Anhydride modified cantharidin analogues: synthesis, inhibition of protein phosphatases 1 and 2A and anticancer activity.
AID164495Inhibitory activity against protein phosphatase-1 from rabbit skeletal muscle2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Modified norcantharidins; synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity.
AID478773Cytotoxicity against human SJ-G2 cells after 72 hrs by MTT assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and biological activity of Delta-5,6-norcantharimides: importance of the 5,6-bridge.
AID200561Exogenous inhibition of Serine/threonine protein phosphatase 1 (PP1)2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID1915852Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay2021Bioorganic & medicinal chemistry, 02-15, Volume: 32Antitumor potential of the protein phosphatase inhibitor, cantharidin, and selected derivatives.
AID1915867Cytotoxicity against human Bone marrow cell assessed as cell growth inhibition by MTS assay2021Bioorganic & medicinal chemistry, 02-15, Volume: 32Antitumor potential of the protein phosphatase inhibitor, cantharidin, and selected derivatives.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID200722Inhibition of Serine/threonine protein phosphatase 1 by anhydride modified Cantharidin analogues2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID998450% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Modified norcantharidins; synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID526424Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D6 assessed as inhibition of parasite LDH activity after 72 hrs by malstat reagent method2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
The antiplasmodial activity of norcantharidin analogs.
AID296229Cytotoxicity against human BE2-C cells2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Heterocyclic substituted cantharidin and norcantharidin analogues--synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity.
AID300542Cytotoxicity against human SW480 cells after 72 hrs by MTT assay2007Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18
Norcantharimides, synthesis and anticancer activity: Synthesis of new norcantharidin analogues and their anticancer evaluation.
AID1915856Anticancer activity against human Liver cancer cell assessed as cell growth inhibition2021Bioorganic & medicinal chemistry, 02-15, Volume: 32Antitumor potential of the protein phosphatase inhibitor, cantharidin, and selected derivatives.
AID1915854Anticancer activity against human KB 3-1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay2021Bioorganic & medicinal chemistry, 02-15, Volume: 32Antitumor potential of the protein phosphatase inhibitor, cantharidin, and selected derivatives.
AID300552Cytotoxicity against human DU145 cells after 72 hrs by MTT assay2007Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18
Norcantharimides, synthesis and anticancer activity: Synthesis of new norcantharidin analogues and their anticancer evaluation.
AID301934Selectivity ratio of IC50 for rabbit skeletal muscle PP1 over IC50 for bovine brain PP2B2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Synthesis and biological evaluation of norcantharidin analogues: towards PP1 selectivity.
AID1915847Inhibition of bovine brain PP2A assessed as dephosphorylation of substrate using P32 labelled peptide DLDVPIPGRFDRRVSVAAE as substrate by radiometric analysis2021Bioorganic & medicinal chemistry, 02-15, Volume: 32Antitumor potential of the protein phosphatase inhibitor, cantharidin, and selected derivatives.
AID1915859Anticancer activity against human leukaemia cell line assessed as cell growth inhibition2021Bioorganic & medicinal chemistry, 02-15, Volume: 32Antitumor potential of the protein phosphatase inhibitor, cantharidin, and selected derivatives.
AID300540Cytotoxicity against human HT29 cells after 72 hrs by MTT assay2007Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18
Norcantharimides, synthesis and anticancer activity: Synthesis of new norcantharidin analogues and their anticancer evaluation.
AID300548Cytotoxicity against human H460 cells after 72 hrs by MTT assay2007Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18
Norcantharimides, synthesis and anticancer activity: Synthesis of new norcantharidin analogues and their anticancer evaluation.
AID300546Cytotoxicity against human A2780 cells after 72 hrs by MTT assay2007Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18
Norcantharimides, synthesis and anticancer activity: Synthesis of new norcantharidin analogues and their anticancer evaluation.
AID526434Inhibition of human PP1 expressed in Escherichia coli BL212010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
The antiplasmodial activity of norcantharidin analogs.
AID1915846Inhibition of PP1 (unknown origin)2021Bioorganic & medicinal chemistry, 02-15, Volume: 32Antitumor potential of the protein phosphatase inhibitor, cantharidin, and selected derivatives.
AID235534The compound was tested for the selectivity against protein phosphatases 2A2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Anhydride modified cantharidin analogues: synthesis, inhibition of protein phosphatases 1 and 2A and anticancer activity.
AID2908Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Anhydride modified cantharidin analogues: synthesis, inhibition of protein phosphatases 1 and 2A and anticancer activity.
AID296225Cytotoxicity against human A2780 cells2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Heterocyclic substituted cantharidin and norcantharidin analogues--synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity.
AID512131Cytotoxicity against rat hepatocyte cells after 48 hrs by MTT assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Therapeutic effects of cantharidin analogues without bridging ether oxygen on human hepatocellular carcinoma cells.
AID219869Inhibition of growth after 72 hr continuous exposure to test compounds in colon HT-29 tumor cell lines2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID296221Inhibition of Protein phosphatase 2A2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Heterocyclic substituted cantharidin and norcantharidin analogues--synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity.
AID478771Cytotoxicity against human DU145 cells after 72 hrs by MTT assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and biological activity of Delta-5,6-norcantharimides: importance of the 5,6-bridge.
AID164503Inhibitory concentration against protein phosphatase 1 was determined2001Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22
Cantharimides: a new class of modified cantharidin analogues inhibiting protein phosphatases 1 and 2A.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID301933Selectivity ratio of IC50 for rabbit skeletal muscle PP1 over IC50 for human PP2A2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Synthesis and biological evaluation of norcantharidin analogues: towards PP1 selectivity.
AID478775Inhibition of rabbit skeletal muscle protein phosphatase 1 assessed as free phosphate ion release after 60 mins by malachite green method2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and biological activity of Delta-5,6-norcantharimides: importance of the 5,6-bridge.
AID478776Inhibition of human red blood cells protein phosphatase 2A assessed as free phosphate ion release after 60 mins by malachite green method2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and biological activity of Delta-5,6-norcantharimides: importance of the 5,6-bridge.
AID296223Cytotoxicity against human SW480 cells2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Heterocyclic substituted cantharidin and norcantharidin analogues--synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity.
AID301930Inhibition of PP1 in rabbit skeletal muscle2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Synthesis and biological evaluation of norcantharidin analogues: towards PP1 selectivity.
AID300544Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay2007Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18
Norcantharimides, synthesis and anticancer activity: Synthesis of new norcantharidin analogues and their anticancer evaluation.
AID300554Cytotoxicity against human BE2C cells after 72 hrs by MTT assay2007Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18
Norcantharimides, synthesis and anticancer activity: Synthesis of new norcantharidin analogues and their anticancer evaluation.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347087qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Confirmatory Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347084qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Confirmatory Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347088qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): Viability assay - Alamar blue signal for LCMV Confirmatory Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347081qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Confirmatory Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (845)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990260 (30.77)18.7374
1990's78 (9.23)18.2507
2000's167 (19.76)29.6817
2010's243 (28.76)24.3611
2020's97 (11.48)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 60.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index60.92 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.94 (4.65)
Search Engine Demand Index142.97 (26.88)
Search Engine Supply Index2.97 (0.95)

This Compound (60.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials27 (3.09%)5.53%
Trials0 (0.00%)5.53%
Reviews55 (6.29%)6.00%
Reviews0 (0.00%)6.00%
Case Studies48 (5.49%)4.05%
Case Studies0 (0.00%)4.05%
Observational1 (0.11%)0.25%
Observational0 (0.00%)0.25%
Other744 (85.03%)84.16%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (16)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Trichloroacetic Acid Versus Cantharone for the Treatment of Perenial Warts [NCT03625960]Phase 412 participants (Actual)Interventional2006-06-15Completed
A Phase 2, Double-Blind, Placebo-Controlled Study to Determine the Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects With External Genital Warts [NCT03981822]Phase 2105 participants (Actual)Interventional2019-06-25Completed
[NCT03017846]Phase 230 participants (Actual)Interventional2016-09-30Completed
A Randomised, Double-blind (Sponsor Open), Placebo-controlled, Three Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single (in Both Fed and Fasted States) or Repeat Doses of GSK3358699 in Healthy Male Participant [NCT03426995]Phase 148 participants (Actual)Interventional2018-03-13Terminated(stopped due to The trial was terminated for strategic reasons following the emergence of new data.)
A Randomized Clinical Trial Examining the Efficacy of Treatment of Cutaneous Verruca Vulgaris in Adult Patients With Combined Liquid Nitrogen Cryotherapy and Topically Applied Cantharidin [NCT01084824]70 participants (Actual)Interventional2007-06-30Completed
A Phase 2, Open Label Study to Evaluate the Efficacy, Safety and Tolerability of VP-102 in Subjects With Common Warts (Verruca Vulgaris) [NCT03487549]Phase 256 participants (Actual)Interventional2018-03-27Completed
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum [NCT03377790]Phase 3266 participants (Actual)Interventional2018-03-21Completed
Efficacy of Cantharidin in Molluscum Contagiosum: A Randomized, Blinded, Placebo-Controlled Prospective Study [NCT00667225]29 participants (Actual)Interventional2008-01-31Completed
Utility of the Cantharidin-induced Skin Blister Assay for Evaluation of Anti-inflammatory Effects of Macrolides in Healthy Volunteers [NCT01026064]Phase 144 participants (Actual)Interventional2009-06-04Completed
Randomized Pilot Study Investigating the Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum [NCT02665260]Phase 294 participants (Actual)Interventional2012-07-31Completed
Investigation of the Distinct Mechanisms Involved in Inflammatory Resolution Between Healthy Men and Women: RESOLVE-SEX [NCT05597098]Early Phase 134 participants (Anticipated)Interventional2022-12-12Active, not recruiting
A Randomised, Single Blind, Placebo-Controlled, Cross-over, Phase 1 Methodology Study to Validate the Cantharidin Blister Model in Healthy Male Volunteers [NCT01762787]Phase 140 participants (Actual)Interventional2010-08-17Completed
Using a Cold Atmospheric Plasma Device to Treat Molluscum Contagiosum and Verruca Vulgaris in Pediatric Patients [NCT05070754]Phase 417 participants (Actual)Interventional2021-12-02Completed
Investigation of the Influence of Gender on Cardiovascular Function and Inflammation [NCT01582321]Early Phase 156 participants (Anticipated)Interventional2012-03-31Completed
An Open Label Parallel Group Study to Investigate the Optimum Methodology for the Use of LPS or GM-CSF as Challenge Agents on Healthy Participants by Assessing Inflammatory Biomarkers in Cantharidin-induced Skin Blisters, Peripheral Blood, and Urine [NCT03306589]Phase 112 participants (Actual)Interventional2017-08-11Completed
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum [NCT03377803]Phase 3262 participants (Actual)Interventional2018-02-14Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00667225 (2) [back to overview]Patients Experiencing Complete Clearance of All Molluscum Lesions.
NCT00667225 (2) [back to overview]Mean Change in Each Group Measured by Lesion Count.
NCT03017846 (4) [back to overview]Number of Participants With Total Lesion Clearance
NCT03017846 (4) [back to overview]Number of Patients Achieving Complete Lesion Clearance Compared to Prior Study (NCT02665260)
NCT03017846 (4) [back to overview]Number of Subjects Who Achieve a Clearance of at Least 90% of Their Molluscum Lesions
NCT03017846 (4) [back to overview]Change in the Total Children's Dermatology Life Quality Index Score
NCT03306589 (25) [back to overview]Part 1:Change From Baseline in Cell Activation Markers by Flow Cytometry on Monocytes in Blister
NCT03306589 (25) [back to overview]Part 1: Absolute Values of Blister Volume
NCT03306589 (25) [back to overview]Part 1: Change From Baseline in Cell Activation Markers by Flow Cytometry on Dendritic Cells in Blood
NCT03306589 (25) [back to overview]Part 1: Change From Baseline in Cell Activation Markers by Flow Cytometry on Dendritic Cells in Blood
NCT03306589 (25) [back to overview]Part 1: Change From Baseline in Primary Soluble Inflammatory Mediators : Urinary Tetranor Prostaglandin D Metabolite (PGDM) LPS Arm
NCT03306589 (25) [back to overview]Part 1: Change From Baseline in Cell Activation Markers by Flow Cytometry on Monocytes in Blood
NCT03306589 (25) [back to overview]Part 1: Change From Baseline in Cell Activation Markers by Flow Cytometry on Monocytes in Blood
NCT03306589 (25) [back to overview]Part 1: Change From Baseline in Cell Numbers in Blister
NCT03306589 (25) [back to overview]Part 1: Change From Baseline in Circulating Leukocyte Numbers in Blood: LPS Arm
NCT03306589 (25) [back to overview]Part 1: Change From Baseline in Primary Soluble Inflammatory Mediators : Urinary Tetranor Prostaglandin D Metabolite (PGDM) LPS Arm
NCT03306589 (25) [back to overview]Part 1: Change From Baseline in Soluble Inflammatory Mediators in Blood: C-reactive Protein (CRP)
NCT03306589 (25) [back to overview]Part 1: Change From Baseline in Soluble Inflammatory Mediators in Blood: TNF-alpha, IL-6 and GM-CSF: GM-CSF Arm
NCT03306589 (25) [back to overview]Part 1: Change From Baseline in White Blood Cell Numbers in Blood: GM-CSF
NCT03306589 (25) [back to overview]Part 1: Change From Baseline Primary Soluble Inflammatory Mediators in Blood: Tumor Necrosis Factor (TNF) Alpha and Interleukin (IL) 6 for LPS Arm
NCT03306589 (25) [back to overview]Part 1: Change From Baseline Soluble Inflammatory Biomarkers in Skin Blister
NCT03306589 (25) [back to overview]Part 1: Change From Baseline Soluble Inflammatory Biomarkers in Skin Blister
NCT03306589 (25) [back to overview]Part 1:Change From Baseline in Cell Activation Markers by Flow Cytometry on Dendritic Cells in Blister
NCT03306589 (25) [back to overview]Part 1:Change From Baseline in Cell Activation Markers by Flow Cytometry on Dendritic Cells in Blister
NCT03306589 (25) [back to overview]Part 1:Change From Baseline in Cell Activation Markers by Flow Cytometry on Macrophages in Blister
NCT03306589 (25) [back to overview]Part 1:Change From Baseline in Cell Activation Markers by Flow Cytometry on Monocytes in Blister
NCT03306589 (25) [back to overview]Part 1:Change From Baseline in Soluble Inflammatory Mediators in Blood
NCT03306589 (25) [back to overview]Part 1:Change From Baseline in Soluble Inflammatory Mediators in Blood
NCT03306589 (25) [back to overview]Part 1:Change From Baseline of CD40+/CD80+ by Flow Cytometry on Dendritic Cells in Blister
NCT03306589 (25) [back to overview]Part 1:Change From Baseline of CD40+/CD80+ by Flow Cytometry on Macrophages in Blister
NCT03306589 (25) [back to overview]Part 1:Change From Baseline of CD40+/CD80+ by Flow Cytometry on Monocytes in Blister
NCT03377790 (10) [back to overview]Percent Change of All Treatable Molluscum Lesions (Baseline and New) From Baseline at the EOS Visit
NCT03377790 (10) [back to overview]Change From Baseline to EOS Day 84 of the Composite Score From the Children's Dermatology Life Quality Index (CDLQI) Assessment at the EOS Visit to Measure the Quality of Life and Impact of Skin Disease in the Subset of Subjects 4 -16 Years of Age.
NCT03377790 (10) [back to overview]Change From Baseline in the Number of Treatable Molluscum Lesions (Baseline and New) at the EOS Visit.
NCT03377790 (10) [back to overview]Percentage of Subjects Exhibiting a 75% or Greater Reduction of All Treatable Molluscum Lesions (Baseline and New) at the EOS Visit.
NCT03377790 (10) [back to overview]Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 63 Visit
NCT03377790 (10) [back to overview]Percentage of Subjects Exhibiting a 90% or Greater Reduction of All Treatable Molluscum Lesions (Baseline and New) at the EOS Visit.
NCT03377790 (10) [back to overview]Subject Reported Spread to Household Members as Measured by Any New Occurrence of Molluscum in Household Members of Subject.
NCT03377790 (10) [back to overview]Proportion of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 21 Visit
NCT03377790 (10) [back to overview]Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 84 Visit (EOS)
NCT03377790 (10) [back to overview]Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 42 Visit
NCT03377803 (10) [back to overview]Change From Baseline in the Number of Treatable Molluscum Lesions (Baseline and New) at the EOS Visit
NCT03377803 (10) [back to overview]Percent Change of All Treatable Molluscum Lesions (Baseline and New) From Baseline at the EOS Visit
NCT03377803 (10) [back to overview]Percentage of Subjects Exhibiting a 75% or Greater Reduction of All Treatable Molluscum Lesions (Baseline and New) at the EOS Visit
NCT03377803 (10) [back to overview]Percentage of Subjects Exhibiting a 90% or Greater Reduction of All Treatable Molluscum Lesions (Baseline and New) at the EOS Visit
NCT03377803 (10) [back to overview]Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 21 Visit
NCT03377803 (10) [back to overview]Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 42 Visit
NCT03377803 (10) [back to overview]Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 63 Visit
NCT03377803 (10) [back to overview]Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 84 Visit (EOS)
NCT03377803 (10) [back to overview]Subject Reported Spread to Household Members as Measured by Any New Occurrence of Molluscum in Household Members of Subject
NCT03377803 (10) [back to overview]Change From Baseline of the Composite Score From the Children's Dermatology Life Quality Index (CDLQI) Assessment at the EOS Visit to Measure the Quality of Life and Impact of Skin Disease in the Subset of Subjects 4 -16 Years of Age
NCT03426995 (48) [back to overview]Part C: Number of Participants With AEs and SAEs
NCT03426995 (48) [back to overview]Part C: Number of Participants With Worst Case Chemistry Results by PCI Criteria Post-Baseline Relative to Baseline
NCT03426995 (48) [back to overview]Part C: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline
NCT03426995 (48) [back to overview]Part C: Number of Participants With Worst Case Hematology Results by PCI Criteria Post-Baseline Relative to Baseline
NCT03426995 (48) [back to overview]Part C: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline
NCT03426995 (48) [back to overview]Part C: Number of Participants With Worst Case Post-Baseline Abnormal ECG Findings
NCT03426995 (48) [back to overview]Part C: Number of Participants With Worst Case Vital Sign Results by PCI Criteria Post-Baseline Relative to Baseline
NCT03426995 (48) [back to overview]Part C: Plasma Concentrations of GSK3206944
NCT03426995 (48) [back to overview]Part C: Plasma Concentrations of GSK3358699
NCT03426995 (48) [back to overview]Part C: t1/2 of GSK3206944
NCT03426995 (48) [back to overview]Part C: t1/2 of GSK3358699
NCT03426995 (48) [back to overview]Part C: Tmax of GSK3206944
NCT03426995 (48) [back to overview]Part C: Tmax of GSK3358699
NCT03426995 (48) [back to overview]Part A: Number of Participants With Worst Case Post-Baseline Abnormal Electrocardiogram (ECG) Findings
NCT03426995 (48) [back to overview]Part A: AUC(0-24) of GSK3206944
NCT03426995 (48) [back to overview]Part A: Apparent Terminal Phase Half-life (t1/2) of GSK3358699
NCT03426995 (48) [back to overview]Part A: Area Under the Plasma Concentration Curve From Time Zero to 24 Hours (AUC[0-24]) of GSK3358699
NCT03426995 (48) [back to overview]Part A: Area Under the Plasma Concentration Curve From Time Zero to Infinity (AUC[0-infinity]) of GSK3358699
NCT03426995 (48) [back to overview]Part A: Area Under the Plasma Concentration Curve From Time Zero to Last Time of Quantifiable Concentration (AUC[0-t]) of GSK3358699
NCT03426995 (48) [back to overview]Part A: AUC(0-infinity) of GSK3206944
NCT03426995 (48) [back to overview]Part A: AUC(0-t) of GSK3206944
NCT03426995 (48) [back to overview]Part A: Cmax of GSK3206944
NCT03426995 (48) [back to overview]Part A: Maximum Plasma Concentration (Cmax) of GSK3358699
NCT03426995 (48) [back to overview]Part A: t1/2 of GSK3206944
NCT03426995 (48) [back to overview]Part A: Time to Cmax (Tmax) of GSK3358699
NCT03426995 (48) [back to overview]Part A: Tmax of GSK3206944
NCT03426995 (48) [back to overview]Part A: Absolute Values of Monocyte Chemotactic Protein (MCP)-1, Interleukin (IL)6, Tumor Necrosis Factor (TNF) Alpha in Blood After Ex-vivo Lipopolysaccharide (LPS) Activation
NCT03426995 (48) [back to overview]Part A: Monocyte Intracellular Concentration of GSK3206944
NCT03426995 (48) [back to overview]Part A: Number of Participants With Abnormal Urinalysis Parameters
NCT03426995 (48) [back to overview]Part A: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT03426995 (48) [back to overview]Part A: Number of Participants With Worst Case Chemistry Results by Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline
NCT03426995 (48) [back to overview]Part A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline
NCT03426995 (48) [back to overview]Part A: Number of Participants With Worst Case Hematology Results by PCI Criteria Post-Baseline Relative to Baseline
NCT03426995 (48) [back to overview]Part A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline
NCT03426995 (48) [back to overview]Part A: Number of Participants With Worst Case Vital Sign Results by PCI Criteria Post-Baseline Relative to Baseline
NCT03426995 (48) [back to overview]Part A: Plasma Concentrations of GSK3206944
NCT03426995 (48) [back to overview]Part A: Plasma Concentrations of GSK3358699
NCT03426995 (48) [back to overview]Part C: Absolute Values of MCP-1, IL6, TNF Alpha in Blood After Ex-vivo LPS Activation
NCT03426995 (48) [back to overview]Part C: AUC(0-24) of GSK3206944
NCT03426995 (48) [back to overview]Part C: AUC(0-24) of GSK3358699
NCT03426995 (48) [back to overview]Part C: AUC(0-infinity) of GSK3206944
NCT03426995 (48) [back to overview]Part C: AUC(0-infinity) of GSK3358699
NCT03426995 (48) [back to overview]Part C: AUC(0-t) of GSK3206944
NCT03426995 (48) [back to overview]Part C: AUC(0-t) of GSK3358699
NCT03426995 (48) [back to overview]Part C: Cmax of GSK3206944
NCT03426995 (48) [back to overview]Part C: Cmax of GSK3358699
NCT03426995 (48) [back to overview]Part C: Monocyte Intracellular Concentration of GSK3206944
NCT03426995 (48) [back to overview]Part C: Number of Participants With Abnormal Urinalysis Parameters
NCT03487549 (21) [back to overview]Cohort 1: Change From Baseline in the Number of Treatable Warts (Baseline and New) at Visit 2, Visit 3, Visit 4 and the EOS Visit
NCT03487549 (21) [back to overview]Cohort 1: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study
NCT03487549 (21) [back to overview]Cohort 1:Percent Reduction of All Treatable Warts (Baseline and New) From Baseline at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study.
NCT03487549 (21) [back to overview]Cohort 2: Change From Baseline in the Number of Treatable Warts (Baseline and New) at Follow-up Visits on Day 105, Day 126 and Day 147
NCT03487549 (21) [back to overview]Cohort 2: Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4 and the EOT Visit (Day 84)
NCT03487549 (21) [back to overview]Cohort 2: Percent Reduction of All Treatable Warts (Baseline and New) From Baseline at Follow-up Visits on Day 105, Day 126 and Day 147
NCT03487549 (21) [back to overview]Cohort 2: Percent Reduction of All Treatable Warts (Baseline and New) From Baseline at Visit 2, Visit 3, Visit 4 and Over Duration of the Study.
NCT03487549 (21) [back to overview]Cohort 2: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Follow-up Visits on Day 105, Day 126 and Day 147
NCT03487549 (21) [back to overview]Cohort 2: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts, (Baseline and New), at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study
NCT03487549 (21) [back to overview]Cohort 2: Proportion of Subjects Exhibiting Reduction of at Least 1 Treatable Wart From Baseline at Visit 2, Visit 3, Visit 4 and at the EOT Visit (Day 84)
NCT03487549 (21) [back to overview]Cohort 1: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at the EOS Visit (Day 84)
NCT03487549 (21) [back to overview]Cohort 1: Proportion of Subjects Exhibiting ≥ 50% Clearance of All Treatable Warts (Baseline and New) at the EOS Visit as Compared to Baseline
NCT03487549 (21) [back to overview]Cohort 2: Change From Baseline in the Number of Treatable Warts (Baseline and New) at the EOT Visit Day 84)
NCT03487549 (21) [back to overview]Cohort 1: Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at the EOT Visit (Day 84).
NCT03487549 (21) [back to overview]Cohort 1-Proportion of Subjects Who Respond to Treatment Defined by a ≥ 50% Reduction in Total Wart Area at EOS Compared to Baseline
NCT03487549 (21) [back to overview]Cohort 2: Change From Baseline in the Percent of Treatable Warts (Baseline and New) at the EOT Visit (Day 84)
NCT03487549 (21) [back to overview]Cohort 2: Proportion of Subjects Exhibiting ≥ 50 % Clearance of All Treatable Warts (Baseline and New) at the EOT Visit (Day 84) as Compared to Baseline
NCT03487549 (21) [back to overview]Cohort 2: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at the EOT Visit (Day 84)
NCT03487549 (21) [back to overview]Cohort 2: Proportion of Subjects Who Respond to Treatment Defined by a ≥ 50% Reduction in Total Wart Area at EOT Compared to Baseline
NCT03487549 (21) [back to overview]Cohort 1-Proportion of Subjects Exhibiting Reduction of at Least 1 Treatable Wart From Baseline at Visit 2, Visit 3, Visit 4 and at the EOS Visit (Day 84)
NCT03487549 (21) [back to overview]Cohort 1: Change From Baseline in the Number of Treatable Warts (Baseline and New) at the EOS Visit (Day 84)
NCT03981822 (8) [back to overview]Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)
NCT03981822 (8) [back to overview]Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)
NCT03981822 (8) [back to overview]Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)
NCT03981822 (8) [back to overview]Proportion of Subjects Exhibiting 90% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)
NCT03981822 (8) [back to overview]Proportion of Subjects Exhibiting 75% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)
NCT03981822 (8) [back to overview]Percent Change From Baseline in the Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)
NCT03981822 (8) [back to overview]Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)
NCT03981822 (8) [back to overview]Change From Baseline in Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)

Patients Experiencing Complete Clearance of All Molluscum Lesions.

(NCT00667225)
Timeframe: Baseline compared to 8 weeks (5 visits)

InterventionParticipants (Number)
Vehicle1
Cantharidin3

[back to top]

Mean Change in Each Group Measured by Lesion Count.

Average change in number of lesions from baseline to 8 weeks (NCT00667225)
Timeframe: Baseline compared to 8 weeks (5 visits)

Interventionlesions (Mean)
Vehicle26.26
Cantharidin35.61

[back to top]

Number of Participants With Total Lesion Clearance

100% reduction in baseline lesion count (NCT03017846)
Timeframe: Assessed at each visit, until final visit on week 12

InterventionParticipants (Count of Participants)
Cantharidin Treatment11

[back to top]

Number of Patients Achieving Complete Lesion Clearance Compared to Prior Study (NCT02665260)

Comparison of the number of subjects achieving complete lesion clearance at study completion (up to 12 weeks) to the same measure obtained in our previous study (NCT02665260) (NCT03017846)
Timeframe: At study completion, up to 12 weeks

InterventionParticipants (Count of Participants)
Current Study11
NCT026652607

[back to top]

Number of Subjects Who Achieve a Clearance of at Least 90% of Their Molluscum Lesions

(NCT03017846)
Timeframe: At study completion, up to 12 weeks

InterventionParticipants (Count of Participants)
Cantharidin Treatment14

[back to top]

Change in the Total Children's Dermatology Life Quality Index Score

"Change in the Total Children's Dermatology Life Quality Index (CDLQI) given Visit 1 prior to the first treatment and at the last study visit, up to 12 weeks. The CDLQI examines how the patient feels about the symptoms and treatment, as well as how it affects leisure, school, personal relationships, sleep, clothing choices. A total score is calculated.~The total score for the CDLQI scores range:~0-1 = no effect on child's life 2-6 = small effect 7-12 = moderate effect 13-18 = very large effect 19-30 = extremely large effect" (NCT03017846)
Timeframe: Baseline (At beginning of study, before treatment) and end of study (at study completion, week 12 or at earlier visit if all lesions have cleared)

Interventionscore on a scale (Mean)
At beginning of study, before treatmentAt end of study
Cantharidin Treatment3.90.38

[back to top]

Part 1:Change From Baseline in Cell Activation Markers by Flow Cytometry on Monocytes in Blister

Blister samples were collected at indicated time-points for the measurement of activation markers by flow cytometry for monocytes in blister. Activation markers included Cluster of Differentiation (CD) 16, CD163, CD206, CD209, CD40, CD80, CD83, CD86 and Human Leukocyte Antigen - antigen D Related (HLA-DR). Latest pre-challenge (LPS or GM-CSF) assessment with a non-missing value, including those from unscheduled visits was considered as Baseline. Change from Baseline was calculated as the value at specified visit minus the Baseline value. NA indicates that data was not available as standard deviation could not be calculated for a single participant. (NCT03306589)
Timeframe: Baseline, Session1: 48 hours Day 3, Session 2: 24 hours Day 2 and 48 hours Day 3

InterventionMean fluorescence intensity (Mean)
CD16+, Session1,Day3, 48 hours, n=2, 4, 2, 4CD16+, Session2,Day2, 24 hours, n=2, 4, 2, 4CD16+, Session2,Day3, 48 hours, n=2, 4, 2, 4CD163+, Session1,Day3, 48 hours, n=2, 4, 2, 4CD163+, Session2,Day2, 24 hours, n=2, 4, 2, 4CD163+, Session2,Day3, 48 hours, n=2, 4, 2, 4CD206+, Session1,Day3, 48 hours, n=2, 2, 2, 4CD209+, Session1,Day3,48 hours, n=2, 4, 2, 4CD209+, Session2,Day2, 24 hours, n=2, 4, 2, 4CD209+, Session2,Day3, 48 hours, n=2, 4, 2, 4CD40, Session1,Day3, 48 hours, n=2, 4, 2, 4CD40, Session2,Day2, 24 hours, n=2, 4, 2, 4CD40, Session2,Day3, 48 hours, n=1, 4, 2, 3CD80, Session1,Day3, 48 hours, n=2, 4, 2, 4CD80, Session2,Day2, 24 hours, n=2, 4, 2, 4CD80, Session2,Day3, 48 hours, n=2, 4, 2, 4CD83, Session1,Day3, 48 hours, n=2, 4, 2, 4CD83, Session2,Day2, 24 hours, n=2, 4, 2, 4CD83, Session2,Day3, 48 hours, n=2, 4, 2, 4CD86+, Session1,Day3, 48 hours, n=2, 4, 2, 4CD86+, Session2,Day2, 24 hours, n=2, 4, 2, 4CD86+, Session2,Day3, 48 hours, n=2, 4, 2, 4HLA-DR, Session1,Day3, 48 hours, n=2, 4, 2, 4HLA-DR, Session2,Day2, 24 hours, n=2, 4, 2, 4HLA-DR, Session2,Day3, 48 hours, n=2, 4, 2, 4
Part 1: LPS 0.75 ng/kg304.409507.721-26.379710.660247.858585.093-562.711256.72163.622767.291131.238-60.255-6.274342.79850.962324.662-816.61944.949-773.455-51.662-241.591312.288-3291.05-9344.96-10329.79

[back to top]

Part 1: Absolute Values of Blister Volume

Blister samples were collected at indicated time-points for analysis of blister volumes. . Latest pre-challenge (LPS or GM-CSF) assessment with a non-missing value, including those from unscheduled visits was considered as Baseline. (NCT03306589)
Timeframe: Baseline, Session 1: 48 hours Day 3. Session 2: 24 hours Day 2, 48 hours Day 3

,,,
InterventionMicroliter (Mean)
BaselineSession 1, Day 3, 48 hoursSession 2, Day 2, 24 hoursSession 2, Day 3, 48 hours
Part 1: GM-CSF 60 µg/m^2230.425216.775105.363108.313
Part 1: LPS 0.5 ng/kg361.325372.125156.225274.625
Part 1: LPS 0.75 ng/kg156.638188.625102.838164.100
Part 1: LPS 1 ng/kg185.550232.175162.975190.650

[back to top]

Part 1: Change From Baseline in Cell Activation Markers by Flow Cytometry on Dendritic Cells in Blood

Blood samples were collected at indicated time-points for the measurement of activation markers by flow cytometry for dendritic cells in blood. Activation markers included CD16, CD163, CD206, CD209, CD40, CD80, CD83, CD86 and HLA-DR. Latest pre-challenge (LPS or GM-CSF) assessment with a non-missing value, including those from unscheduled visits was considered as Baseline. Change from Baseline was calculated as the value at specified visit minus the Baseline value. (NCT03306589)
Timeframe: Baseline, Session 2: 40 minutes, 2 hours 40 minutes, 5 hours 40 minutes, 9 hours 40 minutes on Day 1. Pre-fluid sample on Day 2 and Day 3

,,
InterventionMean fluorescence intensity (Mean)
CD16+, Session2,Day1, 40 minutes, n=2, 4, 2,4CD16+, Session2,Day1, 2 hour 40 minutes, n=2,4,2,4CD16+, Session2,Day1, 5 hour 40 minutes, n=2,4,2,4CD16+,Session2,Day2, Pre-fluid sampling, n=2,4,2,4CD16+,Session2,Day3, Pre-fluid sampling, n=2,4,2,4CD163+, Session2,Day1, 40 minutes, n=2,4,2,4CD163+, Session2,Day1,2 hour 40 minutes, n=2,4,2,4CD163+, Session2,Day1,5 hour 40 minutes, n=2,4,2,4CD163+,Session2,Day2, Pre-fluid sampling,n=2,4,2,4CD163+,Session2,Day3, Pre-fluid sampling,n=2,4,2,4CD206+, Session2,Day1, 40 minutes, n=2,2,2,4CD206+, Session2,Day1,2 hour 40 minutes, n=2,2,2,4CD206+, Session2,Day1,5 hour 40 minutes, n=2,2,2,4CD206+,Session2,Day2, Pre-fluid sampling,n=2,2,2,4CD206+,Session2,Day3, Pre-fluid sampling,n=2,2,2,4CD209+, Session2,Day1, 40 minutes, n=2,4,2,4CD209+, Session2,Day1,2 hour 40 minutes, n=2,4,2,4CD209+, Session2,Day1,5 hour 40 minutes, n=2,4,2,4CD209+,Session2,Day2,Pre-fluid sampling,n=2,4, 2,4CD209+,Session2,Day3, Pre-fluid sampling,n=2,4,2,4CD40, Session2,Day1, 40 minutes, n=2,4,2,4CD40, Session2,Day1,2 hour 40 minutes, n=2,4,2,4CD40, Session2,Day1,5 hour 40 minutes, n=2,4,2,4CD40, Session2,Day2, Pre-fluid sampling,n=2,4, 2,4CD40, Session2,Day3, Pre-fluid sampling,n=2, 4,2,4CD80, Session2,Day1, 40 minutes, n=2, 4,2,4CD80, Session2,Day1,2 hour 40 minutes, n=2,4,2,4CD80, Session2,Day1,5 hour 40 minutes, n=2, 4,2,4CD80,Session2,Day2, Pre-fluid sampling,n=2, 4,2,4CD80,Session2,Day3, Pre-fluid sampling,n=2, 4,2,4CD83, Session2,Day1, 40 minutes, n=2, 4,2,4CD83, Session2,Day1,2 hour 40 minutes, n=2, 4,2,4CD83, Session2,Day1,5 hour 40 minutes, n=2, 4,2,4CD83,Session2,Day2, Pre-fluid sampling,n=2, 4,2,4CD83,Session2,Day3, Pre-fluid sampling,n=2, 4,2,4CD86+, Session2,Day1, 40 minutes, n=2, 4,2,4CD86+, Session2,Day1,2 hour 40 minutes, n=2, 4,2,4CD86+, Session2,Day1,5 hour 40 minutes, n=2, 4,2,4CD86+,Session2,Day2, Pre-fluid sampling,n=2, 4,2,4CD86+,Session2,Day3, Pre-fluid sampling,n=2, 4,2,4HLA-DR, Session2,Day1, 40 minutes, n=2, 4,2,4HLA-DR, Session2,Day1,2 hour 40 minutes, n=2,4,2,4HLA-DR, Session2,Day1,5 hour 40 minutes, n=2,4,2,4HLA-DR,Session2,Day2, Pre-fluid sampling,n=2,4,2,4HLA-DR,Session2,Day3, Pre-fluid sampling,n=2,4,2,4
Part 1: LPS 0.5 ng/kg-1492.500-1561.000-1061.000135.500-564.50041.0000-53.500028.0000-35.000038.0000-75.000570.500-54.5008.500-87.500-46.5000-42.0000-53.50006.5000-64.5000-77.5000-248.5000-191.0000-93.0000-359.9500-4.000-104.500-146.00034.000-47.500-225.000-26.500-127.000-58.000-241.500-93.500014.0000-54.500041.5000-91.0000445.50-2457.50-320.00-1449.00-2292.50
Part 1: LPS 0.75 ng/kg-468.314-579.984-530.365300.3331116.482-3.8803-28.015313.729568.9850175.6860-140.156-130.065-84.21770.416-7.13818.4320-19.1610-3.8503-4.8983-16.777024.1702-37.2498-35.559362.5378108.3750-35.839-95.364-85.52811.10382.9870.262-56.590-54.265125.239142.101-101.1600-121.3668-94.3938126.1853117.9230896.74-1417.49-1744.11688.02-2030.80
Part 1: LPS 1 ng/kg-1418.700-1495.500-1334.500309.500984.000-160.5000-187.5500-41.5000239.000088.5000241.000124.0000.500193.000120.000-105.6500226.5000-42.8500158.5000-9.5000-17.1500-74.1500-55.0500135.5000152.5000666.250-138.800-139.80075.000113.500647.500-17.500-40.000243.50038.50056.0000-144.5000-44.0000194.500082.000041096.00-5430.00-1604.00-2085.00-6379.00

[back to top]

Part 1: Change From Baseline in Cell Activation Markers by Flow Cytometry on Dendritic Cells in Blood

Blood samples were collected at indicated time-points for the measurement of activation markers by flow cytometry for dendritic cells in blood. Activation markers included CD16, CD163, CD206, CD209, CD40, CD80, CD83, CD86 and HLA-DR. Latest pre-challenge (LPS or GM-CSF) assessment with a non-missing value, including those from unscheduled visits was considered as Baseline. Change from Baseline was calculated as the value at specified visit minus the Baseline value. (NCT03306589)
Timeframe: Baseline, Session 2: 40 minutes, 2 hours 40 minutes, 5 hours 40 minutes, 9 hours 40 minutes on Day 1. Pre-fluid sample on Day 2 and Day 3

InterventionMean fluorescence intensity (Mean)
CD16+, Session2,Day1, 40 minutes, n=2, 4, 2,4CD16+, Session2,Day1, 2 hour 40 minutes, n=2,4,2,4CD16+, Session2,Day1, 5 hour 40 minutes, n=2,4,2,4CD16+, Session2,Day1,9 hour 40 minutes,n-0,0,0,4CD16+,Session2,Day2, Pre-fluid sampling, n=2,4,2,4CD16+,Session2,Day3, Pre-fluid sampling, n=2,4,2,4CD163+, Session2,Day1, 40 minutes, n=2,4,2,4CD163+, Session2,Day1,2 hour 40 minutes, n=2,4,2,4CD163+, Session2,Day1,5 hour 40 minutes, n=2,4,2,4CD163+, Session2,Day1, 9 hour 40 minutes,n=0,0,0,4CD163+,Session2,Day2, Pre-fluid sampling,n=2,4,2,4CD163+,Session2,Day3, Pre-fluid sampling,n=2,4,2,4CD206+, Session2,Day1, 40 minutes, n=2,2,2,4CD206+, Session2,Day1,2 hour 40 minutes, n=2,2,2,4CD206+, Session2,Day1,5 hour 40 minutes, n=2,2,2,4CD206+, Session2,Day1,9 hour 40 minutes,n=0,0,0,4CD206+,Session2,Day2, Pre-fluid sampling,n=2,2,2,4CD206+,Session2,Day3, Pre-fluid sampling,n=2,2,2,4CD209+, Session2,Day1, 40 minutes, n=2,4,2,4CD209+, Session2,Day1,2 hour 40 minutes, n=2,4,2,4CD209+, Session2,Day1,5 hour 40 minutes, n=2,4,2,4CD209+, Session2,Day1,9 hour 40 minutes,n=0,0,0,4CD209+,Session2,Day2,Pre-fluid sampling,n=2,4, 2,4CD209+,Session2,Day3, Pre-fluid sampling,n=2,4,2,4CD40, Session2,Day1, 40 minutes, n=2,4,2,4CD40, Session2,Day1,2 hour 40 minutes, n=2,4,2,4CD40, Session2,Day1,5 hour 40 minutes, n=2,4,2,4CD40, Session2,Day1,9 hour 40 minutes,n=0,0,0,4CD40, Session2,Day2, Pre-fluid sampling,n=2,4, 2,4CD40, Session2,Day3, Pre-fluid sampling,n=2, 4,2,4CD80, Session2,Day1, 40 minutes, n=2, 4,2,4CD80, Session2,Day1,2 hour 40 minutes, n=2,4,2,4CD80, Session2,Day1,5 hour 40 minutes, n=2, 4,2,4CD80, Session2,Day1,9 hour 40 minutes, n=0,0,0,4CD80,Session2,Day2, Pre-fluid sampling,n=2, 4,2,4CD80,Session2,Day3, Pre-fluid sampling,n=2, 4,2,4CD83, Session2,Day1, 40 minutes, n=2, 4,2,4CD83, Session2,Day1,2 hour 40 minutes, n=2, 4,2,4CD83, Session2,Day1,5 hour 40 minutes, n=2, 4,2,4CD83, Session2,Day1,9 hour 40 minutes,n=0,0,0,4CD83,Session2,Day2, Pre-fluid sampling,n=2, 4,2,4CD83,Session2,Day3, Pre-fluid sampling,n=2, 4,2,4CD86+, Session2,Day1, 40 minutes, n=2, 4,2,4CD86+, Session2,Day1,2 hour 40 minutes, n=2, 4,2,4CD86+, Session2,Day1,5 hour 40 minutes, n=2, 4,2,4CD86+, Session2,Day1,9 hour 40 minutes,n=0,0,0,4CD86+,Session2,Day2, Pre-fluid sampling,n=2, 4,2,4CD86+,Session2,Day3, Pre-fluid sampling,n=2, 4,2,4HLA-DR, Session2,Day1, 40 minutes, n=2, 4,2,4HLA-DR, Session2,Day1,2 hour 40 minutes, n=2,4,2,4HLA-DR, Session2,Day1,5 hour 40 minutes, n=2,4,2,4HLA-DR, Session2,Day1,9 hour 40 minutes,n=0,0,0,4HLA-DR,Session2,Day2, Pre-fluid sampling,n=2,4,2,4HLA-DR,Session2,Day3, Pre-fluid sampling,n=2,4,2,4
Part 1: GM-CSF 60 µg/m^2-215.981-118.536171.104265.065168.6614.75758.364047.3110-12.9720-24.0198-19.7730-10.6642552.855444.094262.268275.423164.064106.723-6.6660-19.5825-15.8723-45.111846.9815-6.7250-37.4720-11.040078.3045102.043883.18605.2222-11.569-15.96422.82919.21436.58711.9298.2604.970-11.648223.09372.982-33.8698.967830.0005106.9465118.633883.409815.2970-2795.55-1430.37-1347.06-943.38800.49113.79

[back to top]

Part 1: Change From Baseline in Primary Soluble Inflammatory Mediators : Urinary Tetranor Prostaglandin D Metabolite (PGDM) LPS Arm

The post-challenge urine samples were collected during session 2 after LPS challenge. In session 2, participants were encouraged to pass urine immediately before LPS challenge dose and urine voids were collected from after LPS until 12 hours post-LPS and the time of the urine collection were recorded as post-challenge 1 to 11. These samples were collected for measurement of tetranor-PGDM. Latest pre-challenge LPS assessment with a non-missing value, including those from unscheduled visits was considered as Baseline. Change from Baseline was calculated as the value at specified visit minus the Baseline value. The data for normalized Tetranor PGDM was normalized by (Tetranor PGDM [pg/mL] divided by Creatinine [milligram per deciliter]) multiplied by 100. NA indicates that data was not available as standard deviation could not be calculated for a single participant. (NCT03306589)
Timeframe: Baseline, Session 2 Day 1

InterventionPicograms per milligram (Mean)
Session2, Day1,Post challenge1, n=2, 4, 2Session2, Day1,Post challenge 2, n=2, 4, 2Session2, Day1,Post challenge 3, n=2, 4, 2Session2, Day1,Post challenge 4, n=2, 4, 2Session2, Day1,Post challenge 5, n=1, 4, 2
Part 1: LPS 0.5 ng/kg73.84699.43832.006-119.091112.355

[back to top]

Part 1: Change From Baseline in Cell Activation Markers by Flow Cytometry on Monocytes in Blood

Blood samples were collected at indicated time-points for the measurement of activation markers by flow cytometry for monocytes in blood. Activation markers included CD16, CD163, CD206, CD209, CD40, CD80, CD83, CD86 and HLA-DR. Latest pre-challenge (LPS or GM-CSF) assessment with a non-missing value, including those from unscheduled visits was considered as Baseline. Change from Baseline was calculated as the value at specified visit minus the Baseline value. (NCT03306589)
Timeframe: Baseline; Session 2: 40 minutes, 2 hours 40 minutes, 5 hours 40 minutes, 9 hours 40 minutes on Day 1. Pre-fluid sample on Day 2 and Day 3

,,
InterventionMean fluorescence intensity (Mean)
CD16+, Session2,Day1, 40 minutes, n=2, 4, 2,4CD16+, Session2,Day1, 2 hour 40 minutes, n=2,4,2,4CD16+, Session2,Day1, 5 hour 40 minutes, n=2,4,2,4CD16+,Session2,Day2, Pre-fluid sampling, n=2,4,2,4CD16+,Session2,Day3, Pre-fluid sampling, n=2,4,2,4CD163+, Session2,Day1, 40 minutes, n=2,4,2,4CD163+, Session2,Day1,2 hour 40 minutes, n=2,4,2,4CD163+, Session2,Day1,5 hour 40 minutes, n=2,4,2,4CD163+,Session2,Day2, Pre-fluid sampling,n=2,4,2,4CD163+,Session2,Day3, Pre-fluid sampling,n=2,4,2,4CD206+, Session2,Day1, 40 minutes, n=2,3,2,4CD206+, Session2,Day1,2 hour 40 minutes, n=2,2,2,4CD206+, Session2,Day1,5 hour 40 minutes, n=2,2,2,4CD206+,Session2,Day2, Pre-fluid sampling,n=2,2,2,4CD206+,Session2,Day3, Pre-fluid sampling,n=2,4,2,4CD209+, Session2,Day1, 40 minutes, n=2,4,2,4CD209+, Session2,Day1,2 hour 40 minutes, n=2,4,2,4CD209+, Session2,Day1,5 hour 40 minutes, n=2,4,2,4CD209+,Session2,Day2,Pre-fluid sampling,n=2,4, 2,4CD209+,Session2,Day3, Pre-fluid sampling,n=2,4,2,4CD40, Session2,Day1, 40 minutes, n=2,4,2,4CD40, Session2,Day1,2 hour 40 minutes, n=2,4,2,4CD40, Session2,Day1,5 hour 40 minutes, n=2,4,2,4CD40, Session2,Day2, Pre-fluid sampling,n=2,4, 2,4CD40, Session2,Day3, Pre-fluid sampling,n=2, 4,2,4CD80, Session2,Day1, 40 minutes, n=2, 4,2,4CD80, Session2,Day1,2 hour 40 minutes, n=2,4,2,4CD80, Session2,Day1,5 hour 40 minutes, n=2, 4,2,4CD80,Session2,Day2, Pre-fluid sampling,n=2, 4,2,4CD80,Session2,Day3, Pre-fluid sampling,n=2, 4,2,4CD83, Session2,Day1, 40 minutes, n=2, 4,2,4CD83, Session2,Day1,2 hour 40 minutes, n=2, 4,2,4CD83, Session2,Day1,5 hour 40 minutes, n=2, 4,2,4CD83,Session2,Day2, Pre-fluid sampling,n=2, 4,2,4CD83,Session2,Day3, Pre-fluid sampling,n=2, 4,2,4CD86+, Session2,Day1, 40 minutes, n=2, 4,2,4CD86+, Session2,Day1,2 hour 40 minutes, n=2, 4,2,4CD86+, Session2,Day1,5 hour 40 minutes, n=2, 4,2,4CD86+,Session2,Day2, Pre-fluid sampling,n=2, 4,2,4CD86+,Session2,Day3, Pre-fluid sampling,n=2, 4,2,4HLA-DR, Session2,Day1, 40 minutes, n=2, 4,2,4HLA-DR, Session2,Day1,2 hour 40 minutes, n=2,4,2,4HLA-DR, Session2,Day1,5 hour 40 minutes, n=2,4,2,4HLA-DR,Session2,Day2, Pre-fluid sampling,n=2,4,2,4HLA-DR,Session2,Day3, Pre-fluid sampling,n=2,4,2,4
Part 1: LPS 0.5 ng/kg-117.5000-128.9500-130.1500125.5000-24.5000-371.000-499.500-363.5004.500-66.000-502.5001011.000-388.500423.000-496.50015.800-78.65017.35036.450-30.630-96.5000-84.0000-136.500029.5000-184.5000-56.0000-48.5000-80.500046.000045.5000-360.500254.500-441.500-32.000-547.000-93.500015.5000-130.000032.5000-60.5000-1701.500-706.000-1452.000-171.000-957.500
Part 1: LPS 0.75 ng/kg-10.5565-31.4965-35.3433162.8120-6.6285-833.203-902.203-694.390146.4033.801-892.543-583.485-686.465-202.457-469.5504.001-9.406-17.622-3.732-7.759-36.2400-34.9520-3.548076.4310-8.550322.5760-14.4080-28.417533.886311.4885-509.522-192.732136.272185.975-261.969-51.3590-80.7150-85.097343.120320.5612-3036.438-3133.030-2242.108924.615-978.224
Part 1: LPS 1 ng/kg-47.0000-76.6000-94.3000427.5000142.5000-721.000-790.000-522.50022.500-80.00086.500-293.50012.000273.000-9.500-9.700-2.650-44.250174.8505.850340.0000-97.0000-62.00001.00001.5000151.5000-43.0000-112.900048.0000-5.5000341.000-157.50056.500-312.000-618.500-35.0000-62.5000-11.5000120.500035.5000-2247.000-1898.000-1296.5002717.500-3.000

[back to top]

Part 1: Change From Baseline in Cell Activation Markers by Flow Cytometry on Monocytes in Blood

Blood samples were collected at indicated time-points for the measurement of activation markers by flow cytometry for monocytes in blood. Activation markers included CD16, CD163, CD206, CD209, CD40, CD80, CD83, CD86 and HLA-DR. Latest pre-challenge (LPS or GM-CSF) assessment with a non-missing value, including those from unscheduled visits was considered as Baseline. Change from Baseline was calculated as the value at specified visit minus the Baseline value. (NCT03306589)
Timeframe: Baseline; Session 2: 40 minutes, 2 hours 40 minutes, 5 hours 40 minutes, 9 hours 40 minutes on Day 1. Pre-fluid sample on Day 2 and Day 3

InterventionMean fluorescence intensity (Mean)
CD16+, Session2,Day1, 40 minutes, n=2, 4, 2,4CD16+, Session2,Day1, 2 hour 40 minutes, n=2,4,2,4CD16+, Session2,Day1, 5 hour 40 minutes, n=2,4,2,4CD16+, Session2,Day1,9 hour 40 minutes,n-0,0,0,4CD16+,Session2,Day2, Pre-fluid sampling, n=2,4,2,4CD16+,Session2,Day3, Pre-fluid sampling, n=2,4,2,4CD163+, Session2,Day1, 40 minutes, n=2,4,2,4CD163+, Session2,Day1,2 hour 40 minutes, n=2,4,2,4CD163+, Session2,Day1,5 hour 40 minutes, n=2,4,2,4CD163+, Session2,Day1, 9 hour 40 minutes,n-0,0,0,4CD163+,Session2,Day2, Pre-fluid sampling,n=2,4,2,4CD163+,Session2,Day3, Pre-fluid sampling,n=2,4,2,4CD206+, Session2,Day1, 40 minutes, n=2,3,2,4CD206+, Session2,Day1,2 hour 40 minutes, n=2,2,2,4CD206+, Session2,Day1,5 hour 40 minutes, n=2,2,2,4CD206+, Session2,Day1,9 hour 40 minutes,n=0,0,0,4CD206+,Session2,Day2, Pre-fluid sampling,n=2,2,2,4CD206+,Session2,Day3, Pre-fluid sampling,n=2,4,2,4CD209+, Session2,Day1, 40 minutes, n=2,4,2,4CD209+, Session2,Day1,2 hour 40 minutes, n=2,4,2,4CD209+, Session2,Day1,5 hour 40 minutes, n=2,4,2,4CD209+, Session2,Day1,9 hour 40 minutes,n=0,0,0,4CD209+,Session2,Day2,Pre-fluid sampling,n=2,4, 2,4CD209+,Session2,Day3, Pre-fluid sampling,n=2,4,2,4CD40, Session2,Day1, 40 minutes, n=2,4,2,4CD40, Session2,Day1,2 hour 40 minutes, n=2,4,2,4CD40, Session2,Day1,5 hour 40 minutes, n=2,4,2,4CD40, Session2,Day1,9 hour 40 minutes,n=0,0,0,4CD40, Session2,Day2, Pre-fluid sampling,n=2,4, 2,4CD40, Session2,Day3, Pre-fluid sampling,n=2, 4,2,4CD80, Session2,Day1, 40 minutes, n=2, 4,2,4CD80, Session2,Day1,2 hour 40 minutes, n=2,4,2,4CD80, Session2,Day1,5 hour 40 minutes, n=2, 4,2,4CD80, Session2,Day1,9 hour 40 minutes, n=0,0,0,4CD80,Session2,Day2, Pre-fluid sampling,n=2, 4,2,4CD80,Session2,Day3, Pre-fluid sampling,n=2, 4,2,4CD83, Session2,Day1, 40 minutes, n=2, 4,2,4CD83, Session2,Day1,2 hour 40 minutes, n=2, 4,2,4CD83, Session2,Day1,5 hour 40 minutes, n=2, 4,2,4CD83, Session2,Day1,9 hour 40 minutes,n=0,0,0,4CD83,Session2,Day2, Pre-fluid sampling,n=2, 4,2,4CD83,Session2,Day3, Pre-fluid sampling,n=2, 4,2,4CD86+, Session2,Day1, 40 minutes, n=2, 4,2,4CD86+, Session2,Day1,2 hour 40 minutes, n=2, 4,2,4CD86+, Session2,Day1,5 hour 40 minutes, n=2, 4,2,4CD86+, Session2,Day1,9 hour 40 minutes,n=0,0,0,4CD86+,Session2,Day2, Pre-fluid sampling,n=2, 4,2,4CD86+,Session2,Day3, Pre-fluid sampling,n=2, 4,2,4HLA-DR, Session2,Day1, 40 minutes, n=2, 4,2,4HLA-DR, Session2,Day1,2 hour 40 minutes, n=2,4,2,4HLA-DR, Session2,Day1,5 hour 40 minutes, n=2,4,2,4HLA-DR, Session2,Day1,9 hour 40 minutes,n=0,0,0,4HLA-DR,Session2,Day2, Pre-fluid sampling,n=2,4,2,4HLA-DR,Session2,Day3, Pre-fluid sampling,n=2,4,2,4
Part 1: GM-CSF 60 µg/m^2-26.3505-26.6015-29.1195-24.551042.9945-11.7065-511.618-426.253-376.659-314.464-73.24763.254932.8071808.3452051.8722546.8841724.19711.054-16.194-10.00010.936-7.28471.59223.752-74.1970-36.8868-9.827836.284587.4498-33.4253-10.8950-11.1910-5.984213.176051.190029.5018268.284113.359-694.319450.242-72.629-461.28022.13307.4130-77.6915-58.900827.5388-17.0975-1240.116-764.884-126.436798.182904.203-549.404

[back to top]

Part 1: Change From Baseline in Cell Numbers in Blister

Blister samples were collected at indicated time-points for analysis of white blood cell in blister. Latest pre-challenge LPS assessment with a non-missing value, including those from unscheduled visits was considered as Baseline. Change from Baseline was calculated as the value at specified visit minus the Baseline value. (NCT03306589)
Timeframe: Baseline, Session 1: 48 hours Day 3. Session 2: 24 hours Day 2, 48 hours Day 3

,,
InterventionCells per milliliter (Mean)
Session 1, Day 3, 48 hoursSession 2, Day 2, 24 hoursSession 2, Day 3, 48 hours
Part 1: LPS 0.5 ng/kg841250.0-298750.0586250.0
Part 1: LPS 0.75 ng/kg-1405000.0-936062.5-1316000.0
Part 1: LPS 1 ng/kg667500.05447500.03275000.0

[back to top]

Part 1: Change From Baseline in Circulating Leukocyte Numbers in Blood: LPS Arm

Blood samples were collected at indicated time-points for analysis of leukocyte. Latest pre-challenge assessment with a non-missing value, including those from unscheduled visits was considered as Baseline. Change from Baseline was calculated as the value at specified visit minus the Baseline value. (NCT03306589)
Timeframe: Baseline; Session 2: 40 minutes, 2 hours 40 minutes, 5 hours 40 minutes on Day 1. Pre-fluid sample on Day 2 and Day 3

,,
InterventionCells per milliliter (Mean)
Session2, Day 1, 40 minutesSession2, Day 1, 2 hours 40 minutesSession2, Day 1, 5 hours 40 minutesSession2, Day 2, Pre-fluid sampleSession2, Day 3, Pre-fluid sample
Part 1: LPS 0.5 ng/kg-358893.713347754.142116748.36-447452.27-169328.51
Part 1: LPS 0.75 ng/kg-1477705.002423233.004511414.25881299.75-93685.25
Part 1: LPS 1 ng/kg-2065961.835224467.233641780.22442226.6875348.31

[back to top]

Part 1: Change From Baseline in Primary Soluble Inflammatory Mediators : Urinary Tetranor Prostaglandin D Metabolite (PGDM) LPS Arm

The post-challenge urine samples were collected during session 2 after LPS challenge. In session 2, participants were encouraged to pass urine immediately before LPS challenge dose and urine voids were collected from after LPS until 12 hours post-LPS and the time of the urine collection were recorded as post-challenge 1 to 11. These samples were collected for measurement of tetranor-PGDM. Latest pre-challenge LPS assessment with a non-missing value, including those from unscheduled visits was considered as Baseline. Change from Baseline was calculated as the value at specified visit minus the Baseline value. The data for normalized Tetranor PGDM was normalized by (Tetranor PGDM [pg/mL] divided by Creatinine [milligram per deciliter]) multiplied by 100. NA indicates that data was not available as standard deviation could not be calculated for a single participant. (NCT03306589)
Timeframe: Baseline, Session 2 Day 1

,
InterventionPicograms per milligram (Mean)
Session2, Day1,Post challenge1, n=2, 4, 2Session2, Day1,Post challenge 2, n=2, 4, 2Session2, Day1,Post challenge 3, n=2, 4, 2Session2, Day1,Post challenge 4, n=2, 4, 2Session2, Day1,Post challenge 5, n=1, 4, 2Session2, Day1,Post challenge 6, n=0, 4, 1Session2, Day1,Post challenge 7, n=0, 4, 1Session2, Day1,Post challenge 8, n=0, 3, 1Session2, Day1,Post challenge 9, n=0, 2, 1Session2, Day1,Post challenge 10, n=0, 1, 1Session2, Day1,Post challenge 11, n=0, 1, 1
Part 1: LPS 0.75 ng/kg-85.08088.98425.390-68.209-146.294-202.918-227.544-144.855-147.066-172.982-199.316
Part 1: LPS 1 ng/kg134.806276.788200.337140.482184.263-125.8396.336-117.672-30.861-37.732-78.792

[back to top]

Part 1: Change From Baseline in Soluble Inflammatory Mediators in Blood: C-reactive Protein (CRP)

Blood samples were collected at indicated time-points for the analysis of soluble inflammatory mediators like CRP in blood. Latest pre-challenge (LPS or GM-CSF) assessment with a non-missing value, including those from unscheduled visits was considered as Baseline. Change from Baseline was calculated as the value at specified visit minus the Baseline value. (NCT03306589)
Timeframe: Baseline; Session 2: Post challenge Day 1. Pre-fluid sample on Day 2 and Day 3

,,,
InterventionMilligrams per liter (Mean)
Session2,Day1, Post-challengeSession2,Day 2, Pre-fluid sampleSession2,Day 3, Pre-fluid sample
Part 1: GM-CSF 60 µg/m^21.535.802.25
Part 1: LPS 0.5 ng/kg0.207.501.50
Part 1: LPS 0.75 ng/kg2.7521.8010.65
Part 1: LPS 1 ng/kg2.4018.558.45

[back to top]

Part 1: Change From Baseline in Soluble Inflammatory Mediators in Blood: TNF-alpha, IL-6 and GM-CSF: GM-CSF Arm

Blood samples were collected at indicated time-points for the analysis of soluble inflammatory mediators like TNF-alpha, IL-6 and GM-CSF in blood. Latest pre-challenge GM-CSF assessment with a non-missing value, including those from unscheduled visits was considered as Baseline. Change from Baseline was calculated as the value at specified visit minus the Baseline value. (NCT03306589)
Timeframe: Baseline, Session 2: -5, 10, 25, 40 minutes, 1 hour 10 minutes, 1 hour 40 minutes, 2 hours 40 minutes, 5 hours 40 minutes on Day 1. Pre-fluid sample on Day 2 and Day 3

InterventionPicograms per milliliter (Mean)
GM-CSF, Session2,Day1, -5 minutesGM-CSF, Session2,Day1, 10 minutesGM-CSF, Session2,Day1, 25 minutesGM-CSF, Session2,Day1, 40 minutesGM-CSF, Session2,Day1,1 hour 10 minutesGM-CSF, Session2,Day1,1 hour 40 minutesGM-CSF, Session2,Day1,2 hour 40 minutesGM-CSF, Session2,Day1,5 hour 40 minutesGM-CSF, Session2,Day2,Pre-fluid samplingGM-CSF, Session2,Day3,Pre-fluid samplingIL-6, Session2,Day1, -5 minutesIL-6, Session2,Day1, 10 minutesIL-6, Session2,Day1, 25 minutesIL-6, Session2,Day1, 40 minutesIL-6, Session2,Day1, 1hour 10minutesIL-6, Session2,Day1, 1hour 40minutesIL-6, Session2,Day1, 2hour 40minutesIL-6, Session2,Day1, 5hour 40minutesIL-6, Session2,Day2,Pre-fluid sampleIL-6, Session2,Day3,Pre-fluid sampleTNF-alpha, Session2,Day1, -5 minutesTNF-alpha, Session2,Day1, 10 minutesTNF-alpha, Session2,Day1, 25 minutesTNF-alpha, Session2,Day1, 40 minutesTNF-alpha, Session2,Day1, 1 hour 10 minutesTNF-alpha, Session2,Day1, 1 hour 40 minutesTNF-alpha, Session2,Day1, 2 hour 40 minutesTNF-alpha, Session2,Day1, 5 hour 40 minutesTNF-alpha, Session2,Day2, Pre-fluid samplingTNF-alpha, Session2,Day3, Pre-fluid sampling
Part 1: GM-CSF 60 µg/m^21674.2351260.988624.895364.045145.79352.1587.4860.0000.0000.0008.813611.385113.069910.93596.84855.03342.64961.91351.2598-0.03242.67402.48602.54752.21002.13801.96651.60010.95620.5423-0.1194

[back to top]

Part 1: Change From Baseline in White Blood Cell Numbers in Blood: GM-CSF

Blood samples were collected at indicated time-points for analysis of white blood cells. Latest pre-challenge GM-CSF assessment with a non-missing value, including those from unscheduled visits was considered as Baseline. Change from Baseline was calculated as the value at specified visit minus the Baseline value. (NCT03306589)
Timeframe: Baseline, Session 2: 40 minutes, 2 hours 40 minutes, 5 hours 40 minutes, 9 hours 40 minutes on Day 1. Pre-fluid sample on Day 2 and Day 3

InterventionGiga cells per liter (Mean)
Session2, Day 1, 40 minutesSession2, Day 1, 2 hours 40 minutesSession2, Day 1, 5 hours 40 minutesSession2, Day 1, 9 hours 40 minutesSession2, Day 2, Pre-fluid sampleSession2, Day 3, Pre-fluid sample
Part 1: GM-CSF 60 µg/m^20.37546.76095.80833.45580.4224-0.0136

[back to top]

Part 1: Change From Baseline Primary Soluble Inflammatory Mediators in Blood: Tumor Necrosis Factor (TNF) Alpha and Interleukin (IL) 6 for LPS Arm

Blood samples were collected at indicated timepoints for the analysis of primary soluble inflammatory mediators like TNF-alpha and IL-6 in blood. Latest pre-challenge LPS assessment with a non-missing value, including those from unscheduled visits was considered as Baseline. Change from Baseline was calculated as the value at specified visit minus the Baseline value. Each session was for three days. NA indicates that data was not available as standard deviation could not be calculated for a single participant. All participants who were randomized to receive the treatment (LPS or GM-CSF challenge) and received one dose of challenge agent were included in Safety Population. (NCT03306589)
Timeframe: Baseline, Session 2: -5, 10, 25, 40 minutes, 1 hour 10 minutes, 1 hour 40 minutes, 2 hours 40 minutes,5 hours 40 minutes on Day 1. Pre-fluid sample on Day 2 and Day 3

,,
InterventionPicograms per milliliter (Mean)
IL-6, Session2,Day1, -5 minutes, n=2, 4, 2IL-6, Session2,Day1, 10 minutes, n=2, 4, 2IL-6, Session2,Day1, 25 minutes, n=1, 4, 2IL-6, Session2,Day1, 40 minutes, n=2, 4, 2IL-6, Session2,Day1, 1 hour 10 minutes, n=2, 4, 2IL-6, Session2,Day1, 1 hour 40 minutes, n=2, 4, 2IL-6, Session2,Day1, 2 hour 40 minutes, n=2, 4, 2IL-6, Session2,Day1, 5 hour 40 minutes, n=2, 4, 2IL-6, Session2,Day2, Pre-fluid sampling, n=2, 4, 2IL-6, Session2,Day3, Pre-fluid sampling, n=2, 4, 2TNF alpha, Session2,Day1, -5 minutes, n=2, 4, 2TNF alpha, Session2,Day1, 10 minutes, n=2, 4, 2TNF alpha, Session2,Day1, 25 minutes, n=1, 4, 2TNF alpha, Session2,Day1, 40 minutes, n=2, 4, 2TNF alpha, Session2,Day1, 1hour 10minutes, n=2,4,2TNF alpha, Session2,Day1, 1hour 40minutes, n=2,4,2TNF alpha, Session2,Day1, 2hour 40minutes, n=2,4,2TNF alpha, Session2,Day1, 5hour 40minutes, n=2,4,2TNF alpha, Session2,Day2,Pre-fluid sample, n=2,4,2TNF alpha, Session2,Day3,Pre-fluid sample, n=2,4,2
Part 1: LPS 0.5 ng/kg2.40863.64603.314110.807430.639541.322123.93215.699117.8308-0.4610-0.25416.572020.246952.166543.494934.303122.55715.008712.92790.2453
Part 1: LPS 0.75 ng/kg0.27980.24501.36238.762281.0629193.7107133.20632.56453.28800.5909-0.07262.378456.6529157.5403202.6136147.347268.887915.48281.25320.2951
Part 1: LPS 1 ng/kg-0.01260.01231.885411.867251.823265.567532.38424.51410.34420.15426.405612.764784.6080152.9415115.669378.473444.337211.13780.64750.1391

[back to top]

Part 1: Change From Baseline Soluble Inflammatory Biomarkers in Skin Blister

Blister samples were collected at indicated time-points for the analysis of soluble inflammatory mediators like IL-1 beta (b), Interferon-gamma (INFg), IL-6, IL-2, IL-8, Monocyte chemotactic protein-1 (MCP-1) and TNF-alpha. Latest pre-challenge (LPS or GM-CSF) assessment with a non-missing value, including those from unscheduled visits was considered as Baseline. Change from Baseline was calculated as the value at specified visit minus the Baseline value. NA indicates that data was not available as standard deviation could not be calculated for a single participant. (NCT03306589)
Timeframe: Baseline; Session1: 48 hours on Day3; Session 2: 24 hours on Day 2 and 48 hours on Day 3

,
InterventionPicograms per milliliter (Mean)
IL-1b, Session1, Day 3, 48 hours, n=2, 2, 2,3IL-1b, Session2,Day2, 24 hours, n=2, 2, 2,1IL-1b, Session2,Day3, 48 hours, n=2, 2, 2,1IL-2, Session1,Day3, 48 hours, n=2, 2, 2, 3IL-2, Session2,Day2, 24 hours, n=2, 2, 2, 1IL-2, Session2,Day3, 48 hours, n=2, 2, 2, 1MCP-1, Session1,Day3, 48 hours, n=2,4,2,4MCP-1, Session2,Day2, 24 hours, n=2,4,2,4MCP-1, Session2,Day3, 48 hours, n=2,4,2,4TNF alpha,Session1,Day3,48 hours, n=2,2,2,3TNF alpha,Session2,Day2, 24 hours, n=2,2,2,1TNF alpha,Session2,Day3,48 hours, n=2,2,2,1
Part 1: GM-CSF 60 µg/m^235.4452-0.3579-6.83021.24440.00002.1293-10284.384299.94-11416.80-33.5839-29.6573-51.9244
Part 1: LPS 0.75 ng/kg-41.5298-83.1670-81.6788-0.56990.18042.1377-10520.934723.831077.95-98.893053.6996-110.6500

[back to top]

Part 1: Change From Baseline Soluble Inflammatory Biomarkers in Skin Blister

Blister samples were collected at indicated time-points for the analysis of soluble inflammatory mediators like IL-1 beta (b), Interferon-gamma (INFg), IL-6, IL-2, IL-8, Monocyte chemotactic protein-1 (MCP-1) and TNF-alpha. Latest pre-challenge (LPS or GM-CSF) assessment with a non-missing value, including those from unscheduled visits was considered as Baseline. Change from Baseline was calculated as the value at specified visit minus the Baseline value. NA indicates that data was not available as standard deviation could not be calculated for a single participant. (NCT03306589)
Timeframe: Baseline; Session1: 48 hours on Day3; Session 2: 24 hours on Day 2 and 48 hours on Day 3

,
InterventionPicograms per milliliter (Mean)
IL-1b, Session1, Day 3, 48 hours, n=2, 2, 2,3IL-1b, Session2,Day2, 24 hours, n=2, 2, 2,1IL-1b, Session2,Day3, 48 hours, n=2, 2, 2,1IFNg, Session1,Day3, 48 hours, n=2, 0, 2, 0IFNg, Session2,Day2, 24 hours, n=2, 0, 2, 0IFNg, Session2,Day3, 48 hours, n=2, 0, 2, 0IL-2, Session1,Day3, 48 hours, n=2, 2, 2, 3IL-2, Session2,Day2, 24 hours, n=2, 2, 2, 1IL-2, Session2,Day3, 48 hours, n=2, 2, 2, 1IL-6, Session1,Day3,48 hours, n=2, 0, 2, 0IL-6, Session2,Day2, 24 hours, n=1, 0, 1, 0IL-6, Session2,Day3, 48 hours, n=1, 0, 2, 0IL-8, Session1,Day3,48 hours, n=2, 0, 2, 0IL-8, Session2,Day2, 24 hours, n=2, 0, 2, 0IL-8, Session2,Day3, 48 hours, n=2, 0, 2, 0MCP-1, Session1,Day3, 48 hours, n=2,4,2,4MCP-1, Session2,Day2, 24 hours, n=2,4,2,4MCP-1, Session2,Day3, 48 hours, n=2,4,2,4TNF alpha,Session1,Day3,48 hours, n=2,2,2,3TNF alpha,Session2,Day2, 24 hours, n=2,2,2,1TNF alpha,Session2,Day3,48 hours, n=2,2,2,1
Part 1: LPS 0.5 ng/kg-30.9691-48.4241-51.099232.5244-3.81910.66521.34700.25250.2451-1588.01-0.1341.39-127550.93-31850.03-126387.78-36463.42-2842.63-18920.55-69.1140-25.3949-83.6471
Part 1: LPS 1 ng/kg3.62437.97337.678355.9575-4.57722.95560.16230.00000.69681535.45-349.63-25.74-42387.4134295.91-42836.70-18336.3118049.87-16980.85-16.082634.8290-10.5091

[back to top]

Part 1:Change From Baseline in Cell Activation Markers by Flow Cytometry on Dendritic Cells in Blister

Blister samples were collected at indicated time-points for the measurement of activation markers by flow cytometry for dendritic cells in blister. Activation markers included CD16, CD163, CD206, CD209, CD40, CD80, CD83, CD86 and HLA-DR. Latest pre-challenge (LPS or GM-CSF) assessment with a non-missing value, including those from unscheduled visits was considered as Baseline. Change from Baseline was calculated as the value at specified visit minus the Baseline value. NA indicates that data was not available as standard deviation could not be calculated for a single participant. (NCT03306589)
Timeframe: Baseline; Session1: 48 hours Day 3, Session 2: 24 hours Day 2 and 48 hours Day 3

InterventionMean fluorescence intensity (Mean)
CD16+, Session1,Day3, 48 hours, n=2, 4, 2, 4CD16+, Session2,Day2, 24 hours, n=2, 4, 2, 4CD16+, Session2,Day3, 48 hours, n=2, 4, 2, 4CD163+, Session1,Day3, 48 hours, n=2, 4, 2, 4CD163+, Session2,Day2, 24 hours, n=2, 4, 2, 4CD163+, Session2,Day3, 48 hours, n=2, 4, 2, 4CD206+, Session1,Day3, 48 hours, n=2, 2, 2, 4CD209+, Session1,Day3,48 hours, n=2, 4, 2, 4CD209+, Session2,Day2, 24 hours, n=2, 4, 2, 4CD209+, Session2,Day3, 48 hours, n=2, 4, 2, 4CD40, Session1,Day3, 48 hours, n=2, 4, 2, 4CD40, Session2,Day2, 24 hours, n=2, 4, 2, 4CD40, Session2,Day3, 48 hours, n=1, 4, 2, 3CD80, Session1,Day3, 48 hours, n=2, 4, 2, 4CD80, Session2,Day2, 24 hours, n=2, 4, 2, 4CD80, Session2,Day3, 48 hours, n=2, 4, 2, 4CD83, Session1,Day3, 48 hours, n=2, 4, 2, 4CD83, Session2,Day2, 24 hours, n=2, 4, 2, 4CD83, Session2,Day3, 48 hours, n=2, 4, 2, 4CD86+, Session1,Day3, 48 hours, n=2, 4, 2, 4CD86+, Session2,Day2, 24 hours, n=2, 4, 2, 4CD86+, Session2,Day3, 48 hours, n=2, 4, 2, 4HLA-DR, Session1,Day3, 48 hours, n=2, 4, 2, 4HLA-DR, Session2,Day2, 24 hours, n=2, 4, 2, 4HLA-DR, Session2,Day3, 48 hours, n=2, 4, 2, 4
Part 1: LPS 0.75 ng/kg668.512235.293208.225-91.1420-49.4854-124.5144-1057.04765.14038.604297.9361403.00017.3541072.4164155.674-583.0163665.6662806.835-409.1873368.1054689.54-696.707229.6731657.05-3470.2316282.97

[back to top]

Part 1:Change From Baseline in Cell Activation Markers by Flow Cytometry on Dendritic Cells in Blister

Blister samples were collected at indicated time-points for the measurement of activation markers by flow cytometry for dendritic cells in blister. Activation markers included CD16, CD163, CD206, CD209, CD40, CD80, CD83, CD86 and HLA-DR. Latest pre-challenge (LPS or GM-CSF) assessment with a non-missing value, including those from unscheduled visits was considered as Baseline. Change from Baseline was calculated as the value at specified visit minus the Baseline value. NA indicates that data was not available as standard deviation could not be calculated for a single participant. (NCT03306589)
Timeframe: Baseline; Session1: 48 hours Day 3, Session 2: 24 hours Day 2 and 48 hours Day 3

,,
InterventionMean fluorescence intensity (Mean)
CD16+, Session1,Day3, 48 hours, n=2, 4, 2, 4CD16+, Session2,Day2, 24 hours, n=2, 4, 2, 4CD16+, Session2,Day3, 48 hours, n=2, 4, 2, 4CD163+, Session1,Day3, 48 hours, n=2, 4, 2, 4CD163+, Session2,Day2, 24 hours, n=2, 4, 2, 4CD163+, Session2,Day3, 48 hours, n=2, 4, 2, 4CD206+, Session1,Day3, 48 hours, n=2, 2, 2, 4CD206+, Session2,Day2, 24 hours, n=2, 0, 2, 4CD206+, Session2,Day3, 48 hours, n=2, 0, 2, 4CD209+, Session1,Day3,48 hours, n=2, 4, 2, 4CD209+, Session2,Day2, 24 hours, n=2, 4, 2, 4CD209+, Session2,Day3, 48 hours, n=2, 4, 2, 4CD40, Session1,Day3, 48 hours, n=2, 4, 2, 4CD40, Session2,Day2, 24 hours, n=2, 4, 2, 4CD40, Session2,Day3, 48 hours, n=1, 4, 2, 3CD80, Session1,Day3, 48 hours, n=2, 4, 2, 4CD80, Session2,Day2, 24 hours, n=2, 4, 2, 4CD80, Session2,Day3, 48 hours, n=2, 4, 2, 4CD83, Session1,Day3, 48 hours, n=2, 4, 2, 4CD83, Session2,Day2, 24 hours, n=2, 4, 2, 4CD83, Session2,Day3, 48 hours, n=2, 4, 2, 4CD86+, Session1,Day3, 48 hours, n=2, 4, 2, 4CD86+, Session2,Day2, 24 hours, n=2, 4, 2, 4CD86+, Session2,Day3, 48 hours, n=2, 4, 2, 4HLA-DR, Session1,Day3, 48 hours, n=2, 4, 2, 4HLA-DR, Session2,Day2, 24 hours, n=2, 4, 2, 4HLA-DR, Session2,Day3, 48 hours, n=2, 4, 2, 4
Part 1: LPS 0.5 ng/kg-31.250284.750154.000-103.7500-112.7500-132.2500-56.00-430.254.0083.25079.750101.750963.75096.000383.5002609.000-130.0001235.0002342.250-28.0001199.5002590.75-509.751175.251020.00-494.00-4386.50
Part 1: GM-CSF 60 µg/m^283.647225.589268.838-16.622047.1343-32.44642032.273032.02856.3295.1011834.8671822.510923.024293.4851389.5364998.865407.2773958.8383834.100648.3463264.3003936.2994.294132.683242.8611902.8219351.27
Part 1: LPS 1 ng/kg44.50062.750186.250-105.7500267.2500-70.00001372.75-665.00198.75-211.000743.750835.000776.000-10.250783.7502366.000-237.2501407.2502624.000-343.2502924.2502701.50-184.002750.50-2661.75480.501564.00

[back to top]

Part 1:Change From Baseline in Cell Activation Markers by Flow Cytometry on Macrophages in Blister

Blister samples were collected at indicated time-points for the measurement of activation markers by flow cytometry for macrophages in blister. Activation markers included CD16, CD163, CD206, CD209, CD40, CD80, CD83, CD86 and HLA-DR. Latest pre-challenge (LPS or GM-CSF) assessment with a non-missing value, including those from unscheduled visits was considered as Baseline. Change from Baseline was calculated as the value at specified visit minus the Baseline value. NA indicates that data was not available as standard deviation could not be calculated for a single participant. (NCT03306589)
Timeframe: Baseline, Session1: 48 hours Day 3, Session 2: 24 hours Day 2 and 48 hours Day 3

,,,
InterventionMean fluorescence intensity (Mean)
CD16+, Session1,Day3, 48 hours, n=2, 4, 2, 4CD16+, Session2,Day2, 24 hours, n=2, 4, 2, 4CD16+, Session2,Day3, 48 hours, n=2, 4, 2, 4CD163+, Session1,Day3, 48 hours, n=2, 4, 2, 4CD163+, Session2,Day2, 24 hours, n=2, 4, 2, 4CD163+, Session2,Day3, 48 hours, n=2, 4, 2, 4CD206+, Session1,Day3, 48 hours, n=2, 4, 2, 4CD206+, Session2,Day2, 24 hours, n=2, 4, 2, 4CD206+, Session2,Day3, 48 hours, n=2, 4, 2, 4CD209+, Session1,Day3,48 hours, n=2, 4, 2, 4CD209+, Session2,Day2, 24 hours, n=2, 4, 2, 4CD209+, Session2,Day3, 48 hours, n=2, 4, 2, 4CD40, Session1,Day3, 48 hours, n=2, 4, 2, 4CD40, Session2,Day2, 24 hours, n=2, 4, 2, 4CD40, Session2,Day3, 48 hours, n=1, 4, 2, 4CD80, Session1,Day3, 48 hours, n=2, 4, 2, 4CD80, Session2,Day2, 24 hours, n=2, 4, 2, 4CD80, Session2,Day3, 48 hours, n=2, 4, 2, 4CD83, Session1,Day3, 48 hours, n=2, 4, 2, 4CD83, Session2,Day2, 24 hours, n=2, 4, 2, 4CD83, Session2,Day3, 48 hours, n=2, 4, 2, 4CD86+, Session1,Day3, 48 hours, n=2, 4, 2, 4CD86+, Session2,Day2, 24 hours, n=2, 4, 2, 4CD86+, Session2,Day3, 48 hours, n=2, 4, 2, 4HLA-DR, Session1,Day3, 48 hours, n=2, 4, 2, 4HLA-DR, Session2,Day2, 24 hours, n=2, 4, 2, 4HLA-DR, Session2,Day3, 48 hours, n=2, 4, 2, 4
Part 1: GM-CSF 60 µg/m^2-2607.25-1010.00-3653.63723.125169.750789.513-734.8812596.63-2622.75890.885641.132835.13-59.503426.13-70.50304.881215.88-744.88-842.63918.75-1668.6328.25-570.75517.50-5724.2536041.1311460.13
Part 1: LPS 0.5 ng/kg-5027.0013111.25-4621.75888.50049.7501012.00081.004503.00-1229.25931.00474.75565.75593.251007.0074.50884.001250.50-84.75-1139.00420.50-1703.75792.50381.2513.753326.257435.25-882.00
Part 1: LPS 0.75 ng/kg4510.75-2948.25-6203.50400.50048.250411.000-1275.50564.00-2542.63458.8821.63-236.13198.00-43.38-166.131193.63353.63-114.50-556.881243.25-1046.38577.50674.501692.50-7695.3813061.88-20377.25
Part 1: LPS 1 ng/kg-3449.755372.75-3286.25270.250415.250719.250-955.75-1329.50-2193.50-333.001672.251607.75371.75-691.50-480.251403.75-1136.25-1686.502522.002690.50745.752311.50-329.75181.756003.751273.75-8397.75

[back to top]

Part 1:Change From Baseline in Cell Activation Markers by Flow Cytometry on Monocytes in Blister

Blister samples were collected at indicated time-points for the measurement of activation markers by flow cytometry for monocytes in blister. Activation markers included Cluster of Differentiation (CD) 16, CD163, CD206, CD209, CD40, CD80, CD83, CD86 and Human Leukocyte Antigen - antigen D Related (HLA-DR). Latest pre-challenge (LPS or GM-CSF) assessment with a non-missing value, including those from unscheduled visits was considered as Baseline. Change from Baseline was calculated as the value at specified visit minus the Baseline value. NA indicates that data was not available as standard deviation could not be calculated for a single participant. (NCT03306589)
Timeframe: Baseline, Session1: 48 hours Day 3, Session 2: 24 hours Day 2 and 48 hours Day 3

,,
InterventionMean fluorescence intensity (Mean)
CD16+, Session1,Day3, 48 hours, n=2, 4, 2, 4CD16+, Session2,Day2, 24 hours, n=2, 4, 2, 4CD16+, Session2,Day3, 48 hours, n=2, 4, 2, 4CD163+, Session1,Day3, 48 hours, n=2, 4, 2, 4CD163+, Session2,Day2, 24 hours, n=2, 4, 2, 4CD163+, Session2,Day3, 48 hours, n=2, 4, 2, 4CD206+, Session1,Day3, 48 hours, n=2, 2, 2, 4CD206+, Session2,Day2, 24 hours, n=2, 0, 2, 4CD206+, Session2,Day3, 48 hours, n=2, 0, 2, 4CD209+, Session1,Day3,48 hours, n=2, 4, 2, 4CD209+, Session2,Day2, 24 hours, n=2, 4, 2, 4CD209+, Session2,Day3, 48 hours, n=2, 4, 2, 4CD40, Session1,Day3, 48 hours, n=2, 4, 2, 4CD40, Session2,Day2, 24 hours, n=2, 4, 2, 4CD40, Session2,Day3, 48 hours, n=1, 4, 2, 3CD80, Session1,Day3, 48 hours, n=2, 4, 2, 4CD80, Session2,Day2, 24 hours, n=2, 4, 2, 4CD80, Session2,Day3, 48 hours, n=2, 4, 2, 4CD83, Session1,Day3, 48 hours, n=2, 4, 2, 4CD83, Session2,Day2, 24 hours, n=2, 4, 2, 4CD83, Session2,Day3, 48 hours, n=2, 4, 2, 4CD86+, Session1,Day3, 48 hours, n=2, 4, 2, 4CD86+, Session2,Day2, 24 hours, n=2, 4, 2, 4CD86+, Session2,Day3, 48 hours, n=2, 4, 2, 4HLA-DR, Session1,Day3, 48 hours, n=2, 4, 2, 4HLA-DR, Session2,Day2, 24 hours, n=2, 4, 2, 4HLA-DR, Session2,Day3, 48 hours, n=2, 4, 2, 4
Part 1: GM-CSF 60 µg/m^294.943174.016279.814367.626122.859713.9951295.959194.06613.37753.6821386.7762161.95076.408436.294236.171316.76244.488401.521-824.574280.947-529.900-497.4686.398-97.004-2543.3510097.918884.70
Part 1: LPS 0.5 ng/kg255.500512.000220.7501022.00051.7501173.750849.00119.50-1596.50827.000166.750577.750124.750200.750-167.500490.500155.250286.250-832.50083.250-978.250-439.750-275.500-723.250-5189.00388.50-7846.25
Part 1: LPS 1 ng/kg314.000711.250438.250663.750460.500978.7503188.75-1224.50-1812.25377.500982.2501330.2507.500116.500-8.250404.50044.250254.000-373.250791.500-328.250-319.750103.750-292.250-7267.75-2229.25-9340.00

[back to top]

Part 1:Change From Baseline in Soluble Inflammatory Mediators in Blood

Blood samples were collected at indicated timepoints for the analysis of primary soluble inflammatory mediators like IL-1 beta, INFg, IL-2, IL-8, and MCP-1 in blood. Latest pre-challenge (LPS or GM-CSF) assessment with a non-missing value, including those from unscheduled visits was considered as Baseline. Change from Baseline was calculated as the value at specified visit minus the Baseline value. NA indicates that data was not available as standard deviation could not be calculated for a single participant. (NCT03306589)
Timeframe: Baseline, Session 2: -5, 10, 25, 40 minutes, 1 hour 10 minutes, 1 hour 40 minutes, 2 hours 40 minutes, 5 hours 40 minutes on Day 1. Pre-fluid sample on Day 2 and Day 3

InterventionPicograms per milliliter (Mean)
INFg, Session2,Day1, -5 minutes, n=2, 4, 2, 4INFg, Session2,Day1, 10 minutes, n=2, 4, 2, 4INFg, Session2,Day1, 25 minutes, n=1, 4, 2, 4INFg, Session2,Day1, 40 minutes, n=2, 4, 2, 4INFg, Session2,Day1, 1 hour 10 minutes, n=2, 4,2,4INFg, Session2,Day1, 1 hour 40 minutes, n=2, 4,2,4INFg, Session2,Day1, 2 hour 40 minutes, n=2, 4,2,4INFg, Session2,Day1, 5 hour 40 minutes, n=2, 4,2,4INFg, Session2,Day2, Pre-fluid sampling, n=2,4,2,4INFg, Session2,Day3, Pre-fluid sampling, n=2,4,2,4IL-1b, Session2,Day1, -5 minutes, n=2, 4, 2,4IL-1b, Session2,Day1, 10 minutes, n=2, 4, 2,4IL-1b, Session2,Day1, 25 minutes, n=1, 4, 2,4IL-1b, Session2,Day1, 40 minutes, n=2, 4, 2,4IL-1b, Session2,Day1, 1hour 10minutes, n=2,4,2,4IL-1b, Session2,Day1, 1hour 40minutes, n=2,4,2,4IL-1b, Session2,Day1, 2hour 40minutes, n=2,4,2,4IL-1b, Session2,Day1, 5hour 40minutes, n=2,4,2,4IL-1b, Session2,Day2,Pre-fluid sample, n=2,4,2,4IL-1b, Session2,Day3,Pre-fluid sample, n=2,4,2,4IL-2, Session2,Day2, Pre-fluid sampling, n=2,4,2,4IL-2, Session2,Day3, Pre-fluid sampling, n=2,4,2,4IL-8, Session2,Day1, -5 minutes, n=2, 4, 2,4IL-8, Session2,Day1, 10 minutes, n=2, 4, 2,4IL-8, Session2,Day1, 25 minutes, n=1, 4, 2,4IL-8, Session2,Day1, 40 minutes, n=2, 3, 2,4IL-8, Session2,Day1, 1 hour 10 minutes, n=2, 3,2,4IL-8, Session2,Day1, 1 hour 40 minutes, n=2,3, 2,4IL-8, Session2,Day1, 2 hour 40 minutes, n=2,3, 2,4IL-8, Session2,Day1, 5 hour 40 minutes, n=2,3, 2,4IL-8, Session2,Day2, Pre-fluid sampling, n=2,3,2,4IL-8, Session2,Day3, Pre-fluid sampling, n=2,4,2,4MCP-1, Session2,Day1, -5 minutes, n=2, 4, 2,4MCP-1, Session2,Day1, 10 minutes, n=2, 4, 2,4MCP-1, Session2,Day1, 25 minutes, n=1, 4, 2,4MCP-1, Session2,Day1, 40 minutes, n=2, 4, 2,4MCP-1, Session2,Day1, 1 hour 10 minutes, n=2,4,2,4MCP-1, Session2,Day1, 1 hour 40 minutes, n=2,4,2,4MCP-1, Session2,Day1, 2 hour 40 minutes, n=2,4,2,4MCP-1, Session2,Day1, 5 hour 40 minutes, n=2,4,2,4MCP-1, Session2,Day2,Pre-fluid sampling, n=2,4,2,4MCP-1, Session2,Day3,Pre-fluid sampling, n=2,4,2,4
Part 1: LPS 0.5 ng/kg-0.5636-0.4140-0.6996-0.67451.85976.57099.13193.5927-3.7611-4.36280.00000.00000.00000.00000.00000.00000.00000.00000.2225-0.00300.00000.0000-1.48352.28901.79989.4905105.0587214.137249.62477.67723.8330-1.3819-1.9841.716-25.16653.7741092.5582521.2551449.223126.224-0.963-12.333

[back to top]

Part 1:Change From Baseline in Soluble Inflammatory Mediators in Blood

Blood samples were collected at indicated timepoints for the analysis of primary soluble inflammatory mediators like IL-1 beta, INFg, IL-2, IL-8, and MCP-1 in blood. Latest pre-challenge (LPS or GM-CSF) assessment with a non-missing value, including those from unscheduled visits was considered as Baseline. Change from Baseline was calculated as the value at specified visit minus the Baseline value. NA indicates that data was not available as standard deviation could not be calculated for a single participant. (NCT03306589)
Timeframe: Baseline, Session 2: -5, 10, 25, 40 minutes, 1 hour 10 minutes, 1 hour 40 minutes, 2 hours 40 minutes, 5 hours 40 minutes on Day 1. Pre-fluid sample on Day 2 and Day 3

,,
InterventionPicograms per milliliter (Mean)
INFg, Session2,Day1, -5 minutes, n=2, 4, 2, 4INFg, Session2,Day1, 10 minutes, n=2, 4, 2, 4INFg, Session2,Day1, 25 minutes, n=1, 4, 2, 4INFg, Session2,Day1, 40 minutes, n=2, 4, 2, 4INFg, Session2,Day1, 1 hour 10 minutes, n=2, 4,2,4INFg, Session2,Day1, 1 hour 40 minutes, n=2, 4,2,4INFg, Session2,Day1, 2 hour 40 minutes, n=2, 4,2,4INFg, Session2,Day1, 5 hour 40 minutes, n=2, 4,2,4INFg, Session2,Day2, Pre-fluid sampling, n=2,4,2,4INFg, Session2,Day3, Pre-fluid sampling, n=2,4,2,4IL-1b, Session2,Day1, -5 minutes, n=2, 4, 2,4IL-1b, Session2,Day1, 10 minutes, n=2, 4, 2,4IL-1b, Session2,Day1, 25 minutes, n=1, 4, 2,4IL-1b, Session2,Day1, 40 minutes, n=2, 4, 2,4IL-1b, Session2,Day1, 1hour 10minutes, n=2,4,2,4IL-1b, Session2,Day1, 1hour 40minutes, n=2,4,2,4IL-1b, Session2,Day1, 2hour 40minutes, n=2,4,2,4IL-1b, Session2,Day1, 5hour 40minutes, n=2,4,2,4IL-1b, Session2,Day2,Pre-fluid sample, n=2,4,2,4IL-1b, Session2,Day3,Pre-fluid sample, n=2,4,2,4IL-2, Session2,Day1, -5 minutes, n=0, 4, 2,4IL-2, Session2,Day1, 10 minutes, n=0, 4, 2,2IL-2, Session2,Day1, 25 minutes, n=0, 4, 2,4IL-2, Session2,Day1, 40 minutes, n=0, 3, 2,2IL-2, Session2,Day1, 1 hour 10 minutes, n=0, 4,2,4IL-2, Session2,Day1, 1 hour 40 minutes, n=0, 4,2,2IL-2, Session2,Day1, 2 hour 40 minutes, n=0, 4,2,2IL-2, Session2,Day1, 5 hour 40 minutes, n=0, 4,2,2IL-2, Session2,Day2, Pre-fluid sampling, n=2,4,2,4IL-2, Session2,Day3, Pre-fluid sampling, n=2,4,2,4IL-8, Session2,Day1, -5 minutes, n=2, 4, 2,4IL-8, Session2,Day1, 10 minutes, n=2, 4, 2,4IL-8, Session2,Day1, 25 minutes, n=1, 4, 2,4IL-8, Session2,Day1, 40 minutes, n=2, 3, 2,4IL-8, Session2,Day1, 1 hour 10 minutes, n=2, 3,2,4IL-8, Session2,Day1, 1 hour 40 minutes, n=2,3, 2,4IL-8, Session2,Day1, 2 hour 40 minutes, n=2,3, 2,4IL-8, Session2,Day1, 5 hour 40 minutes, n=2,3, 2,4IL-8, Session2,Day2, Pre-fluid sampling, n=2,3,2,4IL-8, Session2,Day3, Pre-fluid sampling, n=2,4,2,4MCP-1, Session2,Day1, -5 minutes, n=2, 4, 2,4MCP-1, Session2,Day1, 10 minutes, n=2, 4, 2,4MCP-1, Session2,Day1, 25 minutes, n=1, 4, 2,4MCP-1, Session2,Day1, 40 minutes, n=2, 4, 2,4MCP-1, Session2,Day1, 1 hour 10 minutes, n=2,4,2,4MCP-1, Session2,Day1, 1 hour 40 minutes, n=2,4,2,4MCP-1, Session2,Day1, 2 hour 40 minutes, n=2,4,2,4MCP-1, Session2,Day1, 5 hour 40 minutes, n=2,4,2,4MCP-1, Session2,Day2,Pre-fluid sampling, n=2,4,2,4MCP-1, Session2,Day3,Pre-fluid sampling, n=2,4,2,4
Part 1: GM-CSF 60 µg/m^25.72556.00716.16055.41424.95083.88042.71811.7041-3.0755-3.28170.00000.00000.00000.00000.00000.00000.00000.00000.0857-0.00150.00000.00000.00000.00000.00000.00000.00000.0000-0.0018-0.001883.153189.012386.417850.451476.670977.3493126.355230.148333.5296-2.04682702.7363692.6474354.0504218.5114119.8652659.0131405.284365.641-14.427-15.571
Part 1: LPS 0.75 ng/kg-0.1278-0.3298-0.3697-0.47711.76736.58638.74983.26720.76301.59620.00000.00080.00000.00080.00080.18750.31940.00080.00080.00080.00000.00310.00310.00000.00310.00310.00310.00310.00310.00310.07610.07140.68149.3036141.7558468.8635340.065788.55748.75440.64657.28015.33522.679108.0053281.5605164.9465189.946588.42438.01628.822
Part 1: LPS 1 ng/kg0.0653-0.2355-0.24320.15016.608313.680915.73065.0294-0.3514-2.66000.00000.00000.00000.00000.00000.00000.00000.0000-0.0030-0.00300.00000.00000.00000.00000.00000.00000.00000.0000-0.0160-0.01600.18490.86133.014227.1507162.3033229.6116111.615519.5090-1.3116-0.8507-12.078-6.9639.360273.2612993.7186182.6636824.798350.071-2.9178.210

[back to top]

Part 1:Change From Baseline of CD40+/CD80+ by Flow Cytometry on Dendritic Cells in Blister

Blister samples were collected at indicated time-points for the measurement of activation markers by flow cytometry for dendritic cells in blister like CD40+/CD80+. Latest pre-challenge (LPS or GM-CSF) assessment with a non-missing value, including those from unscheduled visits was considered as Baseline. Change from Baseline was calculated as the value at specified visit minus the Baseline value. NA indicates that data was not available as standard deviation could not be calculated for a single participant. (NCT03306589)
Timeframe: Baseline, Session1: 48 hours Day 3, Session 2: 24 hours Day 2 and 48 hours Day 3

,,,
InterventionRatio (Mean)
Session1,Day3, 48 hours, n=2, 4, 2, 4Session2,Day2, 24 hours, n=2, 4, 2, 4Session2,Day3, 48 hours, n=1, 4, 2, 3
Part 1: GM-CSF 60 µg/m^239.84536.752338.4313
Part 1: LPS 0.5 ng/kg42.76752.725027.7000
Part 1: LPS 0.75 ng/kg43.20940.082542.6493
Part 1: LPS 1 ng/kg47.81000.090042.5100

[back to top]

Part 1:Change From Baseline of CD40+/CD80+ by Flow Cytometry on Macrophages in Blister

Blister samples were collected at indicated time-points for the measurement of activation markers by flow cytometry for dendritic cells in blister like CD40+/CD80+. Latest pre-challenge (LPS or GM-CSF) assessment with a non-missing value, including those from unscheduled visits was considered as Baseline. Change from Baseline was calculated as the value at specified visit minus the Baseline value. NA indicates that data was not available as standard deviation could not be calculated for a single participant. (NCT03306589)
Timeframe: Baseline, Session1: 48 hours Day 3, Session 2: 24 hours Day 2 and 48 hours Day 3

,,,
InterventionRatio (Mean)
Session1,Day3, 48 hours, n=2, 4, 2, 4Session2,Day2, 24 hours, n=2, 4, 2, 4Session2,Day3, 48 hours, n=1, 4, 2, 4
Part 1: GM-CSF 60 µg/m^2-0.89389.1137-3.2238
Part 1: LPS 0.5 ng/kg11.047515.12250.3500
Part 1: LPS 0.75 ng/kg-1.28371.3537-2.9838
Part 1: LPS 1 ng/kg21.8500-16.0250-8.9750

[back to top]

Part 1:Change From Baseline of CD40+/CD80+ by Flow Cytometry on Monocytes in Blister

Blister samples were collected at indicated time-points for the measurement of activation markers by flow cytometry for monocytes in blister like CD40+/CD80+. Latest pre-challenge (LPS or GM-CSF) assessment with a non-missing value, including those from unscheduled visits was considered as Baseline. Change from Baseline was calculated as the value at specified visit minus the Baseline value. NA indicates that data was not available as standard deviation could not be calculated for a single participant. (NCT03306589)
Timeframe: Baseline, Session1: 48 hours Day 3, Session 2: 24 hours Day 2 and 48 hours Day 3

,,,
InterventionRatio (Mean)
Session1,Day3, 48 hours, n=2, 4, 2, 4Session2,Day2, 24 hours, n=2, 4, 2, 4Session2,Day3, 48 hours, n=1, 4, 2, 3
Part 1: GM-CSF 60 µg/m^2-0.4060-0.0994-0.2698
Part 1: LPS 0.5 ng/kg0.14750.0925-0.1210
Part 1: LPS 0.75 ng/kg0.27640.50620.3015
Part 1: LPS 1 ng/kg0.06100.51080.1300

[back to top]

Percent Change of All Treatable Molluscum Lesions (Baseline and New) From Baseline at the EOS Visit

Percent change of all treatable molluscum lesions (baseline and new) from baseline at the EOS visit. (NCT03377790)
Timeframe: Day 1 (Baseline) compared to Day 84 (EOS)

Interventionpercentage of change in wart count (Mean)
VP-102-69.2
Placebo20.0

[back to top]

Change From Baseline to EOS Day 84 of the Composite Score From the Children's Dermatology Life Quality Index (CDLQI) Assessment at the EOS Visit to Measure the Quality of Life and Impact of Skin Disease in the Subset of Subjects 4 -16 Years of Age.

"Change from Baseline to EOS Day 84 of the Composite Score From the Children's Dermatology Life Quality Index (CDLQI) Assessment at the EOS Visit to Measure the Quality of Life and Impact of Skin Disease in the Subset of Subjects 4 -16 Years of Age.~From responses to that questionnaire, a composite score was calculated. The calculated composite score was the sum of the individual 10 items of the CDLQI and could range from 0-30. For each item on the~CDLQI, a score of 0-3 was assigned using the following scores per response:~3: Very much (or Prevented School, Question 7 only)~2: Quite a lot~1: Only a little~0: Not at all Larger composite CDLQI scores indicate skin condition is having more effect on subjects' lives (worse outcome)." (NCT03377790)
Timeframe: Baseline to Day 84 (EOS)

Interventionunits on a scale (Mean)
VP-102-2.1
Placebo-2.7

[back to top]

Change From Baseline in the Number of Treatable Molluscum Lesions (Baseline and New) at the EOS Visit.

Change from baseline in the number of treatable molluscum lesions (baseline and new) at the EOS visit. (NCT03377790)
Timeframe: Day 1 (Baseline) compared to Day 84 (EOS)

Interventionchange in wart count (Mean)
VP-102-18.3
Placebo-5.9

[back to top]

Percentage of Subjects Exhibiting a 75% or Greater Reduction of All Treatable Molluscum Lesions (Baseline and New) at the EOS Visit.

Percentage of subjects that exhibited a 75% or greater clearance of all treatable molluscum lesions (baseline and new) at the EOS visit. (NCT03377790)
Timeframe: Day 1 (Baseline) compared to Day 84 (EOS)

InterventionParticipants (Count of Participants)
VP-102119
Placebo36

[back to top]

Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 63 Visit

Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 63 visit. (NCT03377790)
Timeframe: Day 1 (Baseline and new) compared to Day 63

InterventionParticipants (Count of Participants)
VP-10251
Placebo18

[back to top]

Percentage of Subjects Exhibiting a 90% or Greater Reduction of All Treatable Molluscum Lesions (Baseline and New) at the EOS Visit.

Percentage of subjects that exhibited a 90% or greater clearance of all treatable molluscum lesions (baseline and new) at the EOS visit. (NCT03377790)
Timeframe: Day 1 (Baseline) compared to Day 84 (EOS)

InterventionParticipants (Count of Participants)
VP-10299
Placebo28

[back to top]

Subject Reported Spread to Household Members as Measured by Any New Occurrence of Molluscum in Household Members of Subject.

Subject reported spread to household members as measured by any new occurrence of molluscum in household members of subject. To be eligible for assessment, subjects had to have at least one household member free of lesions at baseline and have at least 1 post baseline assessment of spread of molluscum lesions. (NCT03377790)
Timeframe: Days 1, 21, 42, 63 and 84 (EOS).

InterventionParticipants (Count of Participants)
VP-1029
Placebo13

[back to top]

Proportion of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 21 Visit

Proportion of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 21 visit. (NCT03377790)
Timeframe: Day 1 (Baseline and new) compared to Day 21

InterventionParticipants (Count of Participants)
VP-10218
Placebo4

[back to top]

Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 84 Visit (EOS)

Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 84 visit (EOS). (NCT03377790)
Timeframe: Day 1 (Baseline and new) compared to Day 84 (EOS)

InterventionParticipants (Count of Participants)
VP-10274
Placebo19

[back to top]

Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 42 Visit

Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 42 visit. (NCT03377790)
Timeframe: Day 1 (Baseline and new) compared to Day 42

InterventionParticipants (Count of Participants)
VP-10233
Placebo10

[back to top]

Change From Baseline in the Number of Treatable Molluscum Lesions (Baseline and New) at the EOS Visit

Change from baseline in the number of treatable molluscum lesions (baseline and new) at the EOS visit. (NCT03377803)
Timeframe: Day 1 (Baseline) compared to Day 84 (EOS)

Interventionchange in wart count from baseline (Mean)
VP-102-17.1
Placebo-10.9

[back to top]

Percent Change of All Treatable Molluscum Lesions (Baseline and New) From Baseline at the EOS Visit

Percent change of all treatable molluscum lesions (baseline and new) from baseline at the EOS visit. (NCT03377803)
Timeframe: Day 1 (Baseline) compared to Day 84 (EOS)

Interventionpercentage change from Baseline (Mean)
VP-102-83.3
Placebo-19.1

[back to top]

Percentage of Subjects Exhibiting a 75% or Greater Reduction of All Treatable Molluscum Lesions (Baseline and New) at the EOS Visit

Percentage of subjects exhibiting a 75% or greater reduction of all treatable molluscum lesions (baseline and new) at the EOS visit. (NCT03377803)
Timeframe: Day 1 (Baseline) compared to Day 84(EOS)

InterventionParticipants (Count of Participants)
VP-102122
Placebo40

[back to top]

Percentage of Subjects Exhibiting a 90% or Greater Reduction of All Treatable Molluscum Lesions (Baseline and New) at the EOS Visit

Percentage of subjects exhibiting a 90% or greater reduction of all treatable molluscum lesions (baseline and new) at the EOS visit. (NCT03377803)
Timeframe: Day 1 (Baseline) compared to Day 84 (EOS)

InterventionParticipants (Count of Participants)
VP-102105
Placebo31

[back to top]

Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 21 Visit

Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 21 visit. (NCT03377803)
Timeframe: Day 1 (Baseline) compared to Day 21

InterventionParticipants (Count of Participants)
VP-1028
Placebo2

[back to top]

Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 42 Visit

Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 42 visit. (NCT03377803)
Timeframe: Day 1 (Baseline) compared to Day 42

InterventionParticipants (Count of Participants)
VP-10219
Placebo4

[back to top]

Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 63 Visit

Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 63 visit. (NCT03377803)
Timeframe: Day 1 (Baseline) compared to Day 63

InterventionParticipants (Count of Participants)
VP-10242
Placebo5

[back to top]

Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 84 Visit (EOS)

Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 84 visit (EOS). (NCT03377803)
Timeframe: Day 1 (Baseline) compared to Day 84 (EOS)

InterventionParticipants (Count of Participants)
VP-10281
Placebo15

[back to top]

Subject Reported Spread to Household Members as Measured by Any New Occurrence of Molluscum in Household Members of Subject

Subject reported spread to household members as measured by any new occurrence of molluscum in household members of subject. (NCT03377803)
Timeframe: Days 1, 21, 42, 63 and 84 (EOS).

InterventionParticipants (Count of Participants)
VP-10210
Placebo7

[back to top]

Change From Baseline of the Composite Score From the Children's Dermatology Life Quality Index (CDLQI) Assessment at the EOS Visit to Measure the Quality of Life and Impact of Skin Disease in the Subset of Subjects 4 -16 Years of Age

"Change from Baseline to EOS Day 84 of the Composite Score From the Children's Dermatology Life Quality Index (CDLQI) Assessment at the EOS Visit to Measure the Quality of Life and Impact of Skin Disease in the Subset of Subjects 4 -16 Years of Age.~From responses to that questionnaire, a composite score was calculated. The calculated composite score was the sum of the individual 10 items of the CDLQI and could range from 0-30. For each item on the~CDLQI, a score of 0-3 was assigned using the following scores per response:~3: Very much (or Prevented School, Question 7 only)~2: Quite a lot~1: Only a little~0: Not at all Larger composite CDLQI scores indicate skin condition is having more effect on subjects' lives (worse outcome)." (NCT03377803)
Timeframe: Day 1 (Baseline), 21, 42, 63 and Day 84 (EOS)

,
Interventionscore on a scale (Mean)
Day 21Day 42Day 63Day 84 (EOS)
Placebo-1.2-1.4-1.6-1.9
VP-102-1.0-1.5-2.0-2.1

[back to top]

Part C: Number of Participants With AEs and SAEs

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, important medical events that may jeopardize the participant or require medical or surgical intervention to prevent one of the outcomes listed before. (NCT03426995)
Timeframe: Up to Day 49

,
InterventionParticipants (Count of Participants)
AEsSAEs
Part C: Cohort 4 and 5- GSK3358699 10 mg RD81
Part C: Cohort 4 and 5- Placebo RD70

[back to top]

Part C: Number of Participants With Worst Case Chemistry Results by PCI Criteria Post-Baseline Relative to Baseline

Blood samples were collected for analysis of chemistry parameters. PCI ranges were <30 g/L (albumin), <2 or >2.75 mmol/L (calcium), >1.3* ULN mmol/L (creatinine), <3 or >9 mmol/L (glucose), <3 or >5.5 mmol/L (potassium), and <130 or >150 mmol/L (sodium). Participants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in To within Range or No Change category. Participants were counted twice if participant had values that changed To Low and To High, so the percentages may not add to 100%. (NCT03426995)
Timeframe: Up to Day 28

,
InterventionParticipants (Count of Participants)
Albumin: To LowAlbumin: To within Range or No ChangeAlbumin: To HighCalcium: To LowCalcium: To within Range or No ChangeCalcium: To HighCreatinine: To LowCreatinine: To within Range or No ChangeCreatinine: To HighGlucose: To LowGlucose: To within Range or No ChangeGlucose: To HighPotassium: To LowPotassium: To within Range or No ChangePotassium: To HighSodium: To LowSodium: To within Range or No ChangeSodium: To High
Part C: Cohort 4 and 5- GSK3358699 10 mg RD014001400140014001400140
Part C: Cohort 4 and 5- Placebo RD011001100110011001100110

[back to top]

Part C: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline

"Clinical chemistry parameters assessed were ALT (<10 or >50 IU/L), ALP (<40 or >129 IU/L), AST (<0 or >37 IU/L), cholesterol (<2.3 or >4.9 mmol/L), DB (<0 or >5 mcmol/L), high DL (<0.9 or >1.5 mmol/L), CRP (<0.0 or >5.0 mg/liter), low DL (<0 or >3.0 mmol/L), total bilirubin (<0 or >20 mcmol/L), total protein (<63 or >83 grams/L), triglycerides (<0 or >2.3 mmol/L) and BUN (<4.76 or >23.24 mg/deciliter). Participants were counted in worst case category that their value changes to (low, normal or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g., High to High) or whose value became normal, are recorded in To Normal or NC category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%." (NCT03426995)
Timeframe: Up to Day 28

,
InterventionParticipants (Count of Participants)
ALT: To Low,n=11,14,0,0,0ALT: To Normal or NC,n=11,14,0,0,0ALT: To High,n=11,14,0,0,0ALP: To Low,n=11,14,0,0,0ALP: To Normal or NC,n=11,14,0,0,0ALP: To High,n=11,14,0,0,0AST: To Low,n=11,14,0,0,0AST: To Normal or NC,n=11,14,0,0,0AST: To High,n=11,14,0,0,0Cholesterol: To Low,n=11,14,0,0,0Cholesterol: To Normal or NC,n=11,14,0,0,0Cholesterol: To High,n=11,14,0,0,0DB: To Low,n=11,14,0,0,0DB:To Normal or NC,n=11,14,0,0,0DB: To High,n=11,14,0,0,0High DL: To Low,n=11,14,0,0,0High DL:To Normal or NC,n=11,14,0,0,0High DL: To High,n=11,14,0,0,0CRP: To Low,n=10,13,0,0,0CRP: To Normal or NC,n=10,13,0,0,0CRP: To High,n=10,13,0,0,0Low DL: To Low,n=11,14,0,0,0Low DL: To Normal or NC,n=11,14,0,0,0Low DL: To High,n=11,14,0,0,0Total bilirubin: To Low,n=11,14,0,0,0Total bilirubin:ToNormal or NC,n=11,14,0,0,0Total bilirubin: To High,n=11,14,0,0,0Total protein: To Low,n=11,14,0,0,0Total protein:To Normal or NC,n=11,14,0,0,0Total protein: To High,n=11,14,0,0,0Triglycerides: To Low,n=11,14,0,0,0Triglycerides:To Normal or NC,n=11,14,0,0,0Triglycerides: To High,n=11,14,0,0,0BUN: To Low,n=11,14,0,0,0BUN: To Normal or NC,n=11,14,0,0,0BUN: To High,n=11,14,0,0,0
Part C: Cohort 4 and 5- GSK3358699 10 mg RD112101400140013101401130012101310140212001310140
Part C: Cohort 4 and 5- Placebo RD011001100101092011011000910830110110001010110

[back to top]

Part C: Number of Participants With Worst Case Hematology Results by PCI Criteria Post-Baseline Relative to Baseline

Blood samples were collected for analysis of hematology parameters. PCI ranges were >0.54 proportion of red blood cells in blood (hematocrit), >180 grams/liter (hemoglobin), <0.8*10^9 cells/L (lymphocyte count), <1.5*10^9 cells/L (total ANC), <100 or >550*10^9 cells/L (platelet count), and <3 or >20*10^9 cells/L (WBC count). Participants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in To within Range or No Change category. Participants were counted twice if the participant had values that changed To Low and To High, so the percentages may not add to 100%. (NCT03426995)
Timeframe: Up to Day 28

,
InterventionParticipants (Count of Participants)
Hematocrit: To LowHematocrit: To within Range or No ChangeHematocrit: To HighHemoglobin: To LowHemoglobin: To within Range or No ChangeHemoglobin: To HighLymphocyte count: To LowLymphocyte count: To within Range or No ChangeLymphocyte count: To HighPlatelet count: To LowPlatelet count: To within Range or No ChangePlatelet count: To HighTotal ANC: To LowTotal ANC: To within Range or No ChangeTotal ANC: To HighWBC: To LowWBC: To within Range or No ChangeWBC: To High
Part C: Cohort 4 and 5- GSK3358699 10 mg RD014001400140014001401130
Part C: Cohort 4 and 5- Placebo RD011001101100011011001100

[back to top]

Part C: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline

"Hematology parameters assessed were APTT (<25 or >37 seconds), basophil count (<0.0 or >0.1*10^9 cells/L), eosinophil count (<0.0 or >0.4*10^9 cells/L), fibrinogen (<1.5 or >4.0 g/L), MCH (<26.0 or >33.5 picogram), MCV (<80 or >99 femtoliter), monocyte count (<0.2 or >1.0*10^9 cells/L), PT (<10 or >12 seconds), RBC count (<4.4 or >5.8*10^12 cells/L) and reticulocyte count (<0.38 or >2.64 percentage of reticulocytes). Participants were counted in worst case category that their value changes to (low, normal or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g., High to High) or whose value became normal, are recorded in To Normal or NC category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%." (NCT03426995)
Timeframe: Up to Day 28

,
InterventionParticipants (Count of Participants)
APTT: To LowAPTT: To Normal or NCAPTT: To HighBasophil count: To LowBasophil count: To Normal or NCBasophil count: To HighEosinophil count: To LowEosinophil count: To Normal or NCEosinophil count: To HighFibrinogen: To LowFibrinogen: To Normal or NCFibrinogen: To HighMCH: To LowMCH: To Normal or NCMCH: To HighMCV: To LowMCV: To Normal or NCMCV: To HighMonocyte count: To LowMonocyte count: To Normal or NCMonocyte count: To HighPT: To LowPT: To Normal or NCPT: To HighRBC: To LowRBC: To Normal or NCRBC: To HighReticulocyte count: To LowReticulocyte count: To Normal or NCReticulocyte count: To High
Part C: Cohort 4 and 5- GSK3358699 10 mg RD0131014001400140014001400140014011300140
Part C: Cohort 4 and 5- Placebo RD1100011001100110011001100110010101100110

[back to top]

Part C: Number of Participants With Worst Case Post-Baseline Abnormal ECG Findings

Twelve lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, and QTcF intervals. Abnormal findings were categorized as clinically significant and not clinically significant. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for number of participants with worst case post-Baseline abnormal ECG findings have been presented. (NCT03426995)
Timeframe: Up to Day 28

,
InterventionParticipants (Count of Participants)
Abnormal - not clinically significantAbnormal - clinically significant
Part C: Cohort 4 and 5- GSK3358699 10 mg RD31
Part C: Cohort 4 and 5- Placebo RD20

[back to top]

Part C: Number of Participants With Worst Case Vital Sign Results by PCI Criteria Post-Baseline Relative to Baseline

"Vital signs included SBP, DBP, heart rate, respiratory rate and body temperature and were measured in a semi-supine position after 5 minutes rest. PCI ranges were, SBP (mmHg): <85 (low) or >160 (high), DBP (mmHg): <45 (low) or >100 (high), heart rate (beats per minute): <40 (low) or >110 (high), respiration rate (breaths per minute): <11 (low) or >20 (high) and body temperature (degrees Celsius) <35.5 (low) or >38.0 (high). Participants were counted in the worst case category that their value changes to (low, within range or no change, or high), unless there is no change in their category. Participants whose vital signs value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the To within Range or No Change category. Participants were counted twice if the participant had values that changed To Low and To High, so the percentages may not add to 100%." (NCT03426995)
Timeframe: Up to Day 49

,
InterventionParticipants (Count of Participants)
SBP: To LowSBP: To within Range or No ChangeSBP: To HighDBP: To LowDBP: To within Range or No ChangeDBP: To HighHeart rate: To LowHeart rate: To within Range or No ChangeHeart rate: To HighRespiratory rate: To LowRespiratory rate: To within Range or No ChangeRespiratory rate: To HighBody temperature: To LowBody temperature: To within Range or No ChangeBody temperature: To High
Part C: Cohort 4 and 5- GSK3358699 10 mg RD01400140113011300140
Part C: Cohort 4 and 5- Placebo RD0110011001011910110

[back to top]

Part C: Plasma Concentrations of GSK3206944

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3206944. PK parameters were calculated using standard non-compartmental analysis. GSK3206944 is a metabolite of GSK3358699. (NCT03426995)
Timeframe: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12 and 24 hours; Days 4, 8 and 12: Pre-dose; Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose

InterventionNanogram per milliliter (Median)
Day 1:Pre-dose,n=14,0,0,0Day 1:15 minutes,n=14,0,0,0Day 1:30 minutes,n=14,0,0,0Day 1:1 hour,n=14,0,0,0Day 1:2 hours,n=14,0,0,0Day 1:4 hours,n=14,0,0,0Day 1:6 hours,n=14,0,0,0Day 1:8 hours,n=14,0,0,0Day 1:12 hours,n=14,0,0,0Day 1:24 hours,n=14,0,0,0Day 4: Pre-dose,n=14,0,0,0Day 8: Pre-dose,n=7,0,0,0Day 12: Pre-dose,n=4,0,0,0Day 14:Pre-dose,n=2,0,0,0Day 14:15 minutes,n=2,0,0,0Day 14:30 minutes,n=2,0,0,0Day 14:1 hour,n=2,0,0,0Day 14:2 hours,n=2,0,0,0Day 14:4 hours,n=2,0,0,0Day 14:6 hours,n=2,0,0,0Day 14:8 hours,n=2,0,0,0Day 14:12 hours,n=2,0,0,0Day 14:24 hours,n=2,0,0,0Day 14:48 hours,n=1,0,0,0
Part C: Cohort 4 and 5- GSK3358699 10 mg RD0.00000.00003.131019.933522.225012.77307.29204.37502.20700.38050.53550.66400.49450.58200.74306.413015.335515.092510.45506.85006.03302.22900.52750.1110

[back to top]

Part C: Plasma Concentrations of GSK3358699

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3358699. PK parameters were calculated using standard non-compartmental analysis. (NCT03426995)
Timeframe: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12 and 24 hours; Days 4, 8 and 12: Pre-dose; Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose

InterventionNanogram per milliliter (Median)
Day 1:Pre-dose,n=14,0,0,0Day 1:15 minutes,n=14,0,0,0Day 1:30 minutes,n=14,0,0,0Day 1:1 hour,n=14,0,0,0Day 1:2 hours,n=14,0,0,0Day 1:4 hours,n=14,0,0,0Day 1:6 hours,n=14,0,0,0Day 1:8 hours,n=10,0,0,0Day 1:12 hours,n=3,0,0,0Day 1:24 hours,n=14,0,0,0Day 4: Pre-dose,n=1,0,0,0Day 8: Pre-dose,n=2,0,0,0Day 12: Pre-dose,n=4,0,0,0Day 14:Pre-dose,n=2,0,0,0Day 14:15 minutes,n=2,0,0,0Day 14:30 minutes,n=2,0,0,0Day 14:1 hour,n=2,0,0,0Day 14:2 hours,n=2,0,0,0Day 14:4 hours,n=2,0,0,0Day 14:6 hours,n=2,0,0,0Day 14:8 hours,n=2,0,0,0Day 14:12 hours,n=1,0,0,0Day 14:24 hours,n=2,0,0,0Day 14:48 hours,n=2,0,0,0
Part C: Cohort 4 and 5- GSK3358699 10 mg RD0.00000.28255.74303.89551.33650.57300.29400.16900.1390NA0.00000.0000NANA4.33906.00653.01701.49050.82950.63600.39200.2730NANA

[back to top]

Part C: t1/2 of GSK3206944

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3206944. PK parameters were calculated using standard non-compartmental analysis. GSK3206944 is a metabolite of GSK3358699. (NCT03426995)
Timeframe: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12 and 24 hours; Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose

InterventionHours (Median)
Day 1, n=14,0,0,0Day 14, n=2,0,0,0
Part C: Cohort 4 and 5- GSK3358699 10 mg RD5.026.15

[back to top]

Part C: t1/2 of GSK3358699

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3358699. PK parameters were calculated using standard non-compartmental analysis. (NCT03426995)
Timeframe: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12 and 24 hours; Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose

InterventionHours (Median)
Day 1, n=7,0,0,0Day 14, n=1,0,0,0
Part C: Cohort 4 and 5- GSK3358699 10 mg RD2.471.57

[back to top]

Part C: Tmax of GSK3206944

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3206944. PK parameters were calculated using standard non-compartmental analysis. GSK3206944 is a metabolite of GSK3358699. (NCT03426995)
Timeframe: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12 and 24 hours; Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose

InterventionHours (Median)
Day 1, n=14,0,0,0Day 14, n=2,0,0,0
Part C: Cohort 4 and 5- GSK3358699 10 mg RD2.000.99

[back to top]

Part C: Tmax of GSK3358699

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3358699. PK parameters were calculated using standard non-compartmental analysis. (NCT03426995)
Timeframe: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12 and 24 hours; Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose

InterventionHours (Median)
Day 1, n=14,0,0,0Day 14, n=2,0,0,0
Part C: Cohort 4 and 5- GSK3358699 10 mg RD0.500.53

[back to top]

Part A: Number of Participants With Worst Case Post-Baseline Abnormal Electrocardiogram (ECG) Findings

Twelve lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, and QT interval corrected using the Fridericia's formula (QTcF) intervals. Abnormal findings were categorized as clinically significant (CS) and not clinically significant (NCS). Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for number of participants with worst case post-Baseline abnormal ECG findings have been presented. (NCT03426995)
Timeframe: Up to Day 193

,,,,,,,
InterventionParticipants (Count of Participants)
Abnormal - not clinically significantAbnormal - clinically significant
Part A: GSK3358699 1 mg SD10
Part A: GSK3358699 10 mg SD00
Part A: GSK3358699 20 mg SD30
Part A: GSK3358699 25 mg SD20
Part A: GSK3358699 3 mg SD00
Part A: GSK3358699 30 mg SD30
Part A: GSK3358699 40 mg SD00
Part A: Placebo SD60

[back to top]

Part A: AUC(0-24) of GSK3206944

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3206944. PK parameters were calculated using standard non-compartmental analysis. GSK3206944 is a metabolite of GSK3358699. (NCT03426995)
Timeframe: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12 and 24 hours post-dose in each treatment period

InterventionHours*nanogram per milliliter (Median)
Part A: GSK3358699 1 mg SD16.44
Part A: GSK3358699 3 mg SD28.27
Part A: GSK3358699 10 mg SD106.55
Part A: GSK3358699 20 mg SD209.96
Part A: GSK3358699 25 mg SD374.49
Part A: GSK3358699 30 mg SD452.66
Part A: GSK3358699 40 mg SD586.70

[back to top]

Part A: Apparent Terminal Phase Half-life (t1/2) of GSK3358699

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3358699. PK parameters were calculated using standard non-compartmental analysis. (NCT03426995)
Timeframe: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose in each treatment period

InterventionHours (Median)
Part A: GSK3358699 1 mg SDNA
Part A: GSK3358699 3 mg SDNA
Part A: GSK3358699 10 mg SD2.44
Part A: GSK3358699 20 mg SD2.75
Part A: GSK3358699 25 mg SD6.02
Part A: GSK3358699 30 mg SD4.77
Part A: GSK3358699 40 mg SD6.88

[back to top]

Part A: Area Under the Plasma Concentration Curve From Time Zero to 24 Hours (AUC[0-24]) of GSK3358699

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3358699. PK parameters were calculated using standard non-compartmental analysis. (NCT03426995)
Timeframe: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12 and 24 hours post-dose in each treatment period

InterventionHours*nanogram per milliliter (Median)
Part A: GSK3358699 1 mg SDNA
Part A: GSK3358699 3 mg SDNA
Part A: GSK3358699 10 mg SD13.17
Part A: GSK3358699 20 mg SD23.86
Part A: GSK3358699 25 mg SD32.69
Part A: GSK3358699 30 mg SD67.38
Part A: GSK3358699 40 mg SD59.05

[back to top]

Part A: Area Under the Plasma Concentration Curve From Time Zero to Infinity (AUC[0-infinity]) of GSK3358699

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3358699. PK parameters were calculated using standard non-compartmental analysis. (NCT03426995)
Timeframe: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose in each treatment period

InterventionHours*nanogram per milliliter (Median)
Part A: GSK3358699 1 mg SDNA
Part A: GSK3358699 3 mg SDNA
Part A: GSK3358699 10 mg SD13.20
Part A: GSK3358699 20 mg SD23.89
Part A: GSK3358699 25 mg SD33.22
Part A: GSK3358699 30 mg SD69.13
Part A: GSK3358699 40 mg SD59.68

[back to top]

Part A: Area Under the Plasma Concentration Curve From Time Zero to Last Time of Quantifiable Concentration (AUC[0-t]) of GSK3358699

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3358699. PK parameters were calculated using standard non-compartmental analysis. (NCT03426995)
Timeframe: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose in each treatment period

InterventionHours*nanogram per milliliter (Median)
Part A: GSK3358699 1 mg SD0.74
Part A: GSK3358699 3 mg SD2.33
Part A: GSK3358699 10 mg SD10.77
Part A: GSK3358699 20 mg SD23.40
Part A: GSK3358699 25 mg SD31.88
Part A: GSK3358699 30 mg SD66.38
Part A: GSK3358699 40 mg SD58.09

[back to top]

Part A: AUC(0-infinity) of GSK3206944

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3206944. PK parameters were calculated using standard non-compartmental analysis. GSK3206944 is a metabolite of GSK3358699. (NCT03426995)
Timeframe: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose in each treatment period

InterventionHours*nanogram per milliliter (Median)
Part A: GSK3358699 1 mg SD17.08
Part A: GSK3358699 3 mg SD29.05
Part A: GSK3358699 10 mg SD108.29
Part A: GSK3358699 20 mg SD189.02
Part A: GSK3358699 25 mg SD357.98
Part A: GSK3358699 30 mg SD492.92
Part A: GSK3358699 40 mg SD649.74

[back to top]

Part A: AUC(0-t) of GSK3206944

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3206944. PK parameters were calculated using standard non-compartmental analysis. GSK3206944 is a metabolite of GSK3358699. (NCT03426995)
Timeframe: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose in each treatment period

InterventionHours*nanogram per milliliter (Median)
Part A: GSK3358699 1 mg SD15.16
Part A: GSK3358699 3 mg SD29.12
Part A: GSK3358699 10 mg SD106.55
Part A: GSK3358699 20 mg SD209.98
Part A: GSK3358699 25 mg SD381.16
Part A: GSK3358699 30 mg SD470.40
Part A: GSK3358699 40 mg SD630.63

[back to top]

Part A: Cmax of GSK3206944

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3206944. PK parameters were calculated using standard non-compartmental analysis. GSK3206944 is a metabolite of GSK3358699. (NCT03426995)
Timeframe: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose in each treatment period

InterventionNanogram per milliliter (Median)
Part A: GSK3358699 1 mg SD3.28
Part A: GSK3358699 3 mg SD6.03
Part A: GSK3358699 10 mg SD19.39
Part A: GSK3358699 20 mg SD50.13
Part A: GSK3358699 25 mg SD71.67
Part A: GSK3358699 30 mg SD102.09
Part A: GSK3358699 40 mg SD121.22

[back to top]

Part A: Maximum Plasma Concentration (Cmax) of GSK3358699

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3358699. PK parameters were calculated using standard non-compartmental analysis. (NCT03426995)
Timeframe: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose in each treatment period

InterventionNanogram per milliliter (Median)
Part A: GSK3358699 1 mg SD0.68
Part A: GSK3358699 3 mg SD1.95
Part A: GSK3358699 10 mg SD6.46
Part A: GSK3358699 20 mg SD16.10
Part A: GSK3358699 25 mg SD17.47
Part A: GSK3358699 30 mg SD64.48
Part A: GSK3358699 40 mg SD34.58

[back to top]

Part A: t1/2 of GSK3206944

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3206944. PK parameters were calculated using standard non-compartmental analysis. GSK3206944 is a metabolite of GSK3358699. (NCT03426995)
Timeframe: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose in each treatment period

InterventionHours (Median)
Part A: GSK3358699 1 mg SD4.97
Part A: GSK3358699 3 mg SD4.91
Part A: GSK3358699 10 mg SD4.10
Part A: GSK3358699 20 mg SD3.80
Part A: GSK3358699 25 mg SD7.81
Part A: GSK3358699 30 mg SD6.98
Part A: GSK3358699 40 mg SD6.76

[back to top]

Part A: Time to Cmax (Tmax) of GSK3358699

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3358699. PK parameters were calculated using standard non-compartmental analysis. (NCT03426995)
Timeframe: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose in each treatment period

InterventionHours (Median)
Part A: GSK3358699 1 mg SD0.50
Part A: GSK3358699 3 mg SD0.50
Part A: GSK3358699 10 mg SD0.50
Part A: GSK3358699 20 mg SD1.00
Part A: GSK3358699 25 mg SD1.00
Part A: GSK3358699 30 mg SD0.76
Part A: GSK3358699 40 mg SD0.51

[back to top]

Part A: Tmax of GSK3206944

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3206944. PK parameters were calculated using standard non-compartmental analysis. GSK3206944 is a metabolite of GSK3358699. (NCT03426995)
Timeframe: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose in each treatment period

InterventionHours (Median)
Part A: GSK3358699 1 mg SD1.00
Part A: GSK3358699 3 mg SD2.00
Part A: GSK3358699 10 mg SD2.00
Part A: GSK3358699 20 mg SD2.01
Part A: GSK3358699 25 mg SD2.00
Part A: GSK3358699 30 mg SD2.00
Part A: GSK3358699 40 mg SD2.00

[back to top]

Part A: Absolute Values of Monocyte Chemotactic Protein (MCP)-1, Interleukin (IL)6, Tumor Necrosis Factor (TNF) Alpha in Blood After Ex-vivo Lipopolysaccharide (LPS) Activation

Whole blood samples of 1 milliliter (mL) were collected in TruCulture tubes, containing LPS and incubated for 24 hours, post which the inflammatory mediators (MCP-1, IL-6 and TNF alpha) were analyzed. (NCT03426995)
Timeframe: Day 1: 1, 4, 8, 12, 24 and 48 hours

,,,,,,
InterventionPicogram per milliliter (Median)
Day 1: IL6, 1 hour, n=17,5,3,6,6,0,6,6Day 1: IL6, 4 hours, n=17,5,3,6,6,0,6,6Day 1: IL6, 8 hours, n=17,5,3,6,6,0,6,6Day 1: IL6, 12 hour, n=17,5,3,6,6,0,6,6Day 1: IL6, 24 hours, n=17,5,3,6,6,0,6,6Day 1: IL6, 48 hours, n=17,5,3,6,6,0,6,6Day 1: MCP-1, 1 hour, n=17,5,2,6,6,0,6,6Day 1: MCP-1, 4 hours, n=17,5,3,6,6,0,6,6Day 1: MCP-1, 8 hours, n=17,5,3,6,6,0,6,6Day 1: MCP-1, 12 hour, n=17,5,3,6,6,0,6,6Day 1: MCP-1, 24 hours, n=17,5,3,6,6,0,6,6Day 1: MCP-1, 48 hours, n=17,5,3,6,6,0,6,6Day 1: TNF alpha, 1 hour, n=17,5,3,6,6,0,6,6Day 1: TNF alpha, 4 hours, n=17,5,3,6,6,0,6,6Day 1: TNF alpha, 8 hours, n=17,5,3,6,6,0,6,6Day 1: TNF alpha, 12 hour, n=17,5,3,6,6,0,6,6Day 1: TNF alpha, 24 hours, n=17,5,3,5,6,0,6,6Day 1: TNF alpha, 48 hours, n=17,5,3,6,6,0,6,6
Part A: GSK3358699 1 mg SD15208.1213851.6113629.6013890.3916961.7916209.142997.622638.952911.872738.202349.622306.832281.203452.273630.473680.344528.144077.77
Part A: GSK3358699 10 mg SD12820.7215636.7516564.7918712.8214387.3914786.711273.191410.011606.852003.411691.591729.873455.534493.554612.795139.535576.014186.10
Part A: GSK3358699 20 mg SD15596.9512900.0717019.4815622.2512593.5313685.441278.421648.511533.331297.531062.861200.153916.762672.584908.423079.373543.623963.40
Part A: GSK3358699 3 mg SD20385.2519431.6128805.8128948.1323634.2227160.992539.153774.023145.663048.562216.411621.464340.003381.529631.198736.934694.5810364.95
Part A: GSK3358699 30 mg SD10057.6412074.2816486.9612305.8812894.0214374.441604.852604.002312.122062.412275.171595.511971.773618.725233.222846.573649.083788.04
Part A: GSK3358699 40 mg SD5728.177544.028688.636754.468705.598359.811047.321643.371863.252270.491988.641828.231552.101876.552934.211729.422741.962404.11
Part A: Placebo SD10352.8713092.0112560.8315125.8212876.7413204.842107.381748.711300.341791.071662.281398.362525.783189.813673.784206.183164.793445.95

[back to top]

Part A: Monocyte Intracellular Concentration of GSK3206944

Blood samples were collected into sodium heparin tubes for the isolation of monocytes and for measurement of GSK3206944 concentrations in monocytes. GSK3206944 is a metabolite of GSK3358699. (NCT03426995)
Timeframe: Day 1: 1, 4, 8, 24 and 48 hours post-dose in each treatment period

,,,,,,
InterventionNanogram per milliliter (Median)
Day 1: 1 hourDay 1: 4 hoursDay 1: 8 hoursDay 1: 24 hoursDay 1: 48 hours
Part A: GSK3358699 1 mg SDNANANANANA
Part A: GSK3358699 10 mg SD0.177NANANANA
Part A: GSK3358699 20 mg SD0.6730.105NANANA
Part A: GSK3358699 25 mg SDNA0.149NANANA
Part A: GSK3358699 3 mg SDNANANANANA
Part A: GSK3358699 30 mg SD1.2430.277NANANA
Part A: GSK3358699 40 mg SD1.4100.297NANANA

[back to top]

Part A: Number of Participants With Abnormal Urinalysis Parameters

Urine samples were collected from participants for analyzing the following urine parameters: potential of hydrogen (pH) and glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocytes levels by dipstick. Urine samples showing any abnormality were sent for microscopic examination to detect the presence of RBC, WBC, cellular casts, granular casts, hyaline casts, and were counted as cells per high-power field (cells/HPF). Number of participants with abnormal urinalysis result by microscopic examination have been presented. (NCT03426995)
Timeframe: Up to Day 193

,,,,,,,
InterventionParticipants (Count of Participants)
RBCWBCCellular castsGranular castsHyaline casts
Part A: GSK3358699 1 mg SD00000
Part A: GSK3358699 10 mg SD00000
Part A: GSK3358699 20 mg SD00000
Part A: GSK3358699 25 mg SD10000
Part A: GSK3358699 3 mg SD00000
Part A: GSK3358699 30 mg SD01000
Part A: GSK3358699 40 mg SD00000
Part A: Placebo SD20000

[back to top]

Part A: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, important medical events that may jeopardize the participant or require medical or surgical intervention to prevent one of the outcomes listed before. Safety Population consisted of all randomized participants who took at least 1 dose of study treatment. (NCT03426995)
Timeframe: Up to Day 193

,,,,,,,
InterventionParticipants (Count of Participants)
AEsSAEs
Part A: GSK3358699 1 mg SD20
Part A: GSK3358699 10 mg SD20
Part A: GSK3358699 20 mg SD30
Part A: GSK3358699 25 mg SD80
Part A: GSK3358699 3 mg SD30
Part A: GSK3358699 30 mg SD40
Part A: GSK3358699 40 mg SD30
Part A: Placebo SD80

[back to top]

Part A: Number of Participants With Worst Case Chemistry Results by Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline

Blood samples were collected for analysis of clinical chemistry parameters. PCI ranges were <30 grams per liter (g/L) (albumin), <2 or >2.75 millimoles/L (mmol/L) (calcium), >1.3* upper limit of normal (ULN) mmol/L (creatinine), <3 or >9 mmol/L (glucose), <3 or >5.5 mmol/L (potassium), and <130 or >150 mmol/L (sodium). Participants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in To within Range or No Change (NC) category. Participants were counted twice if participant had values that changed To Low and To High, so the percentages may not add to 100%. (NCT03426995)
Timeframe: Up to Day 193

,,,,,,,
InterventionParticipants (Count of Participants)
Albumin: To LowAlbumin: To within Range or No ChangeAlbumin: To HighCalcium: To LowCalcium: To within Range or No ChangeCalcium: To HighCreatinine: To LowCreatinine: To within Range or No ChangeCreatinine: To HighGlucose: To LowGlucose: To within Range or No ChangeGlucose: To HighPotassium: To LowPotassium: To within Range or No ChangePotassium: To HighSodium: To LowSodium: To within Range or No ChangeSodium: To High
Part A: GSK3358699 1 mg SD050050050050050050
Part A: GSK3358699 10 mg SD060060060060060060
Part A: GSK3358699 20 mg SD060060060060060060
Part A: GSK3358699 25 mg SD012001200120012001200120
Part A: GSK3358699 3 mg SD030030030030030030
Part A: GSK3358699 30 mg SD060060060060060060
Part A: GSK3358699 40 mg SD060060060060060060
Part A: Placebo SD023002300230022102300230

[back to top]

Part A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline

"Clinical chemistry parameters assessed were alanine aminotransferase(ALT)(<10 or >50 international units per liter[IU/L]),alkaline phosphatase(ALP)(<40 or >129 IU/L),aspartate aminotransferase(AST)(<0 or >37 IU/L),cholesterol(<2.3 or >4.9 mmol/L),direct bilirubin(DB)(<0 or >5 micromoles[mcmol]/L),high density lipoprotein (DL)(<0.9 or >1.5 mmol/L),C-reactive protein(CRP)(<0.0 or >5.0mg/liter),low DL(<0 or >3.0 mmol/L), total bilirubin (<0 or >20 mcmol/L),total protein(<63 or >83 grams/L),triglycerides(<0 or >2.3 mmol/L) and blood urea nitrogen(BUN)(<4.76 or >23.24 mg/deciliter).Participants were counted in worst case category that their value changes to (low, normal or high), unless there is NC in their category.Participants whose laboratory value category was unchanged(e.g.,High to High) or whose value became normal, are recorded in To Normal or NC category.Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%." (NCT03426995)
Timeframe: Up to Day 193

,,,,,,,
InterventionParticipants (Count of Participants)
ALT: To Low,n=23,5,3,6,6,12,6,6ALT: To Normal or NC,n=23,5,3,6,6,12,6,6ALT: To High,n=23,5,3,6,6,12,6,6ALP: To Low,n=23,5,3,6,6,12,6,6ALP: To Normal or NC,n=23,5,3,6,6,12,6,6ALP: To High,n=23,5,3,6,6,12,6,6AST: To Low,n=23,5,3,6,6,12,6,6AST: To Normal or NC,n=23,5,3,6,6,12,6,6AST: To High,n=23,5,3,6,6,12,6,6Cholesterol: To Low,n=23,5,3,6,6,12,6,6Cholesterol: To Normal or NC,n=23,5,3,6,6,12,6,6Cholesterol: To High,n=23,5,3,6,6,12,6,6DB: To Low,n=23,5,3,6,6,12,6,6DB:To Normal or NC,n=23,5,3,6,6,12,6,6DB: To High,n=23,5,3,6,6,12,6,6High DL: To Low,n=23,5,3,6,6,12,6,6High DL:To Normal or NC,n=23,5,3,6,6,12,6,6High DL: To High,n=23,5,3,6,6,12,6,6CRP: To Low,n=23,5,3,6,4,12,6,6CRP: To Normal or NC,n=23,5,3,6,4,12,6,6CRP: To High,n=23,5,3,6,4,12,6,6Low DL: To Low,n=23,5,3,6,6,12,6,6Low DL: To Normal or NC,n=23,5,3,6,6,12,6,6Low DL: To High,n=23,5,3,6,6,12,6,6Total bilirubin: To Low,n=23,5,3,6,6,12,6,6Total bilirubin:ToNormal or NC,n=23,5,3,6,6,12,6,6Total bilirubin: To High,n=23,5,3,6,6,12,6,6Total protein: To Low,n=23,5,3,6,6,12,6,6Total protein:To Normal or NC,n=23,5,3,6,6,12,6,6Total protein: To High,n=23,5,3,6,6,12,6,6Triglycerides: To Low,n=23,5,3,6,6,12,6,6Triglycerides:To Normal or NC,n=23,5,3,6,6,12,6,6Triglycerides: To High,n=23,5,3,6,6,12,6,6BUN: To Low,n=23,5,3,6,6,12,6,6BUN: To Normal or NC,n=23,5,3,6,6,12,6,6BUN: To High,n=23,5,3,6,6,12,6,6
Part A: GSK3358699 1 mg SD050140050041050221050050050050032050
Part A: GSK3358699 10 mg SD060060060051060150060042060060042060
Part A: GSK3358699 20 mg SD060060060051060060040051060240042060
Part A: GSK3358699 25 mg SD0120012001200102012001110480111011139001200120
Part A: GSK3358699 3 mg SD030030030030021030021021030120021030
Part A: GSK3358699 30 mg SD060060060051060060060051060150033060
Part A: GSK3358699 40 mg SD060060060042060060051042060150042060
Part A: Placebo SD022102300221022102211220018502120221419001760230

[back to top]

Part A: Number of Participants With Worst Case Hematology Results by PCI Criteria Post-Baseline Relative to Baseline

Blood samples collected for analysis of hematology parameters. PCI ranges were >0.54 proportion of red blood cells in blood (hematocrit), >180 grams/liter (hemoglobin), <0.8 *10^9 cells/L (lymphocyte count), <1.5 *10^9 cells/L (total absolute neutrophil count [ANC]), <100 or >550 *10^9 cells/L (platelet count), and <3 or >20*10^9 cells/L (white blood cell [WBC] count). Participants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in To within Range or No Change category. Participants were counted twice if the participant had values that changed To Low and To High, so the percentages may not add to 100%. (NCT03426995)
Timeframe: Up to Day 193

,,,,,,,
InterventionParticipants (Count of Participants)
Hematocrit: To LowHematocrit: To within Range or No ChangeHematocrit: To HighHemoglobin: To LowHemoglobin: To within Range or No ChangeHemoglobin: To HighLymphocyte count: To LowLymphocyte count: To within Range or No ChangeLymphocyte count: To HighPlatelet count: To LowPlatelet count: To within Range or No ChangePlatelet count: To HighTotal ANC: To LowTotal ANC: To within Range or No ChangeTotal ANC: To HighWBC: To LowWBC: To within Range or No ChangeWBC: To High
Part A: GSK3358699 1 mg SD050050050050140050
Part A: GSK3358699 10 mg SD060060060060060060
Part A: GSK3358699 20 mg SD060060060060060060
Part A: GSK3358699 25 mg SD012001202100012001200120
Part A: GSK3358699 3 mg SD030030030030030030
Part A: GSK3358699 30 mg SD060060060060060060
Part A: GSK3358699 40 mg SD060060060060060060
Part A: Placebo SD023002302210023002300230

[back to top]

Part A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline

"Hematology parameters assessed were activated partial thromboplastin time (APTT) (<25 or >37 seconds), basophil count (<0.0 or >0.1*10^9 cells/L), eosinophil count (<0.0 or >0.4*10^9 cells/L), fibrinogen (<1.5 or >4.0 g/L), mean corpuscle hemoglobin (MCH) (<26.0 or >33.5 picogram), mean corpuscle volume (MCV) (<80 or >99 femtoliter), monocyte count (<0.2 or >1.0*10^9 cells/L), prothrombin time (PT) (<10 or >12 seconds), red blood cell (RBC) count (<4.4 or >5.8*10^12 cells/L) and reticulocyte count (<0.38 or >2.64 percentage of reticulocytes). Participants were counted in worst case category that their value changes to (low, normal or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g., High to High) or whose value became normal, are recorded in To Normal or NC category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%." (NCT03426995)
Timeframe: Up to Day 193

,,,,,,,
InterventionParticipants (Count of Participants)
APTT: To LowAPTT: To Normal or NCAPTT: To HighBasophil count: To LowBasophil count: To Normal or NCBasophil count: To HighEosinophil count: To LowEosinophil count: To Normal or NCEosinophil count: To HighFibrinogen: To LowFibrinogen: To Normal or NCFibrinogen: To HighMCH: To LowMCH: To Normal or NCMCH: To HighMCV: To LowMCV: To Normal or NCMCV: To HighMonocyte count: To LowMonocyte count: To Normal or NCMonocyte count: To HighPT: To LowPT: To Normal or NCPT: To HighRBC: To LowRBC: To Normal or NCRBC: To HighReticulocyte count: To LowReticulocyte count: To Normal or NCReticulocyte count: To High
Part A: GSK3358699 1 mg SD050050050050041050050050050041
Part A: GSK3358699 10 mg SD060060060060060060060060060060
Part A: GSK3358699 20 mg SD141051051060060060060060060060
Part A: GSK3358699 25 mg SD111001200120012001200120066012001200120
Part A: GSK3358699 3 mg SD021030030030030030030021021030
Part A: GSK3358699 30 mg SD060060060060060060060060060060
Part A: GSK3358699 40 mg SD042060051051060060060051060060
Part A: Placebo SD0212023002120230023002300194023012200230

[back to top]

Part A: Number of Participants With Worst Case Vital Sign Results by PCI Criteria Post-Baseline Relative to Baseline

"Vital signs included systolic blood pressure(SBP), diastolic blood pressure(DBP), heart rate, respiratory rate and body temperature and were measured in a semi-supine position after 5 minutes rest. PCI ranges were, SBP (millimeters of mercury [mmHg]): <85 (low) or >160 (high), DBP (mmHg): <45 (low) or >100 (high), heart rate (beats per minute): <40 (low) or >110 (high), respiration rate (breaths per minute): <11(low) or >20(high) and body temperature (degrees Celsius) <35.5 (low) or >38.0 (high). Participants were counted in the worst case category that their value changes to (low, within range or no change, or high), unless there is no change in their category. Participants whose vital signs value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the To within Range or No Change category. Participants were counted twice if the participant had values that changed To Low and To High, so the percentages may not add to 100%." (NCT03426995)
Timeframe: Up to Day 193

,,,,,,,
InterventionParticipants (Count of Participants)
SBP: To LowSBP: To within Range or No ChangeSBP: To HighDBP: To LowDBP: To within Range or No ChangeDBP: To HighHeart rate: To LowHeart rate: To within Range or No ChangeHeart rate: To HighRespiratory rate: To LowRespiratory rate: To within Range or No ChangeRespiratory rate: To HighBody temperature: To LowBody temperature: To within Range or No ChangeBody temperature: To High
Part A: GSK3358699 1 mg SD050050050050050
Part A: GSK3358699 10 mg SD060060060060150
Part A: GSK3358699 20 mg SD060060060060060
Part A: GSK3358699 25 mg SD01200120012011100111
Part A: GSK3358699 3 mg SD030030030030030
Part A: GSK3358699 30 mg SD060060060060060
Part A: GSK3358699 40 mg SD060060060060060
Part A: Placebo SD02300230023012200221

[back to top]

Part A: Plasma Concentrations of GSK3206944

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3206944. PK parameters were calculated using standard non-compartmental analysis. GSK3206944 is a metabolite of GSK3358699. (NCT03426995)
Timeframe: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose in each treatment period

,,,,,,
InterventionNanogram per milliliter (Median)
Pre-dose15 minutes30 minutes1 hour2 hours4 hours6 hours8 hours12 hours24 hours48 hours
Part A: GSK3358699 1 mg SD0.00000.20501.20903.03103.28301.91100.94900.58400.25400.0000NA
Part A: GSK3358699 10 mg SD0.00000.05503.193017.145517.653510.67906.77454.65151.84000.26200.0000
Part A: GSK3358699 20 mg SD0.00000.00001.837026.128046.425022.692513.79558.35353.45350.47900.0000
Part A: GSK3358699 25 mg SD0.00000.00004.381033.614570.401046.816523.127513.71655.38301.20200.3440
Part A: GSK3358699 3 mg SD0.0000.20701.84104.22005.56403.24901.57601.02000.46700.1050NA
Part A: GSK3358699 30 mg SD0.00000.057517.224589.1965102.086551.723030.469016.57956.73651.10150.1895
Part A: GSK3358699 40 mg SD0.00000.00006.335074.5130121.222069.231536.830518.48258.72801.50400.2565

[back to top]

Part A: Plasma Concentrations of GSK3358699

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3358699. Pharmacokinetic (PK) parameters were calculated using standard non-compartmental analysis. PK Population consisted of all participants in the Safety Population who received an active dose and for whom a PK sample was obtained and analyzed. (NCT03426995)
Timeframe: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose in each treatment period

,,,,,,
InterventionNanogram per milliliter (Median)
Pre-dose, n=5,3,6,6,12,6,615 minutes, n=5,3,6,6,12,6,630 minutes, n=5,3,6,6,12,6,61 hour, n=5,3,6,6,12,6,62 hours, n=5,3,6,6,12,6,64 hours, n=5,2,6,6,12,6,66 hours, n=5,3,6,6,12,6,68 hours, n=5,3,6,6,12,6,612 hours, n=5,3,2,6,12,6,624 hours, n=5,3,6,6,9,4,548 hours, n=5,3,6,6,6,6,6
Part A: GSK3358699 1 mg SD0.00000.49500.68400.42100.1810NANANANANANA
Part A: GSK3358699 10 mg SD0.00001.04806.45603.51501.69300.52650.31600.21200.1390NANA
Part A: GSK3358699 20 mg SD0.00000.53905.10509.18404.81001.28650.67200.37750.1490NANA
Part A: GSK3358699 25 mg SD0.00000.26205.913011.07856.94951.90951.10200.59150.25100.15100.0000
Part A: GSK3358699 3 mg SD0.00000.64701.95100.99600.47900.1560NANANANANA
Part A: GSK3358699 30 mg SD0.00005.846064.481028.450010.65503.63901.43050.83400.51950.1250NA
Part A: GSK3358699 40 mg SD0.00000.924533.212028.83808.67352.59201.25150.66650.42550.2090NA

[back to top]

Part C: Absolute Values of MCP-1, IL6, TNF Alpha in Blood After Ex-vivo LPS Activation

Whole blood samples of 1 mL were collected in TruCulture tubes, containing LPS and incubated for 24 hours, post which the inflammatory mediators (MCP-1, IL-6 and TNF alpha) were analyzed. (NCT03426995)
Timeframe: Day 1: 1, 4 and 8 hours; Days 2, 4, 8 and 12: Pre-dose; Day 13: Pre-dose, 1, 4 and 8 hours; Day 14: Pre-dose, Pre-LPS challenge, 1, 4, 8, 24 and 48 hours

,
InterventionPicogram per milliliter (Median)
IL6:Day 1,1 hour,n=11,13,0,0,0IL6:Day 1,4 hours,n=11,14,0,0,0IL6:Day 1,8 hours,n=11,14,0,0,0IL6:Day 2,Pre-dose,n=11,14,0,0,0IL6:Day 4,Pre-dose,n=11,14,0,0,0IL6:Day 8,Pre-dose,n=6,7,0,0,0IL6:Day 12,Pre-dose,n=5,4,0,0,0IL6:Day 13,Pre-dose,n=1,1,0,0,0IL6:Day 13,1 hour,n=1,1,0,0,0IL6:Day 13,4 hours,n=1,1,0,0,0IL6:Day 13,8 hours,n=1,1,0,0,0IL6:Day 14,Pre-dose,n=1,1,0,0,0IL6:Day 14,Pre LPS challenge,n=1,1,0,0,0IL6:Day 14,1 hour,n=1,1,0,0,0IL6:Day 14,4 hours,n=1,1,0,0,0IL6:Day 14,8 hours,n=1,1,0,0,0IL6:Day 14,24 hours,n=1,1,0,0,0IL6:Day 14,48 hours,n=1,1,0,0,0MCP-1:Day 1,1 hour,n=11,14,0,0,0MCP-1:Day 1,4 hours,n=11,14,0,0,0MCP-1:Day 1,8 hours,n=11,14,0,0,0MCP-1:Day 2,Pre-dose,n=11,14,0,0,0MCP-1:Day 4,Pre-dose,n=11,14,0,0,0MCP-1:Day 8,Pre-dose,n=6,7,0,0,0MCP-1:Day 12,Pre-dose,n=5,4,0,0,0MCP-1:Day 13,Pre-dose,n=1,1,0,0,0MCP-1:Day 13,1 hour,n=1,1,0,0,0MCP-1:Day 13,4 hours,n=1,1,0,0,0MCP-1:Day 13,8 hours,n=1,1,0,0,0MCP-1:Day 14,Pre-dose,n=1,1,0,0,0MCP-1:Day 14,Pre LPS challenge,n=1,1,0,0,0MCP-1:Day 14,1 hour,n=1,1,0,0,0MCP-1:Day 14,4 hours,n=1,1,0,0,0MCP-1:Day 14,8 hours,n=1,1,0,0,0MCP-1:Day 14,24 hours,n=1,1,0,0,0MCP-1:Day 14,48 hours,n=1,1,0,0,0TNF alpha:Day 1,1 hour,n=11,13,0,0,0TNF alpha:Day 1,4 hours,n=11,14,0,0,0TNF alpha:Day 1,8 hours,n=11,14,0,0,0TNF alpha:Day 2,Pre-dose,n=11,14,0,0,0TNF alpha:Day 4,Pre-dose,n=11,14,0,0,0TNF alpha:Day 8,Pre-dose,n=6,7,0,0,0TNF alpha:Day 12,Pre-dose,n=5,4,0,0,0TNF alpha:Day 13,Pre-dose,n=1,1,0,0,0TNF alpha:Day 13,1 hour,n=1,1,0,0,0TNF alpha:Day 13,4 hours,n=1,1,0,0,0TNF alpha:Day 13,8 hours,n=1,1,0,0,0TNF alpha:Day 14,Pre-dose,n=1,1,0,0,0TNF alpha:Day 14,Pre LPS challenge,n=1,1,0,0,0TNF alpha:Day 14,1 hour,n=1,1,0,0,0TNF alpha:Day 14,4 hours,n=1,1,0,0,0TNF alpha:Day 14,8 hours,n=1,1,0,0,0TNF alpha:Day 14,24 hours,n=1,1,0,0,0TNF alpha:Day 14,48 hours,n=1,1,0,0,0
Part C: Cohort 4 and 5- GSK3358699 10 mg RD9629.7510686.7515475.5812396.7112558.7810766.0210539.8212743.2612508.9411616.5316723.5814654.8311340.7913244.2011543.0812544.559114.1510304.012216.062405.112044.641928.511939.651719.262176.12513.36294.72890.771412.524935.031981.153623.793293.923150.843372.942715.942078.662297.363854.863028.333045.052849.522407.602995.362648.272815.394472.253327.692081.543133.322457.353481.912187.402597.32
Part C: Cohort 4 and 5- Placebo RD9488.659121.3513079.219323.6711002.4711305.849329.369966.6411718.407099.4210722.248918.968696.6510082.239122.2110986.169176.898257.881739.491825.092002.441939.091677.881638.331799.121839.002113.921872.121997.872007.091876.053503.112066.722593.902082.281879.531994.721843.083692.362711.072987.242932.722482.032311.663495.211573.182486.892304.402092.072103.621771.692560.841482.941909.65

[back to top]

Part C: AUC(0-24) of GSK3206944

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3206944. PK parameters were calculated using standard non-compartmental analysis. GSK3206944 is a metabolite of GSK3358699. (NCT03426995)
Timeframe: Days 1 and 14: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12, and 24 hours post-dose

InterventionHours*nanogram per milliliter (Median)
Day 1, n=14,0,0,0Day 14, n=2,0,0,0
Part C: Cohort 4 and 5- GSK3358699 10 mg RD115.31106.19

[back to top]

Part C: AUC(0-24) of GSK3358699

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3358699. PK parameters were calculated using standard non-compartmental analysis. (NCT03426995)
Timeframe: Days 1 and 14: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12, and 24 hours post-dose

InterventionHours*nanogram per milliliter (Median)
Day 1, n=7,0,0,0Day 14, n=1,0,0,0
Part C: Cohort 4 and 5- GSK3358699 10 mg RD9.077.99

[back to top]

Part C: AUC(0-infinity) of GSK3206944

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3206944. PK parameters were calculated using standard non-compartmental analysis. GSK3206944 is a metabolite of GSK3358699. (NCT03426995)
Timeframe: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12 and 24 hours; Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose

InterventionHours*nanogram per milliliter (Median)
Day 1, n=14,0,0,0
Part C: Cohort 4 and 5- GSK3358699 10 mg RD117.25

[back to top]

Part C: AUC(0-infinity) of GSK3358699

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3358699. PK parameters were calculated using standard non-compartmental analysis. (NCT03426995)
Timeframe: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12 and 24 hours; Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose

InterventionHours*nanogram per milliliter (Median)
Day 1, n=7,0,0,0
Part C: Cohort 4 and 5- GSK3358699 10 mg RD9.07

[back to top]

Part C: AUC(0-t) of GSK3206944

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3206944. PK parameters were calculated using standard non-compartmental analysis. GSK3206944 is a metabolite of GSK3358699. (NCT03426995)
Timeframe: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12 and 24 hours; Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose

InterventionHours*nanogram per milliliter (Median)
Day 1, n=14,0,0,0Day 14, n=2,0,0,0
Part C: Cohort 4 and 5- GSK3358699 10 mg RD115.17109.71

[back to top]

Part C: AUC(0-t) of GSK3358699

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3358699. PK parameters were calculated using standard non-compartmental analysis. (NCT03426995)
Timeframe: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12 and 24 hours; Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose

InterventionHours*nanogram per milliliter (Median)
Day 1, n=14,0,0,0Day 14, n=2,0,0,0
Part C: Cohort 4 and 5- GSK3358699 10 mg RD9.4711.70

[back to top]

Part C: Cmax of GSK3206944

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3206944. PK parameters were calculated using standard non-compartmental analysis. GSK3206944 is a metabolite of GSK3358699. (NCT03426995)
Timeframe: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12 and 24 hours; Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose

InterventionNanogram per milliliter (Median)
Day 1, n=14,0,0,0Day 14, n=2,0,0,0
Part C: Cohort 4 and 5- GSK3358699 10 mg RD23.0215.34

[back to top]

Part C: Cmax of GSK3358699

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3358699. PK parameters were calculated using standard non-compartmental analysis. (NCT03426995)
Timeframe: Day 1: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12 and 24 hours; Day 14: Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose

InterventionNanogram per milliliter (Median)
Day 1, n=14,0,0,0Day 14, n=2,0,0,0
Part C: Cohort 4 and 5- GSK3358699 10 mg RD6.196.01

[back to top]

Part C: Monocyte Intracellular Concentration of GSK3206944

Blood samples were collected into sodium heparin tubes for the isolation of monocytes and for measurement of GSK3206944 concentrations in monocytes. GSK3206944 is a metabolite of GSK3358699. (NCT03426995)
Timeframe: Days 1 and 13: 1, 4 and 8 hour; Days 4, 8 and 12: Pre-dose; Day 14: 1, 4, 8, 24 and 48 hours post-dose

InterventionNanogram per milliliter (Median)
Day 1: 1 hour,n=14,0,0,0Day 1: 4 hours,n=14,0,0,0Day 1: 8 hours,n=14,0,0,0Day 4: Pre-dose,n=14,0,0,0Day 8: Pre-dose,n=14,0,0,0Day 12: Pre-dose,n=14,0,0,0Day 13: 1 hour,n=1,0,0,0Day 13: 4 hours,n=1,0,0,0Day 13: 8 hours,n=1,0,0,0Day 14: 1 hour,n=1,0,0,0Day 14: 4 hours,n=1,0,0,0Day 14: 8 hours,n=1,0,0,0Day 14: 24 hours,n=1,0,0,0Day 14: 48 hours,n=1,0,0,0
Part C: Cohort 4 and 5- GSK3358699 10 mg RD0.313NANANANANA0.317NANA0.256NANANANA

[back to top]

Part C: Number of Participants With Abnormal Urinalysis Parameters

Urine samples were collected from participants for analyzing the following urine parameters: pH and glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocytes levels by dipstick. Urine samples showing any abnormality were sent for microscopic examination to detect the presence of RBC, WBC, cellular casts, granular casts, hyaline casts, and were counted as cells/HPF. Number of participants with abnormal urinalysis result by microscopic examination have been presented. (NCT03426995)
Timeframe: Up to Day 28

,
InterventionParticipants (Count of Participants)
RBCWBCCellular castsGranular castsHyaline casts
Part C: Cohort 4 and 5- GSK3358699 10 mg RD01000
Part C: Cohort 4 and 5- Placebo RD01000

[back to top]

Cohort 1: Change From Baseline in the Number of Treatable Warts (Baseline and New) at Visit 2, Visit 3, Visit 4 and the EOS Visit

Cohort 1: Change from baseline in the number of treatable warts (baseline and new) at Visit 2, Visit 3, Visit 4 and the EOS Visit. (NCT03487549)
Timeframe: Baseline, Day 14, 28, 42, and 84 (EOS)

Interventionchange in wart count (Mean)
Treatment Visit 2Treatment Visit 3Treatment Visit 4End of Study
Cohort 1-0.5-0.43-0.76-0.95

[back to top]

Cohort 1: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study

Cohort 1: Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at Visit 2, Visit 3, Visit 4 and over the duration of the study. (NCT03487549)
Timeframe: Baseline, Day 14, 28, 42 and 84 (EOS)

InterventionParticipants (Count of Participants)
Complete Clearance Reported at any Visit?Complete Clearance Reported at Day 14Complete Clearance Reported at Day 28Complete Clearance Reported at Day 42Complete Clearance Reported at Day 84 (EOS)
Cohort 150254

[back to top]

Cohort 1:Percent Reduction of All Treatable Warts (Baseline and New) From Baseline at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study.

Cohort 1: Percent change from baseline in the number of treatable warts (Baseline and new) from Baseline at Visit 2, Visit 3, Visit 4 and over the duration of the study. (NCT03487549)
Timeframe: Baseline, Day 14, 28, 42, and 84 (EOS)

InterventionPercent change in number of warts (Mean)
Treatment Visit 2 Day 14Treatment Visit 3 Day 28Treatment Visit 4 Day 42EOS Day 84
Cohort 1-0.79-12.30-29.29-31.19

[back to top]

Cohort 2: Change From Baseline in the Number of Treatable Warts (Baseline and New) at Follow-up Visits on Day 105, Day 126 and Day 147

Cohort 2: Change from baseline in the number of treatable warts (baseline and new) at follow-up visits on Day 105, Day 126 and Day 147. (NCT03487549)
Timeframe: baseline to Day 105, Day 126 and Day 147

Interventionchange in wart count (Mean)
Day 105Day 126Day 147
VP-102 - Cohort 2-0.82-0.73-0.73

[back to top]

Cohort 2: Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4 and the EOT Visit (Day 84)

Cohort 2: Change from baseline in the number of treatable warts (baseline and new) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4 and the EOT Visit (Day 84). (NCT03487549)
Timeframe: Baseline, Day 14, 28, 42, and 84 (EOS)

Interventionchange in wart count (Mean)
Day 21 (Treatment Visit 2)Day 42 (Treatment Visit 3)Day 63 (Treatment Visit 4)Day 84 (End of Treatment Visit)
VP-102 - Cohort 2-0.39-0.48-0.52-0.85

[back to top]

Cohort 2: Percent Reduction of All Treatable Warts (Baseline and New) From Baseline at Follow-up Visits on Day 105, Day 126 and Day 147

Cohort 2: Percent reduction of all treatable warts (baseline and new) from baseline at follow-up visits on Day 105, Day 126 and Day 147. (NCT03487549)
Timeframe: Baseline to follow-up visits on Day 105, Day 126 and Day 147

Interventionpercentage change from Baseline (Mean)
Day 105Day 126Day 147
VP-102 - Cohort 2-50.91-45.61-45.61

[back to top]

Cohort 2: Percent Reduction of All Treatable Warts (Baseline and New) From Baseline at Visit 2, Visit 3, Visit 4 and Over Duration of the Study.

Cohort 2: Intent to Treat population Cohort 2-Percent reduction of all treatable warts (baseline and new) from baseline at Visit 2, Visit 3, Visit 4 and over duration of the study. (NCT03487549)
Timeframe: Baseline to Treatment Visits 2 (Day 21), 3 (Day 42), 4 (Day 63) through the End of Treatment (Day 84).

Interventionpercentage of change in wart count (Mean)
Day 21 (Treatment Visit 2)Day 42 (Treatment Visit 3)Day 63 (Treatment Visit 4)Day 84 (End of Treatment Visit)
VP-102 - Cohort 2-18.18-29.85-37.12-53.79

[back to top]

Cohort 2: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Follow-up Visits on Day 105, Day 126 and Day 147

Cohort 2: Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at follow-up visits on Day 105, Day 126 and Day 147. (NCT03487549)
Timeframe: Treatment Visit 1 (Baseline) to each follow-up visit Day 105, Day 126 and Day 147.

InterventionParticipants (Count of Participants)
Complete Clearance Reported at Day 105Complete Clearance Reported at Day 126Complete Clearance Reported at Day 147
VP-102 - Cohort 2161313

[back to top]

Cohort 2: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts, (Baseline and New), at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study

Cohort 2: Proportion of subjects exhibiting complete clearance of all treatable warts, (baseline and new), at Visit 2, Visit 3, Visit 4 and over the duration of the study. (NCT03487549)
Timeframe: Baseline, Day 21, 42, 63, and 84 (EOS), 105, 126, and 147

InterventionParticipants (Count of Participants)
Complete Clearance Reported at Day 21 (Treatment Visit 2)Complete Clearance Reported at Day 42 (Treatment Visit 3)Complete Clearance Reported at Day 63 (Treatment Visit 4)Complete Clearance Reported at Day 84 (EOT)Complete Clearance Reported at Day 105Complete Clearance Reported at Day 126Complete Clearance Reported at Day 147
VP-102 - Cohort 2571218161313

[back to top]

Cohort 2: Proportion of Subjects Exhibiting Reduction of at Least 1 Treatable Wart From Baseline at Visit 2, Visit 3, Visit 4 and at the EOT Visit (Day 84)

Cohort 2: Proportion of subjects exhibiting reduction of at least 1 treatable wart from baseline at Visit 2, Visit 3, Visit 4 and at the EOT Visit (Day 84). (NCT03487549)
Timeframe: Baseline, Day 14, 28, 42, and 84 (EOS)

InterventionParticipants (Count of Participants)
Day 21 (Treatment Visit 2)Day 42 (Treatment Visit 3)Day 63 (Treatment Visit 4)Day 84 (End of Treatment Visit)
VP-102 - Cohort 27131520

[back to top]

Cohort 1: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at the EOS Visit (Day 84)

Cohort 1: Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at the EOS Visit (Day 84). (NCT03487549)
Timeframe: Treatment Visit Day 1 (Baseline) compared to Day 84 (EOS) Visit.

InterventionParticipants (Count of Participants)
Cohort 14

[back to top]

Cohort 1: Proportion of Subjects Exhibiting ≥ 50% Clearance of All Treatable Warts (Baseline and New) at the EOS Visit as Compared to Baseline

Cohort 1: Proportion of subjects exhibiting ≥ 50% clearance of all treatable warts (baseline and new) at the EOS visit as compared to baseline. (NCT03487549)
Timeframe: Compare Treatment Visit 1 (Baseline) to End of Study (Day 84).

InterventionParticipants (Count of Participants)
Cohort 17

[back to top]

Cohort 2: Change From Baseline in the Number of Treatable Warts (Baseline and New) at the EOT Visit Day 84)

Cohort 2: Change from baseline in the number of treatable warts (baseline and new) at the EOT Visit Day 84). (NCT03487549)
Timeframe: Baseline, Day 84 (EOS)

Interventionchange in wart count (Mean)
VP-102 - Cohort 2-0.85

[back to top]

Cohort 1: Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at the EOT Visit (Day 84).

Cohort 1: Assessing the percent change from Baseline in the number of treatable warts (Baseline and new) at the EOT visit (Day 84). (NCT03487549)
Timeframe: Baseline (Visit 1) to End of Treatment Visit (Day 84).

InterventionPercent change (Mean)
Cohort 1-31.19

[back to top]

Cohort 1-Proportion of Subjects Who Respond to Treatment Defined by a ≥ 50% Reduction in Total Wart Area at EOS Compared to Baseline

Cohort 1-Proportion of subjects who respond to treatment defined by a ≥ 50% reduction in total wart area at EOS compared to baseline. (NCT03487549)
Timeframe: Baseline, Day 14, 28, 42, and 84 (EOS)

InterventionParticipants (Count of Participants)
Cohort 19

[back to top]

Cohort 2: Change From Baseline in the Percent of Treatable Warts (Baseline and New) at the EOT Visit (Day 84)

Cohort 2: Change from baseline in the percent of treatable warts (baseline and new) at the EOT Visit (Day 84). (NCT03487549)
Timeframe: Baseline (Visit 1) to End of Treatment Visit (Day 84).

Interventionpercentage of change in wart count (Mean)
VP-102 - Cohort 2-53.79

[back to top]

Cohort 2: Proportion of Subjects Exhibiting ≥ 50 % Clearance of All Treatable Warts (Baseline and New) at the EOT Visit (Day 84) as Compared to Baseline

Cohort 2: Proportion of subjects exhibiting ≥ 50 % clearance of all treatable warts (baseline and new) at the EOT Visit (Day 84) as compared to baseline. (NCT03487549)
Timeframe: Baseline to Day 84 (EOT)

InterventionParticipants (Count of Participants)
VP-102 - Cohort 219

[back to top]

Cohort 2: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at the EOT Visit (Day 84)

Cohort 2: Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at the EOT Visit (Day 84). (NCT03487549)
Timeframe: Compare Treatment Visit 1 (Baseline) to EOT Visit (Day 84)

InterventionParticipants (Count of Participants)
VP-102 - Cohort 218

[back to top]

Cohort 2: Proportion of Subjects Who Respond to Treatment Defined by a ≥ 50% Reduction in Total Wart Area at EOT Compared to Baseline

Cohort 2: Proportion of subjects who respond to treatment defined by a ≥ 50% reduction in total wart area at EOT compared to baseline. (NCT03487549)
Timeframe: Baseline to EOT (Day 84)

InterventionParticipants (Count of Participants)
VP-102 - Cohort 223

[back to top]

Cohort 1-Proportion of Subjects Exhibiting Reduction of at Least 1 Treatable Wart From Baseline at Visit 2, Visit 3, Visit 4 and at the EOS Visit (Day 84)

Cohort 1-Proportion of subjects exhibiting reduction of at least 1 treatable wart from baseline at Visit 2, Visit 3, Visit 4 and at the EOS Visit (Day 84). (NCT03487549)
Timeframe: Baseline, Day 14, 28, 42, and 84 (EOS)

InterventionParticipants (Count of Participants)
Reduction of >= 1 Wart from Baseline at any visit?Wart Reduction >= 1 Reported at Day 14 (Visit 2)Wart Reduction >= 1 Reported at Day 28 (Visit 3)Wart Reduction >= 1 Reported at Day 42 (Visit 4)Wart Reduction >= 1 Reported at Day 84 (EOS)
Cohort 191487

[back to top]

Cohort 1: Change From Baseline in the Number of Treatable Warts (Baseline and New) at the EOS Visit (Day 84)

Cohort 1: Change from baseline in the number of treatable warts (baseline and new) at the EOS Visit (Day 84). (NCT03487549)
Timeframe: Change in the number of warts compared at Baseline (Visit 1) to the End of Study Visit (Day 84).

InterventionNumber of warts (Mean)
BaselineEnd of Treatment Visit
Cohort 12.19-0.95

[back to top]

Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)

"Change from baseline in the number of treatable warts (baseline and new) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS).~Number of warts present were recorded at each treatment visit as well as follow-up visits. For each post baseline treatment visit, the change in number of warts from baseline was calculated." (NCT03981822)
Timeframe: Compared from baseline to each study visit, treatment 2 (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.

,,,
InterventionWarts (Mean)
Treatment Visit 2Treatment Visit 3Treatment Visit 4Study Day 84 EOT VisitFollow up Day 112Follow-up Visit Day 147 EOS
Part B Pooled With Part A VP-102 24-hour-5.3-6.3-7.1-7.4-8.1-7.9
Part B Pooled With Part A: Placebo 24-hour0.6-0.50.50.1-0.3-0.1
Part B Pooled With Part A: Placebo 6-hour-0.3-1.1-0.9-1.1-1.1-1.2
Part B Pooled With Part A: VP-102 6-hour-4.0-4.4-5.2-6.1-5.3-5.0

[back to top]

Proportion of Subjects Exhibiting Reduction of ≥ 1 Treatable Wart From Baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)

Proportion of subjects exhibiting reduction of ≥ 1 treatable wart from baseline at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS). (NCT03981822)
Timeframe: Compared from baseline to each study visit, treatment 2 (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.

InterventionParticipants (Count of Participants)
Treatment Visit 272493885Treatment Visit 272493886Treatment Visit 272493884Treatment Visit 272493887Treatment Visit 372493884Treatment Visit 372493885Treatment Visit 372493886Treatment Visit 372493887Treatment Visit 472493884Treatment Visit 472493885Treatment Visit 472493886Treatment Visit 472493887Study Day 84 EOT Visit72493884Study Day 84 EOT Visit72493885Study Day 84 EOT Visit72493886Study Day 84 EOT Visit72493887F/U Visit Day 11272493884F/U Visit Day 11272493885F/U Visit Day 11272493886F/U Visit Day 11272493887F/U Visit Day 147 EOS72493884F/U Visit Day 147 EOS72493885F/U Visit Day 147 EOS72493886F/U Visit Day 147 EOS72493887
NoYes - at least 1 wart reduction from Baseline
Part B Pooled With Part A: VP-102 6-hour22
Part B Pooled With Part A: Placebo 6-hour6
Part B Pooled With Part A VP-102 24-hour23
Part B Pooled With Part A: Placebo 24-hour6
Part B Pooled With Part A: VP-102 6-hour8
Part B Pooled With Part A: Placebo 6-hour18
Part B Pooled With Part A VP-102 24-hour4
Part B Pooled With Part A: Placebo 24-hour12
Part B Pooled With Part A: VP-102 6-hour20
Part B Pooled With Part A VP-102 24-hour21
Part B Pooled With Part A: Placebo 24-hour7
Part B Pooled With Part A: VP-102 6-hour10
Part B Pooled With Part A VP-102 24-hour6
Part B Pooled With Part A: Placebo 24-hour11
Part B Pooled With Part A: VP-102 6-hour23
Part B Pooled With Part A VP-102 24-hour17
Part B Pooled With Part A: Placebo 24-hour4
Part B Pooled With Part A: VP-102 6-hour7
Part B Pooled With Part A VP-102 24-hour10
Part B Pooled With Part A: Placebo 24-hour14
Part B Pooled With Part A: VP-102 6-hour19
Part B Pooled With Part A: Placebo 6-hour9
Part B Pooled With Part A: VP-102 6-hour11
Part B Pooled With Part A: Placebo 6-hour15
Part B Pooled With Part A VP-102 24-hour9
Part B Pooled With Part A: Placebo 6-hour10
Part B Pooled With Part A VP-102 24-hour18
Part B Pooled With Part A: Placebo 6-hour14
Part B Pooled With Part A: VP-102 6-hour13
Part B Pooled With Part A: Placebo 6-hour8
Part B Pooled With Part A VP-102 24-hour19
Part B Pooled With Part A: Placebo 24-hour5
Part B Pooled With Part A: VP-102 6-hour17
Part B Pooled With Part A: Placebo 6-hour16
Part B Pooled With Part A VP-102 24-hour8
Part B Pooled With Part A: Placebo 24-hour13

[back to top]

Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)

Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, and Follow-up Visits on Study Day 112 and Study Day 147 (EOS). (NCT03981822)
Timeframe: Clearance compared from baseline to each study visit, treatment 2 (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.

,,,
InterventionParticipants (Count of Participants)
Treatment Visit 2: Yes, Complete ClearanceTreatment Visit 3: Yes, Complete ClearanceTreatment Visit 4: Yes, Complete ClearanceStudy Day 84 EOT: Yes, Complete ClearanceF/U Visit Day 112: Yes, Complete ClearanceF/U Visit Day 147: Yes, Complete Clearance
Part B Pooled With Part A VP-102 24-hour487988
Part B Pooled With Part A: Placebo 24-hour020022
Part B Pooled With Part A: Placebo 6-hour000123
Part B Pooled With Part A: VP-102 6-hour1461196

[back to top]

Proportion of Subjects Exhibiting 90% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)

Proportion of subjects exhibiting 90% clearance of all treatable warts (baseline and new) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS). (NCT03981822)
Timeframe: Compared from baseline to each study visit, treatment 2 (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.

,,,
InterventionParticipants (Count of Participants)
Treatment Visit 2: Incidence of >=90% Clearance: YESTreatment Visit 3: Incidence of >=90% Clearance: YESTreatment Visit 4: Incidence of >=90% Clearance: YESStudy Day 84 EOT: Incidence of >=90% Clearance: YESF/U Visit Day 112: Incidence of >=90% Clearance: YESF/U Visit Day 147: Incidence of >=90% Clearance: YES
Part B Pooled With Part A VP-102 24-hour4871199
Part B Pooled With Part A: Placebo 24-hour020022
Part B Pooled With Part A: Placebo 6-hour000223
Part B Pooled With Part A: VP-102 6-hour15714119

[back to top]

Proportion of Subjects Exhibiting 75% Clearance of All Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)

Proportion of subjects exhibiting 75% clearance of all treatable warts (baseline and new) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS). (NCT03981822)
Timeframe: Compared from baseline to each study visit, treatment 2, (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.

,,,
InterventionParticipants (Count of Participants)
Treatment Visit 2: Incidence of >=75% Clearance: YESTreatment Visit 3: Incidence of >=75% Clearance: YESTreatment Visit 4: Incidence of >=75% Clearance: YESStudy Day 84 EOT: Incidence of >=75% Clearance: YESF/U Visit Day 112: Incidence of >=75% Clearance: YESF/U Visit Day 147: Incidence of >=75% Clearance: YES
Part B Pooled With Part A VP-102 24-hour61412151313
Part B Pooled With Part A: Placebo 24-hour121232
Part B Pooled With Part A: Placebo 6-hour002234
Part B Pooled With Part A: VP-102 6-hour5811151310

[back to top]

Percent Change From Baseline in the Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)

Percent Change from baseline in the total wart area (sum of individual warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS). (NCT03981822)
Timeframe: Baseline to Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)

,,,
InterventionChange from baseline in % of wart area (Mean)
Study Day 84 (EOT)Follow-up Day 112Follow-up Day 147 (EOS)
Part B Pooled With Part A VP-102 24-hour-64.2-76.4-69.3
Part B Pooled With Part A: Placebo 24-hour-7.313.819.9
Part B Pooled With Part A: Placebo 6-hour-22.3-21.5-11.7
Part B Pooled With Part A: VP-102 6-hour-46.0-48.2-45.8

[back to top]

Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)

Percent Change from Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4, at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS). (NCT03981822)
Timeframe: Percent change from baseline to each study visit, treatment 2 (Day 21), 3 (Day 42), 4 (Day 63) and Day 84, 112 and 147.

,,,
InterventionWart percentage change from Baseline (Mean)
Treatment Visit 2Treatment Visit 3Treatment Visit 4Study Day 84 End of Treatment VisitFollow up Day 112Follow up Visit Day 147 End of Study
Part B Pooled With Part A VP-102 24-hour-58.5-69.3-77.3-77.1-79.2-79.6
Part B Pooled With Part A: Placebo 24-hour-2.6-17.80.6-5.5-14.2-12.9
Part B Pooled With Part A: Placebo 6-hour-6.2-8.9-5.1-1.61.9-6.0
Part B Pooled With Part A: VP-102 6-hour-41.4-49.0-65.8-79.7-68.2-42.5

[back to top]

Change From Baseline in Total Wart Area (Sum of Individual Warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS)

Change from baseline in total wart area (sum of individual warts) at Study Day 84 (EOT), and Follow-up Visits on Study Day 112 and Study Day 147 (EOS). (NCT03981822)
Timeframe: Baseline to Study Day 84, Follow-up Visits at Days 112 and 147 (EOS)

,,,
Interventionmm^2 (Mean)
Study Day 84 (EOT)Follow-up Day 112Follow-up Visit Day 147 (EOS)
Part B Pooled With Part A VP-102 24-hour-72.87-82.79-68.78
Part B Pooled With Part A: Placebo 24-hour1.601.402.21
Part B Pooled With Part A: Placebo 6-hour-23.64-20.35-6.02
Part B Pooled With Part A: VP-102 6-hour-52.60-79.43-59.28

[back to top]